Compositions and methods for modulating LAIR signaling

Immunomodulatory agents targeting LAIR-1 signaling are developed to enhance immune responses in cancer and infectious diseases and suppress immune responses in autoimmune disorders, addressing the unmet need in treating these conditions.

JP7595113B2Active Publication Date: 2024-12-05NEXTCURE INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023088687
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-01-25
Filing Date
2023-05-30
Publication Date
2024-12-05
Estimated Expiration
2037-08-03

AI Technical Summary

Technical Problem

There is a need for compositions and methods to modulate LAIR-1 signaling to treat inflammatory diseases, autoimmune diseases, cancer, and infectious diseases, as existing technologies have not effectively addressed the role of LAIR-1 in immune regulation and its impact on these conditions.

Method used

The development of immunomodulatory agents such as soluble LAIR-2 polypeptides, LAIR-1 fusion proteins, function-blocking anti-LAIR-1 antibodies, and LAIR antibodies that deplete LAIR-1 positive cells to increase or decrease LAIR-1 signaling, thereby enhancing or suppressing immune responses.

Benefits of technology

These agents effectively increase immune responses in subjects with cancer or infectious diseases by decreasing LAIR-1 expression or signaling, and reduce immune responses in subjects with autoimmune disorders by increasing LAIR-1 expression, providing therapeutic benefits in treating conditions like leukemia, ovarian cancer, and rheumatoid arthritis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595113000087
    Figure 0007595113000087
  • Figure 0007595113000088
    Figure 0007595113000088
  • Figure 0007595113000089
    Figure 0007595113000089
Patent Text Reader

Abstract

To provide a composition for adjusting a LAIR-1 and a use method of the same.SOLUTION: There is provided an immune control agent for reducing expression of LAIR-1, ligand coupling, cross linking, negative signal transmission and a combination thereof. Such an action substance can be used for bringing increase of an immune response to a subject who requires the same. An example of the action substance includes: (i) soluble LAIR-2 polypeptide or fusion protein; (ii) soluble LAIR-1 polypeptide or fusion protein; (iii) a function blocking anti LAIR-1 antibody; (iv) an antibody for exhausting an LAIR-1 positive cell; and (v) a combination thereof. There is also provided an immune control action substance for increasing expression of LAIR-1, ligand coupling, cross linking, negative signal transmission and a combination thereof. It is possible to use the action substance for bringing reduction of an immune response to a subject who requires the same.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 370,334, filed August 3, 2016, and U.S. Provisional Patent Application No. 62 / 450,300, filed January 25, 2017, both of which are incorporated by reference in their entireties.

[0002] Sequence Listing Reference The sequence listing submitted on August 3, 2017 as a text file entitled "LAIR1ST25.txt," 136 kilobytes in size, created on August 3, 2017, is hereby incorporated by reference pursuant to 37 C.FR § 1.52(e)(5).

[0003] FIELD OF THE INVENTION The present invention relates generally to the field of immunomodulation, and more particularly to compositions and methods for modulating LAIR-1 signaling to increase or decrease immune responses and for treating leukemia by directly modulating leukemia cell survival and self-renewal. [Background technology]

[0004] Background of the Invention Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is an inhibitory cell surface receptor expressed on many immune cells and mediates inhibitory signaling via two immunoreceptor tyrosine-dependent inhibitory motif (ITIM) domains on its cytoplasmic side (Verbrugge et al., 2006, J. Leukoc. Biol. 79:828-836). LAIR-1 crosslinks various collagens, complement component C1q, and surfactant protein D (SP-D), inducing negative signaling that suppresses immune cell maturation, proliferation, and degranulation (Lebbink et al., 2009, Matrix Biol. 28:202-210; Meyaard et al., 2008, J. Leukoc. Biol. 83:799-803). The human genome, but not the mouse, encodes the soluble LAIR-2 protein (Sun et al., 2014, Gene 552:140-145). The LAIR-2 protein binds to the same ligand as LAIR-1 and may therefore function as a decoy to reduce LAIR-1-mediated inhibitory signaling.

[0005] Inhibitory signaling by LAIR-1 can prevent autoimmune diseases such as lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, and atherosclerosis, as well as contact hypersensitivity (Sun et al., 2014, Gene 552:140-145). Decreased LAIR-1 expression on chronic lymphocytic leukemia cells is associated with disease progression (Poggi et al., 2008, Leukemia 22:980-988; Perbellini et al., 2014, Haematolagica 99:881-887). LAIR-1 has also been shown to be expressed on epithelial ovarian cancer cells and other human tumors, but the function of LAIR-1 expressed on solid tumors remains unclear (Meyaard et al., 1997, Immunity 7:283-290 (Non-Patent Document 7); Cao et al., 2015, Biochem. Biophys. Res. Commun. 458:399-404 (Non-Patent Document 8)).

[0006] LAIR-1 expression on acute myeloid leukemia (AML) cells, and potentially on acute lymphoblastic leukemia (ALL) cells, has been shown to be essential for their growth via a phosphatase-independent LAIR-1-SHP-1-CAMK1-CREB signaling pathway that suppresses apoptosis and differentiation of leukemia stem cells, preserving the self-renewal capacity or "stemness" of these cells (Kang et al., 2015, Nat. Cell Biol. 17:665-677).

[0007] Taken together, the accumulated data regarding LAIR-1 suggests an important role in immune homeostasis, yet there remains a need for compositions and methods that modulate LAIR-1 for the treatment of diseases and disorders.

[0008] It is therefore an object of the present invention to provide compositions that increase negative signaling by LAIR-1 and methods of using same to treat inflammatory diseases and disorders and autoimmune diseases.

[0009] It is a further object of the present invention to provide compositions that reduce negative signaling by LAIR-1 and methods of using same for the treatment of cancer and infectious diseases. [Prior art documents] [Non-patent literature]

[0010] [Non-Patent Document 1] Verbrugge et al.,2006,J.Leukoc.Biol.79:828-836 [Non-patent document 2] Lebbink et al.,2009,Matrix Biol.28:202-210 [Non-patent document 3] Meyaard.,2008,J.Leukoc.Biol.83:799-803 [Non-patent document 4] Sun et al.,2014,Gene 552:140-145 [Non-Patent Document 5] Poggi et al.,2008,Leukemia 22:980-988 [Non-patent document 6] Perbellini et al., 2014, Haematolagica 99:881-887 [Non-Patent Document 7] Meyaard et al., 1997, Immunity 7:283-290 [Non-patent document 8] Cao et al.,2015,Biochem.Biophys.Res.Commun.458:399-404 [Non-Patent Document 9] Kang et al.,2015,Nat.Cell Biol.17:665-677 Summary of the Invention

[0011] Compositions and methods of use for modulating LAIR-1 are provided. For example, immunomodulatory agents that decrease LAIR-1 expression, ligand binding, cross-linking, signal transduction, or a combination thereof are provided. LAIR-1 can be expressed, for example, by myeloid cells, T cells, natural killer (NK) cells, or a combination thereof. Myeloid cells can be antigen-presenting cells, such as monocytes, macrophages, or dendritic cells. In some embodiments, the compositions specifically target one or more of the above cell types.

[0012] The disclosed agents can be used to enhance an immune response in a subject in need thereof. The immune response can be, for example, a primary immune response to an antigen, or an enhancement of effector cell function, such as increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation, or a combination thereof. Exemplary agents include (i) soluble LAIR-2 polypeptides or fusion proteins, (ii) soluble LAIR-1 polypeptides or fusion proteins, (iii) function-blocking anti-LAIR-1 antibodies, (iv) antibodies that can be used to deplete LAIR-1-positive cells, and (v) combinations thereof. In some embodiments, the immunomodulatory agent is an antagonist of LAIR-1.

[0013] In certain embodiments, the agent is a LAIR-2 fusion protein, e.g., a fusion protein comprising the extracellular domain of LAIR-2 or a functional variant thereof linked to an immunoglobulin domain. An exemplary fusion protein comprises the amino acid sequence of SEQ ID NO:16.

[0014] In other embodiments, the agent is an LAIR-2 protein or a functional fragment or variant thereof. For example, the LAIR-2 protein or a functional fragment or variant thereof may have at least 80%, 90%, 95%, or 100% sequence identity with SEQ ID NO:6.

[0015] The agent can be a LAIR-1 fusion protein, e.g., a fusion protein comprising the extracellular domain of LAIR-1 or a functional variant thereof linked to an immunoglobulin domain. An exemplary LAIR-1 fusion protein comprises the amino acid sequence of SEQ ID NO:9.

[0016] In other embodiments, the agent is a soluble LAIR-1 protein or a functional fragment or variant thereof. For example, the soluble LAIR-1 protein may consist of the extracellular domain of LAIR-1 or a functional fragment or variant thereof. Exemplary soluble proteins have at least 80%, 90%, 95%, or 100% sequence identity with SEQ ID NO:2.

[0017] Methods for increasing an immune response in a subject typically involve administering to a subject in need thereof an effective amount of an immunomodulatory agent that decreases LAIR-1 expression, ligand binding, cross-linking, signal transduction, or a combination thereof. The subject may have, for example, cancer or an infectious disease.

[0018] In some embodiments, the subject, cancer, or disease is characterized by increased LAIR-1 expression, increased LAIR-1 ligand expression, decreased LAIR-2 expression, or a combination thereof. In certain embodiments, the cancer is ovarian cancer, lung cancer, gastrointestinal cancer, acute myeloid leukemia (AML), or acute lymphocytic leukemia (ALL). The agent can be administered simultaneously with or in combination with the vaccine or components thereof as a single composition.

[0019] Furthermore, immunomodulatory agents are provided that increase LAIR-1 expression, ligand binding, cross-linking, negative signaling, or a combination thereof. Such agents can be used to reduce immune responses in subjects in need thereof. Exemplary agents include (i) function-stimulating anti-LAIR-1 antibodies, (ii) function-blocking anti-LAIR-2 antibodies, and (iii) combinations thereof.

[0020] One embodiment provides an anti-LAIR antibody produced by a hybridoma selected from the group consisting of 1E11, 1G7, 4B3, 5A6, 5E1, 6B2, 6F4, 6G6, 7G3, 9H6, 11B3, 12E10a, and 12E10b.

[0021] Another embodiment provides an anti-LAIR antibody having at least one light chain or at least one heavy chain of an antibody produced by one or more of the hybridomas selected from the group consisting of 1E11, 1G7, 4B3, 5A6, 5E1, 6B2, 6F4, 6G6, 7G3, 9H6, 11B3, 12E10a, and 12E10b.

[0022] Another embodiment provides an anti-LAIR antibody having a variable light chain that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to a variable light chain having the amino acid sequence of SEQ ID NO: 19, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 107 or 115.

[0023] Another embodiment provides an anti-LAIR antibody having a variable heavy chain that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to a variable heavy chain having the amino acid sequence of SEQ ID NO:23, 31, 39, 47, 55, 63, 71, 79, 87, 95, 103 or 111.

[0024] Another embodiment provides an anti-LAIR antibody having a variable light chain that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to a variable light chain having the amino acid sequence of SEQ ID NO: 19, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 107 or 115, and a variable heavy chain that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to the amino acid sequence of SEQ ID NO: 23, 31, 39, 47, 55, 63, 71, 79, 87, 95, 103 or 111.

[0025] Another embodiment provides an anti-LAIR antibody having a complementarity determining region (CDR) selected from the group of CDRs having an amino acid sequence selected from the group consisting of SEQ ID NOs: 20-22, 24-26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86, 88-90, 92-94, 96-98, 100-102, 104-106, 108-110, 112-114, and 116-118.

[0026] Another embodiment provides an anti-LAIR antibody having a plurality of CDRs selected from the group consisting of SEQ ID NOs: 20-22, 24-26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86, 88-90, 92-94, 96-98, 100-102, 104-106, 108-110, 112-114, and 116-117. The plurality of CDRs may be 2 to 12.

[0027] Another embodiment provides a chimeric antibody having a heavy chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:120 or SEQ ID NO:122, and / or a light chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:124.

[0028] Another embodiment provides a chimeric antibody having a heavy chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:126 or SEQ ID NO:128, and / or a light chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:130.

[0029] Another embodiment provides a chimeric antibody having a heavy chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:132 or SEQ ID NO:134, and / or a light chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:136.

[0030] Another embodiment provides a chimeric antibody having a heavy chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:138 or SEQ ID NO:140, and / or a light chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:142.

[0031] Another embodiment provides a nucleic acid sequence encoding an antibody having a light chain amino acid sequence of SEQ ID NO:124, 130, 136 or 142 and / or a heavy chain amino acid sequence of SEQ ID NO:120, 122, 126, 128, 132, 134, 138 or 140.

[0032] Another embodiment provides a nucleic acid sequence encoding a variable light chain of SEQ ID NO: 19, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 107 or 115 and / or a variable heavy chain of SEQ ID NO: 23, 31, 39, 47, 55, 63, 71, 79, 87, 95, 103 or 111. The nucleic acids encoding the light and / or heavy chains can be part of an expression vector. The nucleic acids can be expressed in a cell. Expression can be inducible or constitutive.

[0033] Another embodiment provides a cell that constitutively or inducibly expresses an antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, wherein the cell has one or more nucleic acids encoding the amino acid sequence of SEQ ID NO:19, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 107, 115, 23, 31, 39, 47, 55, 63, 71, 79, 87, 95, 103, 111, or a combination thereof.

[0034] Another embodiment provides a cell that constitutively or inducibly expresses an antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, the cell having one or more nucleic acids encoding the amino acid sequence of SEQ ID NO:120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, or a combination thereof.

[0035] The method for reducing an immune response in a subject typically comprises administering to a subject in need thereof an effective amount of an immunomodulatory agent that increases LAIR-1 expression, ligand binding, cross-linking, negative signal transduction, or a combination thereof. In some embodiments, the subject has an inflammatory or autoimmune disorder. In certain embodiments, the subject has rheumatoid arthritis.

[0036] In some embodiments, the subject or disease or condition is characterized by decreased LAIR-1 expression, decreased LAIR-1 ligand expression, increased LAIR-2 expression, or a combination thereof.

[0037] Any of the disclosed methods can include administering to a subject an immunomodulatory agent alone or in combination with one or more additional therapeutic agents.

[0038] One embodiment provides a method for treating leukemia in a subject in need thereof by administering to the subject an effective amount of a pharmaceutical composition comprising an LAIR-1 monoclonal antibody, a soluble LAIR-1 polypeptide, a soluble LAIR-2 polypeptide, an LAIR-1 fusion protein, an LAIR-2 fusion protein, or a combination thereof to suppress or reduce LAIR-1 signaling in leukemia cells, thereby suppressing leukemia cell survival or promoting an anti-tumor immune response against the leukemia cells. The leukemia can be acute myeloid leukemia.

[0039] One embodiment provides a method for evaluating or predicting the efficacy of a treatment using an anti-LAIR binding moiety by examining cells of a subject in need of treatment to determine whether the cells express LAIR, a binding partner of LAIR, or both. Examples of cells to be examined include, but are not limited to, cancer cells obtained from the subject. Examples of cancer cells include, but are not limited to, acute myeloid leukemia (AML) cells. Cancer cells expressing multiple interacting inhibitory receptors are believed to respond well to treatment using an anti-LAIR binding moiety. Examples of LAIR binding partners include, but are not limited to, transmembrane collagens (XIII, XVII, and XXIII) and LILRB4. Figure 3 shows predicted treatment outcomes based on the presence of LAIR-1 or a binding partner of LAIR-1 on cancer cells.

[0040] Some embodiments provide a fusion protein of SEQ ID NO:9, 10, 11, 12, 13, 14, 15, 16, 17 or 18. [The present invention 1001] 1. A pharmaceutical composition for producing an enhanced immune response in a subject in need thereof, comprising: (i) a soluble LAIR-2 polypeptide or fusion protein; (ii) a soluble LAIR-1 polypeptide or fusion protein; (iii) LAIR-1 mAb that enhances immune responses; (iv) antibodies that deplete LAIR-1-positive cells, and (iv) any combination thereof an immunomodulatory agent that decreases LAIR-1 expression, ligand binding, cross-linking, negative signaling, or a combination thereof, selected from the group consisting of: The pharmaceutical composition comprising an effective amount of [The present invention 1002] 1001. The pharmaceutical composition of claim 1001, wherein said immunomodulatory agent is a LAIR-2 fusion protein. [The present invention 1003] 1002. The pharmaceutical composition of claim 1002, wherein said LAIR-2 fusion protein comprises the extracellular domain of LAIR-2 linked to an immunoglobulin domain or a functional variant thereof. [The present invention 1004] 1003. The pharmaceutical composition of claim 1003, wherein said LAIR-2 fusion protein comprises the amino acid sequence of SEQ ID NO:16. [The present invention 1005] 1001. The pharmaceutical composition of invention 1001, wherein said immunomodulatory agent is an LAIR-1 fusion protein. [The present invention 1006] 1005. The pharmaceutical composition of the present invention, wherein said LAIR-1 fusion protein comprises the extracellular domain of LAIR-1 or a functional variant thereof linked to an immunoglobulin domain. [The present invention 1007] 1006. The pharmaceutical composition of claim 1006, wherein said LAIR-1 fusion protein comprises the amino acid sequence of SEQ ID NO:9. [The present invention 1008] 1001. The pharmaceutical composition of invention 1001, wherein said immunomodulatory agent is LAIR-2 protein or a functional fragment or variant thereof. [The present invention 1009] 1002. The pharmaceutical composition of the present invention, wherein said LAIR-2 protein or functional fragment or variant thereof comprises at least 80%, 90%, 95% or 100% sequence identity with SEQ ID NO:6. [The present invention 1010] 1001. The pharmaceutical composition of invention 1001, wherein said immunomodulatory agent is a soluble LAIR-1 protein or a functional fragment or variant thereof. [The present invention 1011] 10. The pharmaceutical composition of the present invention, wherein said LAIR-1 protein consists of the extracellular domain of LAIR-1 or a functional fragment or variant thereof. [The present invention 1012] 10. The pharmaceutical composition of claim 10, wherein said LAIR-1 protein or functional fragment or variant thereof comprises at least 80%, 90%, 95% or 100% sequence identity with SEQ ID NO:2. [The present invention 1013] the immune response A primary immune response to an antigen, or Enhancement of effector cell function, such as increased antigen-specific proliferation of T cells, enhanced cytokine production by T cells, stimulation of differentiation, or a combination thereof The pharmaceutical composition of any one of claims 1001 to 1012, [The present invention 1014] A method for bringing about an increased immune response in a subject in need thereof, the method comprising administering to the subject any one of the pharmaceutical compositions of present inventions 1001 to 1013. [The present invention 1015] The method of claim 1014, wherein the subject has cancer. [The present invention 1016] 1015. The method of claim 1015, wherein said cancer is characterized by increased LAIR-1 expression, increased LAIR-1 ligand expression, decreased LAIR-2 expression, or a combination thereof. [The present invention 1017] The method of claim 1014 or claim 1015, wherein the cancer is ovarian cancer, lung cancer or digestive cancer. [The present invention 1018] The method of claim 1014, wherein the subject has an infectious disease. [The present invention 1019] 1019. The method of any of claims 1014 to 1018, wherein said pharmaceutical composition is administered to said subject simultaneously with a vaccine or a component thereof. [The present invention 1020] 1020. The method of any of claims 1014 to 1019, further comprising administering to said subject a second therapeutic agent. [The present invention 1021] 1. A pharmaceutical composition for producing a reduced immune response in a subject in need thereof, comprising: (i) a function-stimulating anti-LAIR-1 antibody, (ii) a function-blocking anti-LAIR-2 antibody, and (iii) any combination thereof an immunomodulatory agent that increases LAIR-1 expression, ligand binding, cross-linking, negative signaling, or a combination thereof, selected from the group consisting of: A pharmaceutical composition comprising an effective amount of [The present invention 1022] the immune response A primary immune response to an antigen, or Enhancement of effector cell function, such as increased antigen-specific proliferation of T cells, enhanced cytokine production by T cells, stimulation of differentiation, or a combination thereof The pharmaceutical composition of the present invention 1021. [The present invention 1023] A method for bringing about a reduced immune response in a subject in need thereof, comprising administering to said subject the pharmaceutical composition of invention 1021 or invention 1022. [The present invention 1024] The method of claim 1023, wherein the subject has inflammation. [The present invention 1025] The method of claim 1023, wherein the subject has an autoimmune disorder. [The present invention 1026] 1026. The method of claim 1025, wherein said autoimmune disorder is rheumatoid arthritis. [The present invention 1027] The method of any of claims 1021 to 1026, wherein said subject or disease or condition is characterized by decreased LAIR-1 expression, decreased LAIR-1 ligand expression, increased LAIR-2 expression, or a combination thereof. [The present invention 1028] The method of any of claims 1021 to 1027, further comprising administering to said subject a second therapeutic agent. [The present invention 1029] Any of the compositions or methods of the preceding inventions, wherein said LAIR-1 is expressed in myeloid cells, T cells, natural killer (NK) cells, or a combination thereof. [The present invention 1030] 1029. The composition or method of claim 1029, wherein said bone marrow cells are antigen-presenting cells. [The present invention 1031] 1030. The composition or method of claim 1030, wherein said antigen-presenting cell is a monocyte, macrophage, or dendritic cell. [The present invention 1032] 1. A method for administering treatment for leukemia to a subject in need thereof, comprising: administering to the subject an effective amount of a pharmaceutical composition comprising a LAIR-1 monoclonal antibody, a soluble LAIR-1 polypeptide, a soluble LAIR-2 polypeptide, a LAIR-1 fusion protein, a LAIR-2 fusion protein, or a combination thereof to inhibit or reduce LAIR-1 signaling in leukemia cells, thereby inhibiting survival of the leukemia cells or promoting an anti-tumor immune response against the leukemia cells. The method comprising: [The present invention 1033] The method of claim 1032, wherein the leukemia is acute myeloid leukemia. [The present invention 1034] An anti-LAIR antibody produced by a hybridoma selected from the group consisting of 1E11, 1G7, 4B3, 5A6, 5E1, 6B2, 6F4, 6G6, 7G3, 9H6, 11B3, 12E10a, and 12E10b. [This invention 1035] An anti-LAIR antibody comprising at least one light chain or at least one heavy chain of an antibody of the present invention. [The present invention 1036] An anti-LAIR antibody comprising a variable light chain that has at least 95% sequence identity to a variable light chain having an amino acid sequence selected from the group of variable light chains consisting of SEQ ID NOs: 19, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 107 and 115. [This invention 1037] An anti-LAIR antibody comprising a variable heavy chain that has at least 95% sequence identity to a variable heavy chain having an amino acid sequence selected from the group of variable heavy chains consisting of SEQ ID NOs: 23, 31, 39, 47, 55, 63, 71, 79, 87, 95, 103 and 111. [The present invention 1038] An anti-LAIR antibody comprising a CDR selected from the group of complementarity-determining regions (CDRs) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 20-22, 24-26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86, 88-90, 92-94, 96-98, 100-102, 104-106, 108-110, 112-114, and 116-118. [This invention 1039] An anti-LAIR antibody having a plurality of CDRs selected from the group consisting of SEQ ID NOs: 20-22, 24-26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86, 88-90, 92-94, 96-98, 100-102, 104-106, 108-110, 112-114, and 116-118. [The present invention 1040] The antibody of the present invention, wherein the plurality of CDRs are 2 to 12 CDRs. [The present invention 1041] A method for treating cancer, comprising administering to a subject in need thereof an effective amount of LAIR-2 Fc in combination with or in place of an anti-PD-1 antibody or an antigen-binding fragment thereof. [The present invention 1042] The method of claim 1040, wherein said cancer is ovarian cancer. [This invention 1043] A method for reducing tumor burden in a subject in need thereof, comprising administering to the subject in need thereof an effective amount of LAIR-2 Fc in combination with or in place of an anti-PD-1 antibody or antigen-binding fragment thereof. [This invention 1044] 1044. The method of claim 1043, wherein the tumor is an ovarian tumor. [This invention 1045] 104. The method of claim 1041 or 1043, wherein said cancer or tumor is lymphoma. [The present invention 1046] A method for promoting primary T cell proliferation in a subject in need thereof, comprising administering a therapeutically effective amount of LAIR-2 Fc to the host. [This invention 1047] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:22; heavy chain complementarity determining regions having the amino acid sequences shown in SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26; The antibody or antigen-binding fragment thereof, comprising: [This invention 1048] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:28, SEQ ID NO:29 and SEQ ID NO:30; heavy chain complementarity determining regions having the amino acid sequences shown in SEQ ID NO:32, SEQ ID NO:33 and SEQ ID NO:34; The antibody or antigen-binding fragment thereof, comprising: [This invention 1049] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:36, SEQ ID NO:37 and SEQ ID NO:38; heavy chain complementarity determining regions having the amino acid sequences shown in SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:42; The antibody or antigen-binding fragment thereof, comprising: [The present invention 1050] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:46; heavy chain complementarity determining regions having the amino acid sequences shown in SEQ ID NO:48, SEQ ID NO:49 and SEQ ID NO:50; The antibody or antigen-binding fragment thereof, comprising: [This invention 1051] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:54; heavy chain complementarity determining regions having the amino acid sequences shown in SEQ ID NO:56, SEQ ID NO:57 and SEQ ID NO:58; The antibody or antigen-binding fragment thereof, comprising: [This invention 1052] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:60, SEQ ID NO:61 and SEQ ID NO:62; heavy chain complementarity determining regions having the amino acid sequences shown in SEQ ID NO:64, SEQ ID NO:65 and SEQ ID NO:66; The antibody or antigen-binding fragment thereof, comprising: [This invention 1053] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:68, SEQ ID NO:69 and SEQ ID NO:70; heavy chain complementarity determining regions having the amino acid sequences shown in SEQ ID NO:72, SEQ ID NO:73 and SEQ ID NO:74; The antibody or antigen-binding fragment thereof, comprising: [This invention 1054] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:76, SEQ ID NO:77 and SEQ ID NO:78; heavy chain complementarity determining regions having the amino acid sequences shown in SEQ ID NO:80, SEQ ID NO:81 and SEQ ID NO:82; The antibody or antigen-binding fragment thereof, comprising: [This invention 1055] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:84, SEQ ID NO:85 and SEQ ID NO:86; heavy chain complementarity determining regions having the amino acid sequences shown in SEQ ID NO:88, SEQ ID NO:89 and SEQ ID NO:90; The antibody or antigen-binding fragment thereof, comprising: [The present invention 1056] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:92, SEQ ID NO:93 and SEQ ID NO:94; heavy chain complementarity determining regions having the amino acid sequences shown in SEQ ID NO:96, SEQ ID NO:97 and SEQ ID NO:98; The antibody or antigen-binding fragment thereof, comprising: [This invention 1057] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:100, SEQ ID NO:101 and SEQ ID NO:102; heavy chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:104, SEQ ID NO:105 and SEQ ID NO:106; The antibody or antigen-binding fragment thereof, comprising: [This invention 1058] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:108, SEQ ID NO:109 and SEQ ID NO:110; heavy chain complementarity determining regions having the amino acid sequences shown in SEQ ID NO:112, SEQ ID NO:113 and SEQ ID NO:114; The antibody or antigen-binding fragment thereof, comprising: [This invention 1059] An antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, light chain complementarity determining regions having the amino acid sequences set forth in SEQ ID NO:116, SEQ ID NO:117 and SEQ ID NO:118; heavy chain complementarity determining regions having the amino acid sequences shown in SEQ ID NO:112, SEQ ID NO:113 and SEQ ID NO:114; The antibody or antigen-binding fragment thereof, comprising: [The present invention 1060] The antibody of any one of 1047 to 1059 of the present invention, which comprises a human Fc domain. [The present invention 1061] a heavy chain having an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:120 or SEQ ID NO:122; and / or a light chain having an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:123 an antibody, [The present invention 1062] a heavy chain having an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:126 or SEQ ID NO:128; and / or a light chain having an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:130 an antibody, [The present invention 1063] a heavy chain having an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:132 or SEQ ID NO:134, and / or a light chain having an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:136 an antibody, [This invention 1064] a heavy chain having an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:138 or SEQ ID NO:140; and / or a light chain having an amino acid sequence that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:142 an antibody, [This invention 1065] the light chain amino acid sequence of SEQ ID NO: 124, 130, 136 or 142, and / or Heavy chain amino acids of SEQ ID NO: 120, 122, 126, 128, 132, 134, 138 or 140 A nucleic acid sequence encoding an antibody comprising: [The present invention 1066] the variable light chain of SEQ ID NO: 19, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 107 or 115, and / or The variable heavy chain of SEQ ID NO: 23, 31, 39, 47, 55, 63, 71, 79, 87, 95, 103 or 111 A nucleic acid sequence encoding [This invention 1067] A cell constitutively or inducibly expressing an antibody or an antigen-binding fragment thereof that specifically binds to LAIR-1, The amino acid sequence of SEQ ID NOs: 19, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 107, 115, 23, 31, 39, 47, 55, 63, 71, 79, 87, 95, 103, 111, or a combination thereof The cell comprising one or more nucleic acids encoding the [The present invention 1068] A cell constitutively or inducibly expressing an antibody or an antigen-binding fragment thereof that specifically binds to LAIR-1, The amino acid sequence of SEQ ID NO: 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142 or a combination thereof The cell comprising one or more nucleic acids encoding the [Brief explanation of the drawings]

[0041] [Figure 1A] 1 is a table showing the amino acid sequences of the variable light chains of anti-LAIR-1 antibodies obtained from clones 1E11, 1G7, 4B3, 5A6, 5E1, 6B2, 6F4, 6G6, 7G3, 9H6, 11B3, 12E10a, and 12E10b. [Figure 1B] 1 is a table showing the amino acid sequences of the variable heavy chains of anti-LAIR-1 antibodies obtained from clones 1E11, 1G7, 4B3, 5A6, 5E1, 6B2, 6F4, 6G6, 7G3, 9H6, 11B3 and 12E10 (a and b). [Figure 2A] 1 is a diagram of a multiple alignment of variable light chains obtained from the indicated hybridomas. [Figure 2B] 1 is a diagram of a multiple alignment of variable heavy chains obtained from the indicated hybridomas. [Figure 3] 1 is a table showing predicted treatment outcomes based on expression of LAIR-1, LAIR-1 binding partners, or combinations thereof. [Figure 4] FIG. 1 is a schematic diagram illustrating LAIR regulation of immune function and homeostasis. [Figure 5] FIG. 1 is a schematic diagram of LAIR-2 Fc and LAIR-1 monoclonal antibodies (mAbs) as therapeutic agents. [Figure 6] Figure 6A shows an SDS PAGE gel of LAIR-2 Fc, and Figure 6B shows a size exclusion chromatogram of LAIR-2 Fc. [Figure 7A] FIG. 7A is a fluorescence-activated cell sorting (FACS) histogram of K562-Col17 cells stained with LAIR-2 Fc followed by anti-hIg-PE. [Figure 7B]FIG. 7B is a FACS histogram of control cells stained with LAIR-2 Fc followed by anti-hIg-PE. [Figure 7C] FIG. 7C is a FACS histogram of control cells stained with LAIR-1 Fc followed by anti-hIg-PE. [Figure 7D] FIG. 7D is a FACS histogram of control cells stained with LAIR-1 Fc followed by anti-hIg-PE. [Figure 7E] Figure 7E is a non-reducing SDS-PAGE gel of LAIR-1 Fc and LAIR-2 Fc. [Figure 7F] Figure 7F is a reducing SDS-PAGE gel of LAIR-1 Fc and LAIR-2 Fc. [Figure 8] Figure 8A is a FACS histogram of Jurkat T cells stained with α-LAIR-1. Figure 8B is a FACS histogram of Jurkat T cells stained with LAIR-1 Fc. Figure 8C is a FACS histogram of Jurkat T cells stained with LAIR-2 Fc. Figure 8D is a FACS histogram of K562 Col17 cells stained with α-LAIR-1. Figure 8E is a FACS histogram of K562 Col17 cells stained with LAIR-1 Fc. Figure 8F is a FACS histogram of K562 Col17 cells stained with LAIR-2 Fc. Figure 8G is a FACS histogram of THP-1 AML cells stained with α-LAIR-1. Figure 8H is a FACS histogram of K562 Col17 cells stained with LAIR-1 Fc. Figure 8I is a FACS histogram of K562 Col17 cells stained with LAIR-2Fc. [Figure 9A] Figure 9A is a line graph of NF-kB-GFP+% versus anti-CD3 (μg / ml), LAIR-2 Fc (●), control Fc (■), and medium (▲). [Figure 9B] Figure 9B is a line graph of NFAT-Lucia (RLU) versus protein (µg / ml) for LAIR-2 Fc (●) and control Fc (■). [Figure 9C]Figure 9C is a bar graph of IL-2 (pg / ml) against 10 μg / ml protein for LAIR-2 Fc on the left and control Fc on the right. [Figure 9D] Figure 9D is a bar graph of TNF-α (pg / ml) against 10 μg / ml of protein, for LAIR-2 Fc on the left and control Fc on the right. [Figure 10] Figure 10A is a line graph of MFI versus protein (μg / ml) showing dose-dependent binding of LAIR-2 Fc (●) to THP-1 cells compared to control Fc (■). Figure 10B is a bar graph. Figure 10B is a bar graph of IRF (interferon regulatory factor) induction-RLU for THP-1 cells treated with 1 μg / ml LPS and LAIR-2 Fc (right bar of each pair) or control Fc (left bar of each pair). Figure 10C is a bar graph of IRF induction-RLU for THP-1 cells treated with RPMI medium and LAIR-2 Fc (right bar of each pair) or control Fc (left bar of each pair). [Figure 11] Figure 11A is a line graph of % T cell proliferation versus OKT3 (μg / ml) as measured by CFSE dilution cell population for CD4+ T cells treated with LAIR-2 Fc (●) or control Fc (▼). Figure 11B is a line graph of % T cell proliferation versus OKT3 (μg / ml) for CD8+ cells treated with LAIR-Fc (●) or control Fc (▼). [Figure 12-1]Figure 12A is a histogram of donor 1710 CD3+CD4+ T cells isolated from peripheral blood mononuclear cells (PBMCs) treated with LAIR-2 Fc. Figure 12B is a histogram of donor 1710 CD3+CD8+ T cells isolated from peripheral blood mononuclear cells (PBMCs) treated with LAIR-2 Fc. Figure 12C is a histogram of donor 1710 CD3-CD16+CD56+ NKC cells isolated from peripheral blood mononuclear cells (PBMCs) treated with LAIR-2 Fc. Figure 12D is a histogram of donor 1710 CD14+ monocytes isolated from peripheral blood mononuclear cells (PBMCs) treated with LAIR-2 Fc. Figure 12E is a histogram of donor 1711 CD3+CD4+ T cells isolated from peripheral blood mononuclear cells (PBMCs) treated with LAIR-2 Fc. Figure 12F is a histogram of donor 1711 CD3+CD8+ T cells isolated from peripheral blood mononuclear cells (PBMCs) treated with LAIR-2 Fc. Figure 12G is a histogram of donor 1711 CD3-CD16+CD56+ NKC cells isolated from peripheral blood mononuclear cells (PBMCs) treated with LAIR-2 Fc. Figure 12H is a histogram of donor 1711 CD14+ monocytes isolated from peripheral blood mononuclear cells (PBMCs) treated with LAIR-2 Fc. Figure 12I is a histogram of donor 1712 CD3+CD4+ T cells isolated from peripheral blood mononuclear cells (PBMCs) treated with LAIR-2 Fc. Figure 12J is a histogram of donor 1712 CD3+CD8+ T cells isolated from peripheral blood mononuclear cells (PBMCs) treated with LAIR-2 Fc. Figure 12CK is a histogram of donor 1712 CD3-CD16+CD56+ NKC cells isolated from peripheral blood mononuclear cells (PBMCs) treated with LAIR-2 Fc. Figure 12L is a histogram of donor 1712 CD14+ monocytes isolated from peripheral blood mononuclear cells (PBMCs) treated with LAIR-2 Fc. [Figure 12-2] See description of Figure 12-1. [Figure 13A]Figure 13B is a line graph of % OT-1 (donor) versus days of OT-1 engraftment for total CD8+ T cells for cells treated with LAIR-2 Fc (□) or control Fc (○). [Figure 13B] See legend to Figure 13A. [Figure 14] Figure 14A is a flow cytometry histogram showing pre-injection assessment of CFSE levels and ratios in mice loaded with CD45.1 splenocytes without ovalbumin (OVA) peptide. Figure 14B is a flow cytometry histogram showing pre-injection assessment of CFSE levels and ratios in mice loaded with OVA peptide-loaded (CFSE-high) CD45.1 splenocytes. Figure 14C is a flow cytometry histogram showing pre-injection assessment of CFSE levels and ratios in mice loaded with CD45.1 splenocytes without OVA peptide-loaded (CFSE-low) and with OVA peptide-loaded (CFSE-high) CD45.1 splenocytes. Figure 14D is a cytometry histogram showing 48 hours after splenocyte transfer, in which labeled cells in the spleen were assessed (screened for CD45.1+ cells) using a naive control (no OT-1) (host cells were CD45.2). Figure 14E shows cytometric histograms 48 hours after splenocyte transfer, assessing labeled cells (filtered by CD45.1+ cells) from spleens treated with OT-I control Fc (host cells are CD45.2). Figure 14F shows cytometric histograms 48 hours after splenocyte transfer, assessing labeled cells (filtered by CD45.1+ cells) from spleens treated with OT-I LAIR-2 Fc (host cells are CD45.2). Figure 14G shows bar graphs of % specific lysis calculated as % specific lysis = [1 - (non-OT-I control ratio) / observed ratio] x 100 for mice treated with OT-I Fc (left bar) and LAIR-2 Fc (right bar). [Figure 15A]Figure 15A is a diagram of the treatment model where 5e6ID8-OVA tumor cells were injected intraperitoneally (ip) on day 0. OT-I T cells were injected ip 3 weeks after tumor. Treatment with 200 μg of LAIR-2 Fc or control Fc was performed every 4 days, starting 1 day after T cell transfer, for a total of 5 doses. [Figure 15B] Figure 15B is a line graph of the weight gain rate (tumor burden) versus days after ID8.OVA inoculation: control (○), LAIR-2 Fc (●). [Figure 15C] Figure 15C is a line graph of percent survival versus days after ID8.OVA inoculation: control (dashed line), LAIR-2 Fc (solid line). [Figure 16] Figure 1 shows a line graph of survival versus days after ID8.OVA inoculation for mice injected with ID8-OVA tumors and treated with 200 μg of LAIR-2 Fc or control Fc every 4 days starting 1 day after T cell transfer for a total of 5 doses, or with the indicated treatment. The data demonstrate that LAIR-2 Fc with anti-PD-1 is an effective combination immunotherapy in ovarian cancer. (□) Cisplatin, (△) Cisplatin + LAIR-2 Fc, (○) Anti-PD-1 + LAIR-2 Fc, (▽) Anti-PD-1, (◇) LAIR-2 Fc, (hexagon) Control IgG. [Figure 17A] FIG. 17A is a diagram of an example lymphoma treatment regimen with LAIR-2 Fc. [Figure 17B] Figure 17B is a line graph of tumor volume versus days post tumor inoculation for mice treated with control Fc (○) or LAIR-2 Fc (□). [Figure 17C] FIG. 17C is a line graph of percent survival versus days post tumor inoculation for mice treated with control Fc (dashed line) or LAIR-2 Fc (solid line). [Figure 18] Bar graphs of percent positive binding of the indicated (monoclonal antibody) mAbs to the following cell lines from left to right in each group: HL-60 (LAIR-1+), MV-4-11 (LAIR-1+), transfected K562-LAIR-1, and U266B1 (negative control). [Figure 19] 1 is a bar graph of absorbance (450 nm) for the indicated mAbs, showing blocking or enhancing binding of LAIR-1 Fc to collagen I and III. For each mAb, collagen I is the left bar and collagen III is the right bar. [Figure 20] 1 is a bar graph of absorbance (450 nm) of the indicated mAbs for binding to C1q and SP-D. The left bar in each pair is C1q and the right bar is SP-D. [Figure 21] 1 is a table showing the results of an LAIR-1 chimeric mAb epitope binding assay. Single-underlined antibodies indicate non-blocking. Double-underlined antibodies indicate blocking. As can be observed when the same mAb is used as the first and second mAb (no underline, spotted background), mAbs binding to the same epitope will be blocked from binding to LAIR-1 Fc due to binding saturation. [Figure 22] Figure 1. LAIR-1 chimeric mAb binning map. This map shows that there is significant overlap of mAbs, while many occupy distinct sites on the LAIR-1 molecule. [Figure 23] 1 is a table showing optimized affinity evaluations for the indicated LAIR-1 mAbs performed using an Octet RED96 instrument (ForteBio). [Figure 24A] FIG. 24A is a bar graph of IRF induction-RLU for the indicated LAIR-1 mAbs, demonstrating the differential induction of interferon reporter activity in THP-1 cells upon coating of the mAbs on the plate. [Figure 24B] FIG. 24B is a bar graph of IRF induction-RLU for the indicated LAIR-1 mAbs, demonstrating the differential induction of interferon reporter activity in THP-1 cells when the mAbs are added as soluble proteins. [Figure 25A]Figure 25A is a bar graph of NFAT induction-RLU for the indicated mAbs, showing the induction of Jurkat T cell reporter activity when plates were coated with 0.5 μg / ml anti-CD3 (OKT3). After aspirating OKT3, plates were coated with 10 μg / ml LAIR-1 mAb or LAIR-2 Fc and control Fc for 24 hours. Unbound protein was aspirated before adding Jurkat T cell NFAT-Lucia pathway reporter cells (Invivogen). Jurkat T cells were seeded at 50,000 cells / well in a total volume of 200 μl. At 48 hours, 10 μl of supernatant was removed and transferred to a separate plate. Quanti-Luc (Invivogen) was added according to the protocol. Luminescence was assessed using a Perkin Elmer Envision plate reader. [Figure 25B] Figure 25B is a bar graph of NFAT induction-RLU for the indicated mAbs, showing the induction of Jurkat T cell reporter activity similar to that in Figure 25A when LAIR-1 mAb, LAIR-2 Fc and control Fc are added in soluble form. DETAILED DESCRIPTION OF THE INVENTION

[0042] Detailed Description of the Invention I. Definition As used herein, a molecule is said to be capable of "immunospecifically binding" to a second molecule if such binding exhibits the specificity and affinity of an antibody for its cognate antigen. An antibody is said to be capable of immunospecifically binding to a target region or conformation ("epitope") of an antigen if such binding involves an antigen recognition site on an immunoglobulin molecule. An antibody that immunospecifically binds to a particular antigen may bind other antigens with lower affinity if the other antigens share sequence or conformational similarity recognized by the antigen recognition site as determined, for example, by immunoassays, BIACORE® assays, or other assays known in the art, but will not bind completely unrelated antigens. However, in some embodiments, antibodies (and antigen-binding fragments thereof) do not cross-react with other antigens. Antibodies may also non-immunospecifically bind to other molecules, such as FcR receptors, via binding domains of other regions / domains of the molecule not involving the antigen recognition site, e.g., the Fc region.

[0043] As used herein, a molecule is said to "biospecifically bind" to a second molecule when such binding exhibits the specificity and affinity of a receptor for its cognate binding ligand. A molecule may be capable of biospecifically binding to more than one other molecule.

[0044] As used herein, the term "antibody" is intended to refer to an immunoglobulin molecule having a "variable region" antigen recognition site. The term "variable region" is intended to distinguish such domains of an immunoglobulin from domains common to most antibodies (e.g., antibody Fc domains). The variable region contains a "hypervariable region" whose residues are responsible for antigen binding. The hypervariable region comprises amino acid residues from the "complementarity determining regions" or "CDRs" (i.e., typically residues 24-34 (L1), 50-56 (L2), and 89-97 (L3) of the light-chain variable domain and residues 27-35 (H1), 50-65 (H2), and 95-102 (H3) of the heavy-chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)), and / or residues from the "hypervariable loops" (i.e., residues 26-32 (L1), 50-52 (L2), and 91-96 (L3) of the light-chain variable domain and residues 26-32 (H1), 53-55 (H2), and 96-101 (H3) of the heavy-chain variable domain; Chothia and Lesk, 1987, J. Mol. Biol. 196:901-917). "Framework Region" or "FR" residues are those variable domain residues other than the hypervariable region residues as herein defined.The term antibody includes monoclonal antibodies, polyspecific antibodies, human antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, camelized antibodies (see, e.g., Muyldermans et al., 2001, Trends Biochem. Sci. 26:230; Nuttall et al., 2000, Cur. Pharm. Biotech. 1:253; Reichmann and Muyldermans, 1999, J. Immunol. Meth. 231:25; International Publication Nos. WO 94 / 04678 and WO 94 / 25591; U.S. Pat. No. 6,005,079), single-chain Fvs (scFvs) (see, e.g., Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, 1999; and U.S. Pat. No. 6,005,079). New York, pp. 269-315 (1994)), single chain antibodies, disulfide-linked Fvs (sdFvs), intrabodies, and anti-idiotypic (anti-Id) antibodies (e.g., anti-Id antibodies and anti-anti-Id antibodies against antibodies). In particular, such antibodies include immunoglobulin molecules of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass.

[0045] As used herein, the term "antigen-binding fragment" of an antibody refers to one or more portions of an antibody that contain the antibody's complementarity-determining regions ("CDRs"), including the antibody's "variable region" antigen recognition site, and optionally framework residues, and that exhibit the ability to immunospecifically bind to an antigen. Such fragments include, for example, Fab', F(ab')2, Fv, single-chain (ScFv), and mutants and naturally occurring variants thereof, as well as fusion proteins comprising the antibody's "variable region" antigen recognition site and a heterologous protein (e.g., a toxin, an antigen recognition site for a different antigen, an enzyme, a receptor, or a receptor ligand, etc.).

[0046] As used herein, the term "fragment" refers to a peptide or polypeptide comprising an amino acid sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino acid residues, at least 70 contiguous amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino acid residues, at least 100 contiguous amino acid residues, at least 125 contiguous amino acid residues, at least 150 contiguous amino acid residues, at least 175 contiguous amino acid residues, at least 200 contiguous amino acid residues or at least 250 contiguous amino acid residues.

[0047] As used herein, the term "modulation" refers to the ability to alter an effect, outcome, or activity (e.g., signal transduction). Such modulation can be agonistic or antagonistic. Antagonistic modulation can be partial (i.e., attenuating but not eliminating) or can completely eliminate such activity (e.g., neutralizing). Modulation can include receptor internalization following antibody binding or reduced expression of the receptor on the target cell. Agonistic modulation can enhance or increase or potentiate an activity (e.g., signal transduction). In further embodiments, such modulation can alter the nature of the interaction between a ligand and its cognate receptor so as to change the nature of the signal transduction that is elicited. For example, a molecule, by binding to a ligand or receptor, can alter the ability of such molecules to bind to other ligands or receptors, thereby altering their overall activity. In some embodiments, such modulation will result in at least a 10% change in measurable immune system activity, at least a 50% change in such activity, or at least a 2-fold, 5-fold, 10-fold, or at least a 100-fold change in such activity.

[0048] The term "substantially," when used with respect to binding or an effect exerted, is intended to indicate that the effect observed is physiologically or therapeutically relevant. Thus, for example, a molecule can substantially block the activity of a ligand or receptor if the degree of blockage is physiologically or therapeutically relevant (e.g., if such degree is greater than 60% complete, greater than 70% complete, greater than 75% complete, greater than 80% complete, greater than 85% complete, greater than 90% complete, greater than 95% complete, or greater than 97% complete). Similarly, a molecule is said to have substantially the same immunospecificity and / or characteristics as another molecule if such immunospecificity and characteristics are greater than 60% identical, greater than 70% identical, greater than 75% identical, greater than 80% identical, greater than 85% identical, greater than 90% identical, greater than 95% identical, or greater than 97% identical.

[0049] As used herein, a "costimulatory" signal encompasses positive costimulatory signals (eg, signals that result in enhanced activity) and negative costimulatory signals (eg, signals that result in suppressed activity).

[0050] The term "derivative" refers to an antibody or antigen-binding fragment thereof that immunospecifically binds to the same target as that of a parent or reference antibody, but differs in amino acid sequence from the parent or reference antibody or antigen-binding fragment thereof by containing one, two, three, four, five, or more amino acid substitutions, additions, deletions, or modifications relative to the parent or reference antibody or antigen-binding fragment thereof. In some embodiments, such a derivative will have substantially the same immunospecificity and / or characteristics as the parent or reference antibody or antigen-binding fragment thereof, or the same immunospecificity and characteristics. The amino acid substitutions or additions of such derivatives may include naturally occurring (i.e., encoded by DNA) or non-naturally occurring amino acid residues. The term "derivative" encompasses, for example, chimeric or humanized variants, and variants with altered CH1, hinge, CH2, CH3, or CH4 regions to form, for example, antibodies with variant Fc regions that exhibit enhanced or attenuated effector or binding characteristics.

[0051] As used herein, a "chimeric antibody" is a molecule in which different portions of the antibody are derived from different immunoglobulin molecules, such as antibodies having a variable region derived from a non-human antibody and a human immunoglobulin constant region.

[0052] As used herein, the term "humanized antibody" refers to an immunoglobulin comprising a human framework region and one or more CDRs from a non-human (usually mouse or rat) immunoglobulin. The non-human immunoglobulin providing the CDRs is referred to as the "donor," and the human immunoglobulin providing the framework is referred to as the "acceptor." Constant regions need not be present, but if present, should be substantially identical to human immunoglobulin constant regions, i.e., at least about 85-99% or about 95% or more identical. Thus, all portions of a humanized immunoglobulin, except possibly for the CDRs, are substantially identical to corresponding portions of native human immunoglobulin sequences. A humanized antibody is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. For example, humanized antibodies do not encompass typical chimeric antibodies, because, for example, the entire variable region of a chimeric antibody is non-human.

[0053] The term "endogenous concentration" refers to the level at which a molecule is naturally expressed (i.e., in the absence of an expression vector or recombinant promoter) by a cell (which may be a normal cell, a cancer cell, or an infected cell).

[0054] As used herein, the terms "treat," "treating," "treatment," and "therapeutic use" refer to the elimination, reduction, or amelioration of one or more symptoms of a disease or disorder. As used herein, a "therapeutically effective amount" refers to an amount of a therapeutic agent sufficient to mediate a clinically meaningful elimination, reduction, or amelioration of such symptoms. An effect is clinically meaningful if its magnitude is sufficient to affect the health or prognosis of the recipient subject. A therapeutically effective amount may refer to an amount of a therapeutic agent sufficient to delay or minimize the onset of a disease, for example, to delay or minimize the spread of cancer. A therapeutically effective amount may also refer to the amount of a therapeutic agent that provides a therapeutic benefit in the treatment or management of a disease.

[0055] As used herein, the term "prophylactic agent" refers to an agent that can be used to prevent a disorder or disease prior to the detection of any symptoms of such disorder or disease. A "prophylactically effective" amount is the amount of a prophylactic agent sufficient to mediate such protection. A prophylactically effective amount can also refer to the amount of a prophylactic agent that provides a prophylactic benefit in the prevention of disease.

[0056] As used herein, the term "cancer" refers to a neoplasm or tumor that results from the uncontrolled, abnormal growth of cells. As used herein, cancer explicitly includes leukemia and lymphoma. The term "cancer" refers to a disease involving cells that have the potential to metastasize to distant sites and that exhibit phenotypic traits distinct from non-cancerous cells, such as colony formation in a three-dimensional substrate such as soft agar or the formation of tubular networks or web-like matrices in three-dimensional basement membranes or extracellular matrix preparations. Non-cancerous cells do not form colonies in soft agar, but form distinct sphere-like structures in three-dimensional basement membranes or extracellular matrix preparations.

[0057] As used herein, "immune cells" refers to any cell derived from the blood, including but not limited to T cells, B cells, monocytes, dendritic cells, and macrophages.

[0058] As used herein, "inflammatory molecules" refers to molecules that produce an inflammatory response, including but not limited to cytokines and metalloproteases, such as, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-18, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs.

[0059] As used herein, "valency" refers to the number of available binding sites per molecule.

[0060] As used herein, the terms "immunologic," "immunological," or "immune" response refer to the development of a beneficial humoral (antibody-mediated) and / or cellular (mediated by antigen-specific T cells or their secretory products) response directed against a peptide in a recipient patient. Such a response can be an active response elicited by administration of an immunogen, or a passive response elicited by administration of antibodies or primed T cells. Cellular immune responses are elicited by the presentation of polypeptide epitopes in association with class I or class II MHC molecules and result in the activation of antigen-specific CD4 + T helper cells and / or CD8 + Activates cytotoxic T cells. The response may also involve activation of monocytes, macrophages, NK cells, basophils, dendritic cells, astrocytes, microglial cells, eosinophils, activation or recruitment of neutrophils or other components of innate immunity. The presence of a cell-mediated immunological response can be determined by proliferation assays (CD4 + The relative contribution of humoral and cellular responses to the protective or therapeutic efficacy of an immunogen can be determined by separately isolating antibodies and T cells from an immunized syngeneic animal and measuring the protective or therapeutic efficacy in a second subject.

[0061] An "immunogenic substance" or "immunogen" is capable of eliciting an immunological response against itself when administered to a mammal, optionally in conjunction with an adjuvant.

[0062] As used herein, the terms "individual," "host," "subject," and "patient" are used interchangeably herein and refer to mammals, including but not limited to humans, rodents, e.g., mice and rats, and other laboratory animals.

[0063] As used herein, the term "polypeptide" refers to a chain of amino acids of any length, regardless of modification (e.g., phosphorylation or glycosylation). The term polypeptide includes proteins and fragments thereof. A polypeptide can be "exogenous" in the sense that it is "heterologous," i.e., foreign to the host cell being utilized, e.g., a human polypeptide produced by a bacterial cell. Polypeptides are disclosed herein as amino acid residue sequences. The sequences are written from left to right, from the amino terminus to the carboxy terminus. According to standard nomenclature, amino acid residue sequences are designated by either a three-letter or one-letter code as follows: alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine ​​(Cys, C), glutamine (Gln, Q), glutamic acid (Glu, E), glycine (Gly, G), histidine (His, H), isoleucine (Ile, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), and valine (Val, V).

[0064] As used herein, the term "variant" refers to a polypeptide or polynucleotide that differs from a reference polypeptide or polynucleotide, but retains essential properties. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Differences are generally limited so that the sequences of the reference and variant are similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more modifications (e.g., substitutions, additions, and / or deletions). A substituted or inserted amino acid residue may or may not be encoded by the genetic code. A polypeptide variant may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally.

[0065] Modifications and changes can be made to the structure of the polypeptides of the present disclosure and still obtain a molecule with similar properties to the polypeptide (e.g., conservative amino acid substitutions). For example, certain amino acids in the sequence can be substituted with other amino acids without appreciable loss of activity. Because the biological functional activity of a polypeptide is determined by the polypeptide's ability and properties to interact, certain amino acid sequence substitutions can be made in the polypeptide sequence and still obtain a polypeptide with similar properties.

[0066] The hydropathic index of an amino acid may be considered when making such changes. The importance of the hydropathic amino acid index in conferring interactive biological function on a polypeptide is generally understood in the art. It is known that certain amino acids can be substituted with other amino acids having similar hydropathic indices or scores and still obtain polypeptides with similar biological activity. Each amino acid is assigned a hydropathic index based on its hydrophobicity and charge characteristics. These indices are: isoleucine (+4.5), valine (+4.2), leucine (+3.8), phenylalanine (+2.8), cysteine / cystine (+2.5), methionine (+1.9), alanine (+1.8), glycine (-0.4), threonine (-0.7), serine (-0.8), tryptophan (-0.9), tyrosine (-1.3), proline (-1.6), histidine (-3.2), glutamate (-3.5), glutamine (-3.5), aspartate (-3.5), asparagine (-3.5), lysine (-3.9), and arginine (-4.5).

[0067] The relative hydrophobicity of amino acids is believed to determine the secondary structure of a resulting polypeptide, which in turn determines the interaction of the polypeptide with other molecules, such as enzymes, substrates, receptors, antibodies, antigens, and cofactors. It is known in the art that amino acids can be substituted with amino acids having a similar hydrophobicity index and still obtain a functionally equivalent polypeptide. Among such changes, substitution of amino acids with hydrophobicity indices within ±2 is preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred.

[0068] Substitutions of similar amino acids can also be made on the basis of hydrophilicity, particularly when the resulting biologically functional equivalent polypeptide or peptide is for use in immunological embodiments. The following hydrophilicity values ​​have been assigned to amino acid residues: arginine (+3.0), lysine (+3.0), aspartate (+3.0±1), glutamate (+0.3±1), serine (+0.3), asparagine (+0.2), glutamine (+0.2), glycine (0), proline (-0.5±1), threonine (-0.4), alanine (-0.5), histidine (-0.5), cysteine ​​(-1.0), methionine (-1.3), valine (-1.5), leucine (-1.8), isoleucine (-1.8), tyrosine (-2.3), phenylalanine (-2.5), tryptophan (-3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, particularly an immunologically equivalent, polypeptide. In such changes, substitution of amino acids whose hydrophilicity values ​​are within ±2 are preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred.

[0069] As outlined above, amino acid substitutions are typically based on the relative similarity of the amino acid side-chain substituents, e.g., their hydrophobicity, hydrophilicity, charge, size, etc. Exemplary substitutions taking into consideration various of the above characteristics are well known to those of skill in the art and include (original residue: exemplary substitution): (Ala:Gly, Ser), (Arg:Lys), (Asn:Gln, His), (Asp:Glu, Cys, Ser), (Gln:Asn), (Glu:Asp), (Gly:Ala), (His:Asn, Gln), (Ile:Leu, Val), (Leu:Ile, Val), (Lys:Arg), (Met:Leu, Tyr), (Ser:Thr), (Thr:Ser), (Tip:Tyr), (Tyr:Trp, Phe), and (Val:Ile, Leu). Thus, in embodiments of the present disclosure, functional or biological equivalents of the polypeptides as set forth above are contemplated. Specifically, embodiments of the polypeptide may include variants that have about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the polypeptide of interest.

[0070] The term "percent sequence identity (%)" is defined as the percentage of nucleotides or amino acids in a candidate sequence that are identical to the nucleotides or amino acids in a reference nucleic acid sequence, after aligning the sequences, optionally introducing gaps, to obtain the maximum percent sequence identity. Alignment for determining percent sequence identity can be accomplished in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Suitable parameters for measuring alignment can be determined by known methods, including any algorithms required to achieve maximum alignment across the entire length of the sequences being compared.

[0071] For purposes herein, the % sequence identity of a given nucleotide or amino acid sequence C to, with, or compared to a given nucleic acid sequence D (alternatively, this can be expressed as a given sequence C having or containing a particular % sequence identity to, with, or compared to a given sequence D) is calculated as follows: Multiply the fraction W / Z by 100 (Where W is the number of nucleotides or amino acids that a sequence alignment program will evaluate as an identical match in its alignment of C and D, and Z is the total number of nucleotides or amino acids in D.) It will be understood that if the length of sequence C is not the same as the length of sequence D, then the % sequence identity of C to D will not equal the % sequence identity of D to C.

[0072] As used herein, the term "pharmaceutically acceptable carrier" includes any of the standard pharmaceutical carriers, such as phosphate buffered saline, water and emulsions, such as oil-in-water or water-in-oil emulsions, and various types of wetting agents.

[0073] II. Composition LAIR-binding moieties useful for modulating signaling through LAIR proteins are provided. Figure 4 shows LAIR regulation of immune function and homeostasis. Figure 5 shows how LAIR-1 mAb and LAIR-2 Fc can be used as therapeutic agents.

[0074] A. LAIR Polypeptides Disclosed are LAIR-1 and LAIR-2 polypeptides, which may comprise the amino acid sequence of a full-length LAIR-1 or LAIR-2 protein, or a fragment or variant thereof, or a fusion protein thereof.

[0075] LAIR-1 is an inhibitory cell surface receptor expressed on many immune cells and mediates inhibitory signaling via two cytoplasmic immunoreceptor tyrosine-dependent inhibitory motifs (ITIMs) (Verbrugge et al., 2006) (Figure 4). The human and nonhuman primate genomes, but not mice, encode the LAIR-2 gene, a soluble homolog of LAIR-1 (Sun et al., 2014). LAIR-2 lacks transmembrane and cytoplasmic domains but binds the same ligands as LAIR-1 and may therefore function as a decoy to reduce LAIR-1-mediated inhibitory signaling (Meyaard, 2008). LAIR-1 and LAIR-2 interact with a variety of collagens, including fibrillar collagens I and III and transmembrane collagens 13, 17, and 23, but can also bind to various other collagens to varying degrees due to recognition of the canonical Gly-Pro-Hyp hydroxyproline repeat (Meyaard, 2008). LAIR-1 and LAIR-2 also bind to complement component C1q, surfactant protein D (SP-D), and mannose-binding lectin (MBL). Cross-linking of these molecules with LAIR-1 on the leukocyte plasma membrane induces negative signaling that suppresses immune cell maturation, proliferation, and degranulation (Lebbink et al., (2009), Meyaard et al., (2008)).

[0076] Inhibitory signaling by LAIR-1 can prevent autoimmune diseases such as lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, and atherosclerosis, as well as contact hypersensitivity (Sun et al., 2014). On the other hand, overexpression of LAIR-2 can promote autoimmunity through decoy binding of LAIR-1 ligands. LAIR-2 binding to LAIR-1 ligands can essentially reduce cell surface cross-linking of LAIR-1, limiting the inhibitory signaling pathways that lead to overreactive immune function. Conversely, it has been hypothesized that increased levels of LAIR-2 can promote antitumor immunity by the same mechanism.

[0077] Decreased LAIR-1 expression on chronic lymphocytic leukemia (CLL) cells is associated with disease progression (Poggi et al., 2008; Perbellini et al., 2014). Conversely, studies suggest that increased LAIR-1 expression in acute myeloid leukemia (AML) promotes AML survival by maintaining a stem cell-like state and preventing differentiation and apoptosis (Kang et al., 2015). Supporting this view, other studies have also shown increased LAIR-1 expression in AML and acute lymphoblastic leukemia (ALL) cancers (Mirkowska et al., Blood, 2013; Chen et al., Nature, 2015; Zhang et al., review in life.sciechina.com, 2015). LAIR-1 has also been shown to be expressed on epithelial ovarian cancer cells and other human tumors, although the function of LAIR-1 expressed on solid tumors remains unclear ( Meyaard et al., 1997 , Cao et al., 2015 ).

[0078] The tumor microenvironment is often rich in extracellular matrix proteins (ECM), including collagen (Rygiel et al., 2011). Therefore, LAIR-1-expressing cells localized in the tumor microenvironment can be significantly suppressed by Lair-1 collagen cross-linking and subsequent inhibitory signaling. Interestingly, both collagen and C1q have been shown to limit or alter LAIR-1-mediated differentiation and activation of antigen-presenting cells (monocytes / macrophages / DCs). Studies have shown that Lair-1 cross-linking can suppress the proliferation and function of NK cells and their T cells. However, the role of LAIR-1 in regulating antitumor immunity requires further investigation.

[0079] Taken together, the accumulated data on LAIR-1 suggest an important role in immune regulation. However, the differential expression of LAIR-1 on mouse and human cells and the presence of LAIR-2 in humans but not in mice suggest that mouse studies may not represent the function of LAIR-1 / LAIR-2 in humans. On the other hand, it is hypothesized that the human system may be more easily employed therapeutically due to the presence of LAIR-2. In other words, LAIR-2 could be therapeutically utilized to regulate LAIR-1 function in humans, which is not possible in the mouse system. Therefore, LAIR-2 Fc decoy proteins or blocking (antagonist) LAIR-1 mAbs may be effective in cancer immunotherapy, enhancing immune function by preventing signaling through cell surface LAIR-1 (Figure 5). Conversely, agonistic LAIR-1 mAbs, or blockade of LAIR-2 by mAbs, could be used to treat autoimmune diseases, as they would essentially increase LAIR-1-mediated signaling and therefore downregulate the immune response.

[0080] 1. LAIR-1 The sequence of LAIR-1 is provided. In some embodiments, the initial methionine amino acid is cleaved off in the post-translational form of the protein.

[0081] a. Human LAIR-1 The sequence of human LAIR-1 is known in the art. For example, the consensus sequence for LAIR-1a (isoform 1) is: TIFF0007595113000001.tif24128 (SEQ ID NO:1, UniProtKB-Q6GTX8(LAIR1_HUMAN)), in which amino acids 1-21 are the signal sequence, amino acids 22-165 (underlined) are the extracellular domain, amino acids 166-186 are the transmembrane domain, and amino acids 187-287 are the cytoplasmic domain. Amino acids 29-117 form the Ig-like C2 domain. Amino acids 249-254 and 279-284 form ITIM motifs 1 and 2, respectively. LAIR-1b (also known as isoform 2) lacks amino acids 122-138 compared to SEQ ID NO:1. LAIR-1c (also known as isoform 3) lacks amino acids 23-23 and 122-138 compared to SEQ ID NO:1. LAIR-1d (also known as isoform 4) is missing amino acids 210-287 compared to SEQ ID NO:1.

[0082] As presented above, the extracellular domain of human LAIR-1 is TIFF0007595113000002.tif13136 (SEQ ID NO:2) or a fragment thereof, such as the Ig-like C2 domain (amino acids 8-96 underlined in SEQ ID NO:2), or the region formed by cysteines forming a disulfide bond between amino acids 49-101 of SEQ ID NO:1 (amino acids 28-80 of SEQ ID NO:2, shown in italics).

[0083] Known variants and mutations of LAIR-1 include E63D, Y251F, and Y251F compared to SEQ ID NO: 1. Evidence indicates that Y215F reduces tyrosine phosphorylation and loses binding to PTPN6 and CSK, as well as complete loss of inhibitory activity, and in the case of F-281, loss of phosphorylation and calcium mobilization inhibition (Xu, et al., J. Biol. Chem. 275:17440-17446 (2000); Verbrugge, et al., Int. Immunol., 15:1349-1358 (2003); Verbrugge, et al., Eur. J. Immunol., 36:190-198 (2006)). Y281F exhibits reduced tyrosine phosphorylation, loss of binding to PTPN6, and partial inhibition of cytotoxic activity.

[0084] Meyaard, 2008, J. Leukoc. Biol. 83:799-803, suggests that LAIR-1 is widely expressed on human immune cells. Examination of actual flow cytometry expression data from research studies indicates that LAIR-1 is much more highly expressed in myeloid lineage cells, such as monocytes, macrophages, and dendritic cells, than in T cells and NK cells (Meyaard et al., 1997, Immunity 7:283-290). However, B cells differentially express high levels of LAIR-1 during differentiation (van der Vuurst de Vries et al., 1999, Eur. J. Immunol. 29:3160-3167). LAIR-1 has also been found to be expressed on acute myeloid leukemia cells, acute lymphoblastic leukemia cells, and chronic lymphocytic leukemia cells (van der Vuurst de Vries et al., 1999, Eur. J. Immunol. 29:3160-3167; Poggi et al., 2000, Eur. J. Immunol. 30:2751-2758; Zocchi et al., 2001, Eur. J. Immunol. 31:3667-3675; Perbellini et al., 2014, Haematologica, 99:881-887; (Kang et al., 2015, Nat. Cell Biol. 17:665-677). Finally, LAIR-1 has been shown to be expressed in several human tumor cell lines (Meyaard et al. al.,1997,Immunity 7:283-290, Cao et al.,2015,Biochem.Biophys,Res.Commun.458:399-404, (Kang et al.,2015,Nat.Cell Biol.17:665-677).

[0085] In humans and mice, LAIR-1 binds with high affinity to several types of collagen (Meyaard, 2008, J. Leukoc. Biol. 83:799-803, and Meyaard, 2010, Immunol. Lett. 128:26-28). Furthermore, in humans, LAIR-1 has been shown to bind to the complement component C1q (Son et al., 2012, Proc. Natl. Acad. Sci. USA 109:E3160-3167) and to the collagen-like C-type lectin, surfactant protein D (SP-D), a collagen-like carbohydrate-binding glycoprotein (collectin) that plays an important role in the pulmonary innate immune response to bacterial and antigenic challenge (Olde Nordkamp et al., 2014, J. Leukoc. Biol. 96:105-111). The ability of mouse LAIR-1 to bind C1q and SP-D has not been examined.

[0086] Systemic lupus erythematosus (SLE) is a classic autoimmune disease characterized by a loss of immune tolerance. The immunosuppressive role of C1q is supported by the high incidence of SLE in C1q-deficient individuals. Dr. Son and her Feinstein Institute collaborators, Dr. Betty Diamond, Dr. Frances Santiago-Schwarz, and Dr. Yousef Al-Abed, have shown that C1q is a functional ligand for LAIR-1, a universal collagen receptor. They further demonstrated that C1q promotes tolerance by suppressing monocyte-to-DC differentiation and pDC activation through engagement of LAIR-1 (Son and Diamond, Mol. Med., 2015, 20:559-568; Son et al., PNAS, 109(46):E3160-3167). This discovery has a major impact on the lupus field, as it sheds light on the mechanism by which the complement system regulates tolerance to prevent autoimmune diseases such as lupus.

[0087] All collagens consist of three polypeptide chains characterized by a repeating sequence of Gly-X-X', where X is often proline and X' is frequently 4-R-hydroxyproline (Hyp,O) (Brondijk, Blood, 115(7):1364-1373 (2010)). This GPO triad is an almost exclusive feature of collagen and allows the formation of the characteristic triple-helical collagen structure.

[0088] The ectodomains of the known immunoglobulin superfamily collagen receptors, LAIR-1, GPVI, and OSCAR, consist of one or two immunoglobulin-like domains. GPVI and LAIR-1 are functionally distinct, but they have similar collagen-binding properties. However, as discussed in Zhou, et al., Blood, 127(5):529-537 (2016), the three proteins have very different collagen recognition sites despite their structural homology. GPVI binds to the glycine-proline-hydroxyproline (GPO)-rich region of collagen III (GPO). 10 LAIR-1 binds most strongly to model collagen-related peptides with the sequence of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122,

[0089] Mutagenesis and nuclear magnetic resonance titration studies suggested that a segment of residues in the membrane-distal region of LAIR-1 contacts a triple-helical peptide (THP) model located in a groove consisting of the C, C9, F, and FG loops (Brondijk, Blood, 115(7):1364-1373 (2010), specifically incorporated by reference in its entirety). For example, adhesion to immobilized collagens I, III, and IV was significantly reduced in the R59A, E61A, R65A, and E111A mutants, although the magnitude of the effect depended on the type of collagen tested. Furthermore, the R62A and N69A mutants exhibited somewhat reduced adhesion, and they exhibited collagen binding properties similar to those of wild-type mutants in flow cytometry assays. Brondijk et al. reported that LAIR-1 residues E61, S66, Y68, I102, W109, and Y115 provide van der Waals interactions, whereas hydrogen bonds with ligands often involve LAIR-1 residues R59, E63, R100, E111, and Q112. They concluded that R59, E61, and even W109 constitute the core of the collagen-binding site, while more outer residues such as E111 contribute less to binding (residues, for example, related to SEQ ID NO:1).

[0090] b. Mouse LAIR-1 The sequence of mouse LAIR-1 (mLAIR-1) is known in the art. For example, the consensus sequence of mLAIR-1a (isoform 1) is: TIFF0007595113000003.tif24128 (SEQ ID NO:3, UniProtKB-Q8BG84(LAIRl_MOUSE)), in which amino acids 1-21 are the signal sequence, amino acids 22-144 (underlined) are the extracellular domain, amino acids 145-165 are the transmembrane domain, and amino acids 166-263 are the cytoplasmic domain. Amino acids 27-115 form the Ig-like C2 domain. Amino acids 226-231 and 255-260 form ITIM motifs 1 and 2, respectively. mLAIR-1b (also known as isoform 2) lacks amino acids 124-133 compared to SEQ ID NO:3. Isoform 3 lacks amino acids 25-56 [of SEQ ID NO:3] compared to SEQ ID NO:3. TIFF0007595113000004.tif3128(SEQ ID NO:7)] It is replaced by TIFF0007595113000005.tif2128 (SEQ ID NO:8), which is missing amino acids 57-263. mLAIR-1d (also known as isoform 5) is missing amino acids 24-172 compared to SEQ ID NO:3. mLAIR-1e (also known as isoform 6) is missing amino acids 134-172.

[0091] As presented above, the extracellular domain of mouse LAIR-1 is TIFF0007595113000006.tif9136 (SEQ ID NO:4) or a fragment thereof, such as the Ig-like C2 domain (amino acids 6-94 underlined in SEQ ID NO:4), or the region formed by the cysteines that form a disulfide bond between amino acids 49-99 of SEQ ID NO:3 (amino acids 28-78 of SEQ ID NO:4, shown in italics). An example alignment of the human and mouse extracellular domains is shown below. TIFF0007595113000007.tif33134Query1 is SEQ ID NO:2 and Sbjct is SEQ ID NO:4.

[0092] Known variants and mutations of LAIR-1 include IYI→MYM, V149G, L154P, and H263R at amino acid positions 143-145 relative to SEQ ID NO:3.

[0093] Meyaard (2008, J. Leukoc. Biol. 83:799-803) suggested that LAIR-1 is widely expressed on mouse immune cells, with one major difference being that LAIR-1 appears negative on B cells, in contrast to its high expression in a subset of human B cells. Examination of actual flow cytometry data for LAIR-1 expression in relation to human expression patterns again reveals that LAIR-1 is highly expressed on monocytes, macrophages, and DCs, whereas T cells, NK cells, and Gr-1+ cells express LAIR-1 at relatively lower levels (Lebbink et al., 2007 Int. Immunol. 19:1011-1019; Tang et al., 2012, J. Immunol. 188:548-558).

[0094] Tang et al. (2012, J. Immunol. 188:548-558) investigated the phenotype of LAIR-1-deficient mice. KO mice were healthy and fertile and exhibited signs of altered immune function, but lacked the severe autoimmunity or inflammation observed in CTLA-4 KO mice. LAIR-1 KO mice exhibited increased numbers of dendritic cells, splenic B cells, and regulatory T cells, as well as higher frequencies of activated and memory T cells, suggesting enhanced T cell reactivity. However, there were no differences between LAIR-1 wt and KO mice in EAE and colitis disease models. These disease models may not have been optimal for examining the LAIR-1 KO phenotype, and functional studies of LAIR-1-deficient immune cell subsets in vitro have not been performed. It is also speculated that LAIR-1 KO mice may not represent the role of LAIR-1 in humans due to the differential expression and presence of soluble LAIR-2 in humans. Differences in the genetic pathway of LAIR-1 in the visceral organs between mice and humans are discussed in Sun, et al., Gene, 552:14-145 (2014) and may provide an explanation when designing and evaluating experiments using mouse models.

[0095] 2. LAIR-2 The sequences of LAIR-2 and its fusion proteins are provided. In some embodiments, the initial methionine amino acid is cleaved in the post-translational form of the protein.

[0096] The sequence of human LAIR-2 is known in the art. For example, the consensus sequence for LAIR-2a (isoform 1) is: TIFF0007595113000008.tif14128 (SEQ ID NO:5, UniProtKB-Q6ISS4(LAR2_HUMAN)), where amino acids 1-21 are the signal sequence and amino acids 22-152 (underlined) are the leukocyte-associated immunoglobulin-like receptor 2 domain. Amino acids 29-117 form the Ig-like C2 domain. LAIR-2b (also known as isoform 2) lacks amino acids 122-138 compared to SEQ ID NO:5.

[0097] As presented above, the leukocyte-associated immunoglobulin-like receptor 2 domain of human LAIR-2 is TIFF0007595113000009.tif13128 (SEQ ID NO:6) or a fragment thereof, such as the Ig-like C2 domain (amino acids 8-96 underlined in SEQ ID NO:6), or the region formed by cysteines forming a disulfide bond between amino acids 49-101 of SEQ ID NO:1 (amino acids 28-80 of SEQ ID NO:6, shown in italics).

[0098] Known variants and mutations of LAIR-2 include G78S, H87R and F115Y compared to SEQ ID NO:5.

[0099] In humans, LAIR-2 has been shown to bind to collagen and SP-D with higher affinity than LAIR-1 (Meyaard, 2008, J. Leukoc. Biol. 83:799-803). Dr. Linde Meyaard showed that LAIR-2 also binds to C1q and mannose-binding lectin (MBL), both of which contain collagen-like domains (Olde Nordkamp et al., J. Innate Immun., 2014, 6(3):284-92). This finding supports evidence by Son et al. that LAIR-2 binds to C1q (Son et al., 2012, Proc. Natl. Acad. Sci. USA 109:E3160-3167). While collagen and C1q are ubiquitously expressed, SP-D is primarily restricted to mucosal surfaces (alveolar surfaces and the gastrointestinal tract), where it functions as a first line of natural defense against pathogens (Herias et al., 2007, Mol. Immunol. 44:3324-3332).

[0100] An example of an alignment of the extracellular domains of human LAIR-1 and human LAIR-2 is shown below. TIFF0007595113000010.tif29132Query is SEQ ID NO:2 and Sbjct is SEQ ID NO:6.

[0101] B. Immunomodulatory agents Immunomodulatory agents are provided, including agonists and antagonists of LAIR-1 and antagonists of LAIR-2. Agonists of LAIR-1 typically induce, enhance, or activate negative signaling by LAIR-1. Antagonists of LAIR-1 typically prevent, reduce, or block negative signaling by LAIR-1. Antagonists of LAIR-2 typically reduce or block the ability of LAIR-2 to bind to its ligand, including the common ligand of LAIR-1 and LAIR-2. The compositions and methods can be used to modulate negative signaling by LAIR-1 in myeloid cells, including, for example, antigen-presenting cells (e.g., monocytes, macrophages, or dendritic cells), T cells, natural killer (NK) cells, or combinations thereof. In some embodiments, the compositions are specifically directed to one or more cell types. Exemplary molecules that can be agonists or antagonists of LAIR-1 and antagonists of LAIR-2 are described in more detail below.

[0102] In some embodiments, LAIR-1 antagonists, including anti-LAIR-1 function-blocking antibodies, bind to or interfere with the collagen-binding domain, C1q-binding domain, SP-D-binding domain, or a combination thereof of LAIR-1. For example, in some embodiments, the LAIR-1 antagonist binds to, blocks, creates a conformational change in, or interferes with residues R59, E61, R62, E63, R65, S66, Y68, N69, I102, R100, W109, E111, Q112, and Y115 of LAIR-1, or any combination of any of the above. In some embodiments, the LAIR-1 function-blocking antibody or functional fragment thereof specifically binds to an epitope comprising one or more of R59, E61, R62, E63, R65, S66, Y68, N69, I102, R100, W109, E111, Q112 and Y115 (e.g., with respect to SEQ ID NO:1). In some embodiments, the immunomodulatory agent does not interfere with OSCAR binding or activity, GPVI binding or activity, or a combination thereof.

[0103] 1. Antibodies The immunomodulatory agent may be an antibody. Suitable antibodies are known in the art or can be generated by one skilled in the art. The nucleic acid and polypeptide sequences of LAIR-1 and LAIR-2 are known in the art, and exemplary protein sequences are provided above. As described in more detail below, the sequences can be used by one skilled in the art to generate antibodies or antigen-binding fragments thereof that are specific for LAIR-1 or LAIR-2. Thus, the antibodies or antigen-binding fragments may be agonists or antagonists of LAIR-1 or LAIR-2.

[0104] The activity of an antibody or antigen-binding fragment thereof (i.e., agonist or antagonist) specific for LAIR-1 or LAIR-2 can be determined using functional assays known in the art, including those described below. Typically, the assay involves determining whether the antibody or antigen-binding fragment thereof increases (i.e., is an agonist) or decreases (i.e., is an antagonist) signaling through LAIR-1. In some embodiments, the assay involves determining whether the antibody or antigen-binding fragment thereof decreases (i.e., is an agonist) or enhances (i.e., is an antagonist) an immune response that is negatively regulated by LAIR-1.

[0105] In some embodiments, the disclosed antibodies and antigen-binding fragments thereof immunospecifically bind to LAIR-1 or LAIR-2 (e.g., any one of SEQ ID NOs: 1-6). In some embodiments, the antibodies bind to the extracellular domain of LAIR-1 or LAIR-2.

[0106] For example, the following molecules capable of immunospecifically binding to LAIR-1 are provided: (I) Lined on the surface of cells (especially living cells), (II) They line the surface of cells (especially living cells) at endogenous concentrations. (III) They line the surface of living cells and regulate the binding of LAIR-1 to its ligands. (IV) They line the surface of living cells and attenuate or inhibit LAIR-1-mediated immunosuppression. (V) line the surface of live cells and induce or enhance LAIR-1-mediated immunosuppression; (VI) lining the surface of living cells, the cells being myeloid cells, including antigen-presenting cells (e.g., monocytes, macrophages, or dendritic cells), T cells, natural killer (NK) cells, or combinations thereof; (VII) A combination of I to IV and VI; (VIII) A combination of I to III and V to IV, and (IX) They line the surface of live cancer cells (AML or ALL) of bone marrow or lymphoid origin, enhancing apoptosis and differentiation and reducing the self-renewal of cancer stem cells.

[0107] Additionally, molecules capable of immunospecifically binding to soluble endogenous LAIR-2 are provided. In some embodiments, the molecules reduce or prevent LAIR-2 from binding to or interacting with its ligand.

[0108] In some embodiments, the molecule is capable of inducing cell apoptosis of LAIR-1 expressing cells by antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or other mechanisms.

[0109] To generate antibodies or antigen-binding fragments thereof that specifically bind to LAIR-1 or LAIR-2, purified proteins, polypeptides, fragments, fusions, or epitopes to LAIR-1 or LAIR-2, or polypeptides expressed from their nucleic acid sequences, can be used. Antibodies or antigen-binding fragments thereof can be generated using any suitable method known in the art, as described in more detail below.

[0110] a. Human and humanized antibodies Many non-human antibodies (e.g., those derived from mice, rats, or rabbits) are naturally antigenic in humans and therefore may provoke an unwanted immune response when administered to humans. Therefore, the use of human or humanized antibodies in the methods helps to reduce the likelihood that antibodies administered to humans will provoke an unwanted immune response.

[0111] Transgenic animals (e.g., mice) can be employed that are capable, upon immunization, of producing the full range of human antibody repertoires in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (J(H)) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array into such germ-line mutant mice will result in the production of human antibodies upon antigen challenge.

[0112] Optionally, antibodies are generated in other species and "humanized" for administration to humans. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding sequences of antibodies) that contain minimal sequence derived from the non-human immunoglobulin. Humanized antibodies comprise a human immunoglobulin (recipient antibody) in which residues from a complementarity-determining region (CDR) of the recipient antibody are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some cases, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also contain residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. Generally, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. Optionally, the humanized antibody will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.

[0113] Methods for humanizing non-human antibodies are well known in the art. See, for example, Jones, PT, et al. (1986). Replacing the complementarity determining regions in a human antibody with those from a mouse. Nature 321, 522-525. Generally, humanized antibodies have one or more amino acid residues introduced from a non-human source. These non-human amino acid residues are often referred to as "import" residues, which typically come from an "import" variable domain. Antibody humanization techniques typically involve the use of recombinant DNA technology to manipulate the DNA sequence encoding one or more polypeptide chains of an antibody molecule. Humanization can essentially be performed by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Thus, humanized forms of non-human antibodies (or fragments thereof) are chimeric antibodies or fragments in which significantly less than an entire human variable domain has been replaced with the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[0114] The selection of human variable domains to be used to create humanized antibodies, whether light or heavy chain, is crucial to reducing antigenicity. According to the "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human sequence that is closest to the rodent is then accepted as the human framework (FR) for the humanized antibody. Another method uses a specific framework derived from the consensus sequence of all human antibodies of a particular light or heavy chain subgroup. The same framework can be used for several different humanized antibodies.

[0115] It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, humanized antibodies can be generated by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available that illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the role that the residues may play in the function of the candidate immunoglobulin, i.e., analysis of residues that influence the ability of the candidate immunoglobulin to bind to its antigen. In this way, FR residues can be selected and combined from the consensus and import sequences to obtain the desired antibody characteristic, e.g., improved affinity for the target antigen(s). In general, CDR residues have the most direct and greatest influence on antigen binding.

[0116] The antibody can be conjugated to a substrate or labeled with a detectable moiety, or both conjugated and labeled. Detectable moieties contemplated for the compositions of the invention include, for example, fluorescent, enzymatic, and radioactive markers.

[0117] b. Single chain antibody Methods for producing single-chain antibodies are well known to those skilled in the art. Single-chain antibodies are created by fusing heavy and light chain variable domains together using a short peptide linker, thereby reconstituting an antigen-binding site on a single molecule. Single-chain antibody variable fragments (scFvs) have been developed in which the C-terminus of one variable domain is tethered to the N-terminus of the other variable domain by a 15-25 amino acid peptide or linker without significantly disrupting antigen binding or binding specificity. The linker is selected to enable the heavy and light chains to bind in their appropriate conformational orientation. These Fvs lack the constant region (Fc) present in the heavy and light chains of natural antibodies.

[0118] C. monovalent antibody In vitro methods are also suitable for producing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly Fab fragments, can be accomplished using conventional techniques known in the art. For example, digestion can be carried out using papain. Papain digestion of antibodies typically produces two identical antigen-binding fragments, called Fab fragments, each with a single antigen-binding site, and a residual Fc fragment. Pepsin treatment produces a fragment called the F(ab')2 fragment, which has two antigen-binding sites and is still capable of cross-linking antigen.

[0119] Fab fragments produced by antibody digestion also contain the constant domain of the light chain and the first constant domain of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain domain, including one or more cysteines from the antibody hinge region. F(ab')2 fragments are bivalent fragments containing two Fab' fragments linked by disulfide bridges at the hinge region. Fab'-SH is the designation used herein for Fab' in which the cysteine ​​residue(s) in the constant domains bear a free thiol group. Antibody fragments were originally produced as pairs of Fab' fragments with hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

[0120] d. Hybrid antibodies Antibodies can also be hybrid antibodies. In hybrid antibodies, one heavy-light chain pair is homologous to that found in an antibody raised against one epitope, while the other heavy-light chain pair is homologous to that found in an antibody raised against a different epitope. This confers the property of multifunctional valency, i.e., the ability to simultaneously bind to at least two different epitopes. Such hybrids can be formed by fusion of hybridomas producing each component antibody or by recombinant techniques. Of course, chimeric chains can also be used to form such hybrids.

[0121] e. Antibody fragment conjugates or fusions The targeting function of an antibody can be used therapeutically by linking the antibody or fragment thereof to a therapeutic agent, which can be achieved by forming an immunoconjugate or a fusion protein comprising the antibody or antibody fragment and the therapeutic agent.

[0122] Such linking of the antibody or fragment to a therapeutic agent can be achieved by forming an immunoconjugate including the antibody or antibody fragment and the therapeutic agent, or by forming a fusion protein, or by linking the antibody or fragment to a nucleic acid such as an siRNA.

[0123] In some embodiments, antibodies are modified to alter their half-life. In some embodiments, it is desirable to extend the half-life of an antibody so that it remains in the circulation or at the site of treatment for a longer period of time. For example, it may be desirable to maintain the titer of an antibody in the circulation or at the site of treatment for an extended period of time. For example, antibodies with Fc variants that extend their half-life can be constructed using, for example, Xtend™ Antibody Half-Life Extension Technology (Xencor, Monrovia, CA). In other embodiments, the half-life of an anti-DNA antibody is shortened to reduce potential side effects. The disclosed conjugates can be used to modify a given biological response. The drug moiety should not be construed as limited to classical chemotherapeutic agents. For example, the drug moiety can be a protein or polypeptide with a desired biological activity. Such proteins include toxins such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin.

[0124] f. Exemplary Antibodies One embodiment provides an anti-LAIR antibody produced by a hybridoma selected from the group consisting of 1E11, 1G7, 4B3, 5A6, 5E1, 6B2, 6F4, 6G6, 7G3, 9H6, 11B3, 12E10a, and 12E10b.

[0125] Another embodiment provides an anti-LAIR antibody having at least one light chain or at least one heavy chain of an antibody produced by one or more of the hybridomas selected from the group consisting of 1E11, 1G7, 4B3, 5A6, 5E1, 6B2, 6F4, 6G6, 7G3, 9H6, 11B3, 12E10a, and 12E10b.

[0126] Another embodiment provides an anti-LAIR antibody having a variable light chain that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to a variable light chain having the amino acid sequence of SEQ ID NO: 19, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 107 or 115.

[0127] Another embodiment provides an anti-LAIR antibody having a variable heavy chain that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to a variable heavy chain having the amino acid sequence of SEQ ID NO:23, 31, 39, 47, 55, 63, 71, 79, 87, 95, 103 or 111.

[0128] Another embodiment provides an anti-LAIR antibody having a variable light chain that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to a variable light chain having the amino acid sequence of SEQ ID NO: 19, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 107 or 115, and a variable heavy chain that has at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% sequence identity to the amino acid sequence of SEQ ID NO: 23, 31, 39, 47, 55, 63, 71, 79, 87, 95, 103 or 111.

[0129] Another embodiment provides an anti-LAIR antibody comprising a CDR selected from the group of complementarity determining regions (CDRs) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 20-22, 24-26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86, 88-90, 92-94, 96-98, 100-102, 104-106, 108-110, 112-114, and 116-118.

[0130] Another embodiment provides an anti-LAIR antibody having a plurality of CDRs selected from the group consisting of SEQ ID NOs: 20-22, 24-26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86, 88-90, 92-94, 96-98, 100-102, 104-106, 108-110, 112-114, and 116-117. The plurality of CDRs may be 2 to 12.

[0131] Another embodiment provides a chimeric antibody having a heavy chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:120 or SEQ ID NO:122, and / or a light chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:124.

[0132] Another embodiment provides a chimeric antibody having a heavy chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:126 or SEQ ID NO:128, and / or a light chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:130.

[0133] Another embodiment provides a chimeric antibody having a heavy chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:132 or SEQ ID NO:134, and / or a light chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:136.

[0134] Another embodiment provides a chimeric antibody having a heavy chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:138 or SEQ ID NO:140, and / or a light chain having an amino acid sequence that is at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99 or 100% identical to the amino acid sequence set forth in SEQ ID NO:142.

[0135] Another embodiment provides a nucleic acid sequence encoding an antibody having a light chain amino acid sequence of SEQ ID NO:124, 130, 136 or 142 and / or a heavy chain amino acid sequence of SEQ ID NO:120, 122, 126, 128, 132, 134, 138 or 140.

[0136] Another embodiment provides a nucleic acid sequence encoding a variable light chain of SEQ ID NO: 19, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 107 or 115 and / or a variable heavy chain of SEQ ID NO: 23, 31, 39, 47, 55, 63, 71, 79, 87, 95, 103 or 111. The nucleic acids encoding the light and / or heavy chains can be part of an expression vector. The nucleic acids can be expressed in a cell. Expression can be inducible or constitutive.

[0137] 2. Proteins and Polypeptides a. Protein and Polypeptide Compositions The immunomodulatory agent can be a protein, polypeptide, or fusion protein. For example, the immunomodulatory agent can be an isolated or recombinant LAIR-1 or LAIR-2 protein or polypeptide, or a functional fragment, variant, or fusion protein thereof.

[0138] The protein or polypeptide, or its functional fragment, variant, or fusion protein, can be an agonist or antagonist. For example, in some embodiments, the LAIR-1 antagonist is an LAIR-1 or LAIR-2 polypeptide, or its fragment, or fusion protein, that binds to the LAIR-1 ligand. The polypeptide can be a soluble fragment, such as the extracellular domain of LAIR-1 or LAIR-2, or its functional fragment, or its fusion protein. In some embodiments, the soluble ligand of LAIR-1 can act as an agonist and increase signal transduction via LAIR-1.

[0139] The activity of an LAIR-1 or LAIR-2 protein or polypeptide, or any fragment, variant, or fusion protein thereof (i.e., agonist or antagonist), can be determined using functional assays known in the art, including those described below. Typically, the assay involves determining whether the protein, polypeptide, or fragment, variant, or fusion protein thereof increases (i.e., is an agonist) or decreases (i.e., is an antagonist) signaling through the LAIR-1 receptor. In some embodiments, the assay involves determining whether the protein, polypeptide, or fragment, variant, or fusion protein thereof increases (i.e., is an agonist) or decreases (i.e., is an antagonist) an immune response associated with LAIR-1 (i.e., is costimulatory or co-inhibitory). Typically, the assay involves determining whether the protein, polypeptide, or fragment, variant, or fusion protein thereof increases (i.e., is an agonist) or decreases (i.e., is an antagonist) signaling through LAIR-1. In some embodiments, the assay involves determining whether the protein, polypeptide, or fragment, variant, or fusion protein thereof decreases (i.e., is an agonist) or increases (i.e., is an antagonist) an immune response that is negatively regulated by LAIR-1. In some embodiments, the assay involves determining whether the protein, polypeptide, or fragment, variant, or fusion protein thereof increases (i.e., is an antagonist) apoptosis and differentiation of acute myeloid leukemia and acute lymphoblastic leukemia cells, thereby reducing the self-renewal capacity of AML and ALL stem cells.

[0140] Nucleic acid and polypeptide sequences for LAIR-1 and LAIR-2 are known in the art, and exemplary protein and peptide sequences are provided above. As described in more detail below, the sequences can be used by those skilled in the art to generate any LAIR-1 or LAIR-2 protein or polypeptide, or any fragment, variant, or fusion protein thereof. LAIR-1 and LAIR-2 proteins, polypeptides, variants, and fusions thereof are typically expressed from nucleic acids containing sequences encoding a signal sequence. Typically, the signal sequence is cleaved from the immature polypeptide to generate a mature polypeptide lacking the signal sequence. Standard molecular biology techniques can be used to replace the signal sequence with that of another polypeptide to affect the expression level, secretion, solubility, or other properties of the polypeptide. LAIR-1 and LAIR-2 are disclosed both with and without a signal sequence. As known or described in the art, in some cases, the mature protein, i.e., the protein sequence without the signal sequence, is a putative mature protein. During normal cellular expression, the signal sequence may be removed by cellular peptidases to generate the mature protein. The sequence of the mature protein can be determined or confirmed using methods known in the art.

[0141] i. Fragment As used herein, LAIR-1 or LAIR-2 refers to any subset of a polypeptide that is at least one amino acid shorter than the full-length protein. Useful fragments include those that retain the ability to bind to one or more of its natural ligands. A polypeptide that is a fragment of any full-length LAIR-1 or LAIR-2 typically has at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, 100%, or even more than 100% of the ability to bind to its natural ligand compared to the full-length protein, respectively.

[0142] Fragments of LAIR-1 and LAIR-2 include cell-free fragments. Cell-free polypeptides can be fragments of full-length transmembrane polypeptides that are excreted, secreted, or extracted from producing cells. Cell-free fragments of polypeptides can include some or all of the extracellular domain of the polypeptide and can lack some or all of the intracellular and / or transmembrane domains of the full-length protein. In one embodiment, the polypeptide fragment includes the entire extracellular domain of the full-length protein. In other embodiments, cell-free fragments of polypeptides include fragments of the extracellular domain that retain the biological activity of the full-length protein. The extracellular domain can include 1, 2, 3, 4, or 5 consecutive amino acids from the transmembrane domain and / or 1, 2, 3, 4, or 5 consecutive amino acids from the signal sequence. Alternatively, the extracellular domain can have 1, 2, 3, 4, 5, or more amino acids removed from the C-terminus, N-terminus, or both. In some embodiments, the extracellular domain is the only functional domain of the fragment (e.g., the ligand-binding domain).

[0143] ii. Mutant Also provided are variants of LAIR-1 and LAIR-2 and fragments thereof. In some embodiments, the variants are at least 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to any of SEQ ID NOs: 1-6. Useful variants include those that enhance biological activity in any of the assays described herein, or that increase the half-life or stability of the protein. LAIR-1 or LAIR-2 proteins and polypeptides, as well as fragments, variants, and fusion proteins thereof, can be engineered to improve biological activity. For example, in some embodiments, an LAIR-2 polypeptide, protein, or variant or fusion thereof is modified by at least one amino acid substitution, deletion, or insertion that enhances its function.

[0144] Other variants are those engineered to selectively bind to one or more types of LAIR-1 and / or LAIR-2 ligands over other LAIR-1 and / or LAIR-2 ligands. For example, variants can be engineered to preferentially bind to one or more of collagen, SP-D, C1q, or MBL, or a specific combination thereof. Preferential binding refers to binding to one type of ligand at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more stronger than another type of ligand.

[0145] Still other variants can be engineered to bind less strongly to one ligand than to another, and these variants can be used in combination with variants with stronger binding properties to modulate the immune response with moderate impact.

[0146] In yet other embodiments, mutants can be engineered to bind less favorably to one or more collagen-binding sites than others. As discussed in Brondijk, et al., Blood, 18(115); 1364-73 (2010), mutations of residues in LAIR-1 can differentially affect binding to various collagen ligands. For example, the R59A, E61A, R65A, and E111A mutants significantly reduced adhesion to immobilized collagens I, III, and IV, although the magnitude of the effect depended on the type of collagen tested. Furthermore, mutants R62A and N69A showed somewhat reduced adhesion. In some embodiments, mutants are mutated at one or more of R59, E61, R62, E63, R65, S66, Y68, N69, I102, R100, W109, E111, Q112, and Y115 compared to SEQ ID NO: 1. In some embodiments, the variant is mutated at one or more of R59, E61, R65, E111, R62A, and N69A. In particular embodiments, the mutation(s) is a substitution with alanine.

[0147] Finally, mutant polypeptides can be engineered to have a longer half-life than the wild-type. These mutants are typically modified to resist enzymatic digestion. Exemplary modifications include modified amino acid residues and modified peptide bonds that resist enzymatic digestion. Various modifications to achieve this are known in the art. The mutants can be modified to adjust the effect of receptor affinity on the half-life of the protein, polypeptide, fragment, or fusion thereof at serum and endosomal pH.

[0148] iii. Fusion proteins A fusion polypeptide comprises a first fusion partner comprising all or a portion of the polypeptide LAIR-1 or Liar-2 fused to a second polypeptide, either directly or via a linker peptide sequence fused to the second polypeptide. The fusion protein optionally contains a domain that functions to dimerize or multimerize two or more fusion proteins. The peptide / polypeptide linker domain may be a separate domain or may be contained within one of the other domains of the fusion protein (the first polypeptide or the second polypeptide). Similarly, the domain that functions to dimerize or multimerize the fusion protein may be a separate domain or may be contained within one of the other domains of the fusion protein (the first polypeptide, the second polypeptide, or the peptide / polypeptide linker domain). In certain embodiments, the dimerization / multimerization domain and the peptide / polypeptide linker domain are the same.

[0149] The fusion proteins disclosed herein have the formula I: N-R1-R2-R3-C where "N" represents the N-terminus of the fusion protein and "C" represents the C-terminus of the fusion protein. In some embodiments, "R1" is an LAIR-1 or Liar-2 polypeptide or protein, or a fragment or variant thereof, "R2" is an optional peptide / polypeptide linker domain, and "R3" is a second polypeptide. Alternatively, R3 may be an LAIR-1 or Liar-2 polypeptide or protein, or a fragment or variant thereof, and R1 may be a second polypeptide. In some embodiments, the LAIR-1 or Liar-2 polypeptide is an extracellular domain or fragment thereof, such as an Ig-like C2 domain, or a region defined by disulfide-bond-forming cysteines as described above.

[0150] Dimerization or multimerization can occur between two or more fusion proteins via a dimerization or multimerization domain. Alternatively, dimerization or multimerization of fusion proteins can occur by chemical crosslinking. The resulting dimers or multimers can be homodimers / homomultimers or heterodimers / heteromultimers.

[0151] In some embodiments, the fusion protein comprises the extracellular domain of LAIR-1 or LAIR-2, or a fragment or variant thereof, fused to an Ig Fc region. Recombinant Ig fusion proteins can be generated by fusing the coding region of the extracellular domain, or a fragment or variant thereof, to the Fc region of human IgG1, IgG2, IgG3, or IgG4, or mouse IgG2a, or other suitable Ig domain as previously described (Chapoval, et al., Methods Mol. Med., 45:247-255 (2000)).

[0152] iv. Exemplary Fusion Proteins Exemplary fusion proteins are provided below. The signal sequence is double-underlined, the LAIR-1 or LAIR-2 extracellular domain is single-underlined, and the Ig domain is italicized. The signal sequence is typically removed from the mature protein. Additionally, signal peptides from other polypeptides or organisms can be used (e.g., substituted) to enhance secretion of the fusion protein from the host during production.

[0153] hLAIR1.hG1 In some embodiments, the human LAIR1-hIg fusion protein (hIgG1) (hLAIR1.hG1) has the amino acid sequence: The sequence identity to TIFF0007595113000011.tif31136 (SEQ ID NO:9) is at least 80%, 85%, 90%, 95%, 99% or 100%, with or without a signal sequence.

[0154] SEQ ID NO:9, which does not include a signal sequence, is TIFF0007595113000012.tif31136 (SEQ ID NO: 10).

[0155] Human LAIR1-hIg (hIgG1) (hLAIR1.hG1) can act as a decoy for LAIR-1 ligands, thereby acting as an antagonist of LAIR-1 signaling and can be used to treat cancer or infectious diseases. hLAIR1.hG1 can also be used as a control to test the activity of hLAIR2.hG1.

[0156] hLAIR1.mG2a In some embodiments, the human LAIR1-mIg fusion protein (mIgG2a) (hLAIR1.mG2a) has the amino acid sequence: The sequence identity to TIFF0007595113000013.tif29136 (SEQ ID NO:11) is at least 80%, 85%, 90%, 95%, 99% or 100%, with or without a signal sequence.

[0157] SEQ ID NO:11, which does not include the signal sequence, is TIFF0007595113000014.tif29136 (SEQ ID NO: 12).

[0158] In some embodiments, human LAIR1-mIg fusion protein (mIgG2a) (hLAIR1.mG2a) can be used to generate anti-hLAIR1 antibodies. For example, the antibody can be an LAIR-1 antagonist antibody (e.g., a mAb or fragment thereof), which can be used to treat cancer, or the antibody can be an LAIR-1 agonist antibody (e.g., a mAb or fragment thereof), which can be used to treat autoimmune disease.

[0159] mLAIR1.mG2a In some embodiments, the mouse LAIR1-mIg fusion protein (mLAIR1.mG2a) has the amino acid sequence: The sequence identity to TIFF0007595113000015.tif31136 (SEQ ID NO: 13) is at least 80%, 85%, 90%, 95%, 99% or 100%, with or without a signal sequence.

[0160] SEQ ID NO:13, which does not include the signal sequence, is TIFF0007595113000016.tif24136 (SEQ ID NO: 14).

[0161] In some embodiments, the mouse LAIR1-mIg fusion protein is the mouse analog used for in vivo studies in mouse models.

[0162] hLAIR2.hG1 In some embodiments, the human LAIR2-hIg fusion protein (hIgG1) (hLAIR2.hG1) has the amino acid sequence: The sequence identity to TIFF0007595113000017.tif30136 (SEQ ID NO: 15) is at least 80%, 85%, 90%, 95%, 99% or 100%, with or without a signal sequence.

[0163] SEQ ID NO:15, which does not include the signal sequence, is TIFF0007595113000018.tif29136 (SEQ ID NO: 16).

[0164] The human LAIR2-hIg fusion protein (hIgG1) (hLAIR2.hG1) can act as a decoy for the LAIR-1 ligand, thereby antagonizing Liar-1 signaling and potentially being used to treat cancer or infectious diseases.

[0165] LAIR2.mIg In some embodiments, the human LAIR2.mIg fusion protein (mIgG2a) has the amino acid sequence: The sequence identity to TIFF0007595113000019.tif29136 (SEQ ID NO: 17) is at least 80%, 85%, 90%, 95%, 99% or 100%, with or without a signal sequence.

[0166] SEQ ID NO:17, which does not include the signal sequence, is TIFF0007595113000020.tif29136 (SEQ ID NO: 18).

[0167] The human LAIR2.mIg fusion protein (mIgG2a) can be used to generate antagonistic anti-LAIR2 (eg, mAb or fragments thereof), which can be used for the treatment of autoimmune diseases.

[0168] v. Polypeptide Modification Polypeptides and fusion proteins may be modified with chemical moieties that may be present on polypeptides in their normal cellular environment, such as phosphorylation, methylation, amidation, sulfation, acylation, glycosylation, sumoylation, and ubiquitination. Fusion proteins may also be modified with labels capable of directly or indirectly providing a detectable signal, including, but not limited to, radioisotopes and fluorescent compounds.

[0169] Polypeptides and fusion proteins may also be modified with chemical moieties not normally added to polypeptides in a cellular environment. For example, the disclosed fusion proteins may be modified by the covalent attachment of polymer chains, including but not limited to polyethylene glycol polymer (PEG) chains (i.e., PEGylation). Conjugation of macromolecules with PEG has recently emerged as an effective strategy for altering the pharmacokinetic (PK) profiles of various drugs, thereby improving their therapeutic potential. PEG conjugation increases drug retention in the circulation by protecting them from enzymatic digestion, delays renal filtration, and reduces the development of neutralizing antibodies. Furthermore, PEG conjugation can be used to enable multimerization of fusion proteins.

[0170] Modifications can be introduced into the molecule by reacting the amino acid residues of the target polypeptide with organic derivatizing agents capable of reacting with selected side chains or terminal residues. Another modification is protein cyclization.

[0171] Examples of chemical derivatives of polypeptides include lysinyl and amino-terminal residues derivatized with succinic or other carboxylic acid anhydrides. Derivatization with cyclic carboxylic acid anhydrides has the effect of reversing the charge of lysinyl residues. Other suitable reagents for derivatizing amino-containing residues include, for example, imidoesters such as methyl picolinimidate, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid, O-methylisourea, 2,4-pentanedione, and transaminase-catalyzed reactions with glyoxylate. Carboxyl side groups, aspartyl, or glutamyl can be selectively modified by reaction with carbodiimides (RN=C=N--R'), such as 1-cyclohexyl-3-(2-morpholinyl-(4-ethyl)carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl)carbodiimide. Furthermore, aspartyl and glutamyl residues can be converted to asparaginyl and glutaminyl residues by reaction with ammonia. Fusion proteins may also contain one or more D-amino acids replacing one or more L-amino acids.

[0172] vi. Altered binding properties The binding characteristics of proteins, polypeptides, fragments, variants, and fusions thereof are related to the dose and dosing regimen administered. In one embodiment, the disclosed proteins, polypeptides, fragments, variants, and fusions thereof have binding characteristics with an LAIR-1 ligand that exhibit a stronger expression or occupy a higher percentage of binding sites (e.g., on the ligand) than other receptor molecules that bind to the LAIR-1 ligand. In other embodiments, the disclosed proteins, polypeptides, fragments, variants, and fusions thereof have reduced affinity for an LAIR-1 ligand compared to the wild-type protein.

[0173] In some embodiments, the proteins, polypeptides, fragments, variants, and fusions thereof have a relatively high affinity for the LAIR-1 ligand, and therefore a relatively slow dissociation rate. In other embodiments, the proteins, polypeptides, fragments, variants, and fusions thereof are administered intermittently over a period of days, weeks, or months to allow the immune response to weaken in preparation for recovery before the next administration, which may serve to alter the immune response without completely enabling or abolishing it and may avoid long-term side effects.

[0174] 3. Isolated Nucleic Acid Molecules Disclosed herein are isolated nucleic acid sequences that encode proteins, polypeptides, fragments, variants, and fusions thereof. As used herein, an "isolated nucleic acid" refers to a nucleic acid that is separated from other nucleic acid molecules present in a mammalian genome, including nucleic acids that are normally adjacent to the nucleic acid on one or both sides in the mammalian genome. The term "isolated," as used herein with respect to nucleic acids, also includes combinations with any non-naturally occurring nucleic acid sequences, since such non-naturally occurring sequences are not found in nature and do not have immediately adjacent sequences in a naturally occurring genome.

[0175] An isolated nucleic acid can be, for example, a DNA molecule, provided that one of the nucleic acid sequences normally found immediately flanking the DNA molecule in a naturally occurring genome has been removed or is absent. Thus, isolated nucleic acids include, but are not limited to, DNA molecules that exist as separate molecules independent of other sequences (e.g., chemically synthesized nucleic acids, or cDNA or genomic DNA fragments generated by PCR or restriction endonuclease treatment), and recombinant DNA molecules integrated into vectors, autonomously replicating plasmids, viruses (e.g., retroviruses, lentiviruses, adenoviruses, or herpes viruses), or the genomic DNA of prokaryotes or eukaryotes. Furthermore, isolated nucleic acids can include engineered nucleic acids, such as recombinant DNA molecules that are part of hybrid or fusion nucleic acids. A nucleic acid present among hundreds to millions of other nucleic acids, for example, in a cDNA library or genomic library, or in a gel slice containing a genomic DNA restriction digest, should not be considered an isolated nucleic acid.

[0176] Nucleic acids encoding proteins, polypeptides, fragments, variants, and fusions thereof can be optimized for expression in a selected expression host. To account for differences in codon usage between the mammal from which the nucleic acid sequence originates and the expression host, codons can be replaced with alternative codons that encode the same amino acid. Thus, nucleic acids can be synthesized using codons preferred by the expression host.

[0177] The nucleic acid can be in sense or antisense orientation, or can be complementary to a reference sequence encoding a LAIR-1 or LAIR-2 polypeptide or protein. The nucleic acid can be DNA, RNA, or a nucleic acid analog. The nucleic acid analog can be modified at the base moiety, sugar moiety, or phosphate backbone. Such modifications can improve, for example, the stability, hybridization, or solubility of the nucleic acid. Modifications at the base moiety can include, for example, deoxyuridine instead of deoxythymidine, and 5-methyl-2'-deoxycytidine or 5-bromo-2'-deoxycytidine instead of deoxycytidine. Modifications at the sugar moiety can include, for example, modifying the 2' hydroxyl of the ribose sugar to form a 2'-O-methyl or 2'-O-allyl sugar. The deoxyribose phosphate backbone can be modified to generate morpholino nucleic acids, in which each base moiety is linked to a six-membered morpholino ring, or peptide nucleic acids, in which the deoxyphosphate backbone is replaced with a pseudopeptide backbone and four bases are retained. See, e.g., Summerton and Weller (1997) Antisense Nucleic Acid Drug Dev. 7:187-195 and Hyrup et al. (1996) Bioorgan. Med. Chem. 4:5-23. Furthermore, the deoxyphosphate backbone can be replaced with, for example, a phosphorothioate or phosphorodithioate backbone, a phosphoramidite, or an alkyl phosphotriester backbone.

[0178] The nucleic acid encoding the polypeptide can be administered to a subject in need thereof. Nuclear delivery involves introducing a "foreign" nucleic acid into a cell and ultimately into a living animal. Compositions and methods for delivering nucleic acids to a subject are known in the art (see, Understanding Gene Therapy, Lemoine, NR, ed., BIOS Scientific Publishers, Oxford, 2008).

[0179] 4. Vectors and host cells Vectors encoding proteins, polypeptides, fragments, variants, and fusions thereof are also provided. Nucleic acids, such as those described above, can be inserted into vectors for expression in cells. As used herein, a "vector" is a replicon, such as a plasmid, phage, virus, or cosmid, into which another DNA segment can be inserted to cause replication of the inserted segment. The vector can be an expression vector. An "expression vector" is a vector that contains one or more expression control sequences, and an "expression control sequence" is a DNA sequence that controls and regulates the transcription and / or translation of another DNA sequence.

[0180] The nucleic acid in the vector can be operably linked to one or more expression control sequences. As used herein, "operably linked" means incorporated into a genomic construct so that the expression control sequence effectively controls the expression of the coding sequence of interest. Examples of expression control sequences include promoters, enhancers, and transcription termination regions. A promoter is an expression control sequence consisting of a region typically located within 100 nucleotides upstream of the transcription start site of a DNA molecule (usually near the RNA polymerase II initiation site). For a coding sequence to be under the control of a promoter, the translation start site of the translation reading frame of the polypeptide must be located 1 to approximately 50 nucleotides downstream of the promoter. Enhancers provide expression specificity with respect to time, location, and level. Unlike promoters, enhancers can function when located at various distances from the transcription site. Enhancers can also be located downstream of the transcription start site. A coding sequence is "operably linked" and "under the control" of expression control sequences in a cell if RNA polymerase is capable of transcribing the coding sequence into mRNA, which can then be translated into the protein encoded by the coding sequence.

[0181] Suitable expression vectors include, but are not limited to, plasmids and viral vectors derived from, for example, bacteriophage, baculovirus, tobacco mosaic virus, herpes virus, cytomegalovirus, retrovirus, vaccinia virus, adenovirus, and adeno-associated virus. Numerous vectors and expression systems are commercially available from companies such as Novagen (Madison, WI), Clontech (Palo Alto, CA), Stratagene (La Jolla, CA), and Invitrogen Life Technologies (Carlsbad, CA).

[0182] The expression vector can include a tag sequence. The tag sequence is typically expressed as a fusion with the encoded polypeptide. Such tags can be inserted anywhere within the polypeptide, including at the carboxy or amino terminus. Examples of useful tags include, but are not limited to, green fluorescent protein (GFP), glutathione S-transferase (GST), polyhistidine, c-myc, hemagglutinin, Flag™ tag (Kodak, New Haven, CT), maltose E binding protein, and protein A. In one embodiment, a nucleic acid molecule encoding one of the disclosed polypeptides is encoded by a sequence encoding, for example, the hinge, Cγ1, or Cγ2 sequence of the human immunoglobulin Cγ1 chain. H 2 and C H The three regions are present in a vector containing nucleic acid encoding one or more domains of an Ig heavy chain constant region having amino acid sequences corresponding to the three regions.

[0183] A vector containing a nucleic acid to be expressed can be introduced into a host cell. The term "host cell" is intended to include prokaryotic and eukaryotic cells into which a recombinant expression vector can be introduced. As used herein, "transformed" and "transfected" encompass the introduction of a nucleic acid molecule (e.g., a vector) into a cell by one of many techniques. Without being limited to a particular technique, several of these techniques are well established in the art. For example, prokaryotic cells can be transformed with a nucleic acid by electroporation or calcium chloride-mediated transformation. Nucleic acids can be transfected into mammalian cells by techniques including, for example, calcium phosphate co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, or microinjection. Host cells (e.g., prokaryotic or eukaryotic cells, such as CHO cells) can be used to produce, for example, the proteins, polypeptides, fragments, variants, and fusions thereof described herein.

[0184] The described vectors can be used to express proteins, polypeptides, fragments, variants, and fusions thereof intracellularly. Exemplary vectors include, but are not limited to, adenoviral vectors. One approach involves nucleic acid transfer into primary cells in culture followed by autonomous transplantation of the transformed cells ex vivo into a host, either whole or into a specific organ or tissue. Ex vivo methods can include, for example, harvesting cells from a subject, culturing the cells, transducing them with an expression vector, and maintaining the cells under conditions suitable for expression of the encoded polypeptide. These methods are known in the art of molecular biology. The transduction step can be accomplished by any standard means used in ex vivo gene therapy, including, for example, calcium phosphate, lipofection, electroporation, viral infection, and biolistic gene transfer. Alternatively, liposomes or polymeric microparticles can be used. Successfully transduced cells can then be selected, for example, for expression of a coding sequence or a drug resistance gene. The cells can then be lethally irradiated (if desired) and injected or implanted into the subject. In certain embodiments, an expression vector containing a nucleic acid encoding the fusion protein is transfected into cells that are administered to a subject in need thereof.

[0185] In vivo nucleic acid therapy can be achieved by directly transferring functionally active DNA into mammalian somatic tissues or organs in vivo.For example, nucleic acids encoding the polypeptides disclosed herein can be directly administered to lymphatic tissue.Alternatively, lymphatic tissue-specific targeting can be achieved using lymphatic tissue-specific transcriptional regulatory elements (TREs), such as TREs specific to B lymphocytes, T lymphocytes, or dendritic cells.Lymphatic tissue-specific TREs are known in the art.

[0186] Nucleic acids may also be administered in vivo by viral means. As is well known in the art, a packaging cell line that produces replication-deficient retroviruses may be used to package a nucleic acid molecule encoding a fusion protein into a retroviral vector. Other viral vectors may also be used, including recombinant adenoviruses and vaccinia viruses that can be made replication-incompetent. In addition to naked DNA or RNA, or viral vectors, engineered bacteria may also be used as vectors.

[0187] Nucleic acids may also be delivered in other carriers, including liposomes, polymeric microparticles and nanoparticles, and polycations, eg, asialoglycoprotein / polylysine.

[0188] In addition to virus- and carrier-mediated in vivo gene transfer, physical means well known in the art can be used for direct transfer of DNA, including administration of plasmid DNA and particle bombardment-mediated gene transfer.

[0189] One embodiment provides a cell that constitutively or inducibly expresses an antibody or antigen-binding fragment thereof that specifically binds to LAIR-1, wherein the cell has one or more nucleic acids encoding the amino acid sequence of SEQ ID NO:19, 27, 35, 43, 51, 59, 67, 75, 83, 91, 99, 107, 115, 23, 31, 39, 47, 55, 63, 71, 79, 87, 95, 103, 111, or a combination thereof.

[0190] 5.Small molecules Immunomodulatory agents can be small molecules. Small molecule agonists and antagonists of LAIR-1 and antagonists of LAIR-2 are known in the art or can be identified using routine screening methods.

[0191] In some embodiments, screening assays can involve random screening of large libraries of test compounds. Alternatively, assays can be used that focus on specific classes of compounds suspected of modulating LAIR-1 or LAIR-2 levels. Assays can include determining LAIR-1 signaling activity or LAIR-1-mediated inhibitory responses. Other assays can include determining nucleic acid transcription or translation, mRNA levels, mRNA stability, mRNA degradation, transcription rates, and translation rates.

[0192] C. Pharmaceutical Compositions Pharmaceutical compositions containing the disclosed immunomodulatory agents are provided. The pharmaceutical compositions containing the immunomodulatory agents can be for administration by parenteral (intramucosal, intraperitoneal, intravenous (IV), or subcutaneous injection), transdermal (passive, or using iontophoresis or electroporation), or transmucosal (nasal, vaginal, rectal, or sublingual) routes of administration or using biodegradable inserts, and can be formulated into dosage forms suitable for each route of administration.

[0193] In some in vivo approaches, a therapeutically effective amount of the compositions disclosed herein is administered to a subject. As used herein, the term "effective amount" or "therapeutically effective amount" refers to a dosage sufficient to treat, suppress, or alleviate one or more symptoms of the disorder being treated, or otherwise provide the desired pharmacological and / or physiological effect. The exact dosage will vary depending on various factors, such as subject-dependent variables (e.g., age, immune system health, etc.), the disease, and the treatment being effected.

[0194] For the disclosed immunomodulatory agents, as further research is conducted, information regarding appropriate dosage levels for treating various conditions in various patients will become apparent, and one of skill in the art will be able to ascertain appropriate dosages taking into account the recipient's treatment, age, and overall health. The selected dosage will depend on the desired therapeutic effect, route of administration, and desired duration of treatment. For the disclosed immunomodulatory agents, dosages at levels of 0.001 to 20 mg / kg body weight are often administered daily to mammals. Dosages for intravenous injection or infusion may often be lower.

[0195] In certain embodiments, the immunomodulatory agent is administered locally, for example, by direct injection into the site to be treated. Typically, the injection results in an increased local concentration of the immunomodulatory agent composition that is higher than the local concentration that can be achieved by systemic administration. The immunomodulatory agent composition can be used in combination with a matrix, as described above, which helps create an increased local concentration of the polypeptide composition by reducing passive diffusion of the polypeptide out of the site to be treated.

[0196] 1. Formulations for parenteral administration In some embodiments, compositions disclosed herein, including those containing peptides and polypeptides, are administered in aqueous solution via parenteral injection. Formulations may also be in the form of suspensions or emulsions. Generally, pharmaceutical compositions are provided that contain an effective amount of a peptide or polypeptide, and optionally a pharmaceutically acceptable diluent, preservative, solubilizer, emulsifier, adjuvant, and / or carrier. Such compositions optionally contain one or more of the following: diluents, sterile water, buffers (e.g., Tris-HCl, acetate, phosphate), buffered saline solutions of various pH and ionic strengths, and additives such as surfactants and solubilizers (e.g., TWEEN 20 (polysorbate 20), TWEEN 80 (polysorbate 80)), antioxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., thimerosal, benzyl alcohol), and bulking agents (e.g., lactose, mannitol). Examples of non-aqueous solutions or vehicles are propylene glycol, polyethylene glycol, vegetable oils such as olive oil and corn oil, gelatin, and injectable organic esters such as oleic acid esters.The formulations may be lyophilized and redissolved / resuspended immediately before use.The formulations may be sterilized, for example, by filtering through a bacteria-retaining filter, incorporating a sterilizing agent into the composition, irradiating the composition, or heating the composition.

[0197] 2. Formulations for oral administration In embodiments, the compositions are formulated for oral delivery. Oral solid dosage forms are generally described in Chapter 89 of Remington's Pharmaceutical Sciences, 18th Ed. 1990 (Mack Publishing Co., Easton, Pa. 18042). Solid dosage forms include, for example, tablets, capsules, pills, lozenges or lozenges, cachets, pellets, powders, or granules, or those incorporating the material in microparticle preparations of polymeric compounds such as polylactic acid, polyglycolic acid, or liposomes. Such compositions can affect the physical state, stability, in vivo release rate, and in vivo clearance rate of the disclosed compositions. See, for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa. 18042), pp. 1435-1712, incorporated herein by reference. The compositions may be prepared in liquid form or in dry powder (e.g., lyophilized) form. The composition may be formulated using liposomal or proteinaceous encapsulation. Liposomal encapsulation may be used, and the liposomes may be derivatized with various polymers (e.g., U.S. Pat. No. 5,013,556). See also Marshall, K. In: Modern Pharmaceutics Edited by GS Banker and CT Rhodes Chapter 10, 1979. The formulation usually contains a peptide (or a chemically modified form thereof) and an inactive ingredient that protects the peptide in the stomach environment and releases the biologically active material in the intestine.

[0198] The active substance can be chemically modified to make the oral delivery of the derivative effective. Generally, the contemplated chemical modification is the attachment of at least one moiety to the component molecule itself, which allows the component to be taken up into the bloodstream from the stomach or intestine or directly into the intestinal mucosa. Also desired is the improvement of the overall stability of one or more components and the extension of their circulation time in the body. Pegylation is a typical example of chemical modification for pharmaceutical use. Other moieties that can be used include, for example, propylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, polyproline, poly-1,3-dioxolane, and poly-1,3,6-trioxolane (see, e.g., Abuchowski and Davis (1981) "Soluble Polymer-Enzyme Adducts," in Enzymes as Drugs, Hocenberg and Roberts, eds. (Wiley-Interscience: New York, NY) pp. 367-383, and Newmark, et al. (1982) J. Appl. Biochem. 4:185-189).

[0199] Another embodiment provides liquid dosage forms for oral administration, including pharmaceutically acceptable emulsions, solutions, suspensions, and syrups, which may contain other ingredients including inert diluents; adjuvants, such as wetting agents, emulsifying agents, and suspending agents; and sweetening, flavoring, and perfuming agents.

[0200] Controlled-release oral formulations may be desirable. The drug can be incorporated into an inert matrix, such as a gum, that allows release by either diffusion or leaching mechanisms. Alternatively, a slowly degrading matrix may be incorporated into the formulation. Another form of controlled release is based on the Oros Therapeutic System (Alza Corp.), in which the drug is encapsulated in a semipermeable membrane that allows water to enter and push the drug out through a single small opening due to osmotic effects.

[0201] For oral formulations, the location of release can be the stomach, the small intestine (duodenum, jejunum, or ileum), or the large intestine. In some embodiments, release will avoid the adverse effects of the gastric environment by protecting the drug (or derivative) or releasing the drug (or derivative) prior to the gastric environment, e.g., in the intestine. To ensure adequate gastric resistance, a coating that is impermeable to at least pH 5.0 is essential. Examples of more common inert materials used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate (HPMCP), HPMCP50, HPMCP55, polyvinyl acetate phthalate (PVAP), Eudragit L30D™, Aquateric™, cellulose acetate phthalate (CAP), Eudragit L™, Eudragit S™, and Shellac™. These coatings may also be used as mixed films.

[0202] 3. Formulations for topical administration The disclosed immunomodulatory agents can be applied topically, which is not very effective for most peptide formulations, but can be effective, particularly when applied to the lungs, nasal mucosa, oral mucosa (sublingual, buccal), vaginal mucosa, or rectal mucosa.

[0203] When delivered as either an aerosol or spray-dried particles having an aerodynamic diameter of less than about 5 microns, the composition can be delivered to the lungs during inhalation and can cross the lung epithelial lining into the bloodstream.

[0204] A wide variety of mechanical devices designed for pulmonary delivery of therapeutic products can be used, including, but not limited to, nebulizers, metered-dose inhalers, and powder inhalers, all of which are well known to those skilled in the art. Some specific examples of commercially available devices are the Ultravent nebulizer (Mallinckrodt Inc., St. Louis, Mo.), the Acorn II nebulizer (Marquest Medical Products, Englewood, Colo.), the Ventolin metered-dose inhaler (Glaxo Inc., Research Triangle Park, N.C.), and the Spinhaler powder inhaler (Fisons Corp., Bedford, Mass.). Nektar, Alkermes, and Mannkind all have approved or investigational insulin powder formulations for inhalation, and their technology could be applied to the formulations described herein.

[0205] Formulations for administration to mucosal membranes will typically be spray-dried drug particles, which may be incorporated into tablets, gels, capsules, suspensions, or emulsions. Standard pharmaceutical excipients can be obtained from any formulation manufacturer.

[0206] Transdermal formulations may also be prepared. These will typically be ointments, lotions, sprays, or patches, all of which can be prepared using standard techniques. Transdermal formulations may require the inclusion of a penetration enhancer.

[0207] 4. Controlled Delivery Polymer Matrices The immunomodulatory agents disclosed herein can also be administered as controlled-release formulations. Implantation of polymeric devices (rods, cylinders, films, disks) or injection (microparticles) can result in controlled-release polymeric devices for systemic, prolonged release. The matrix can be in the form of microparticles, such as microspheres, in which the agent is dispersed within a solid polymer matrix or microcapsules, the core of which is composed of various materials different from the polymer shell and may be liquid or solid in nature, with the peptide dispersed or suspended within the core. Unless specifically defined herein, microparticles, microspheres, and microcapsules are used interchangeably. Alternatively, the polymers can be shaped into thin plates or films ranging from a few nanometers to 4 centimeters in size, powders produced by milling or other standard techniques, or even gels, such as hydrogels.

[0208] Either non-biodegradable or biodegradable matrices can be used for delivery of fusion polypeptides or nucleic acids encoding the fusion polypeptides, although biodegradable matrices are preferred in some embodiments. These can be natural or synthetic polymers, although synthetic polymers are preferred in some embodiments due to their better characteristics regarding degradation and release profiles. The polymer is selected based on the desired release period. In some cases, linear release may be most useful, while in other cases, pulsed or "bulk release" may provide more effective results. The polymer may be in the form of a hydrogel (typically absorbing less than about 90% water by weight), optionally crosslinked with multivalent ions or polymers.

[0209] The matrix can be formed by solvent evaporation, spray drying, solvent extraction, and other methods known to those skilled in the art. Biodegradable microspheres can be made using any of the methods developed to make microspheres for drug delivery, such as those described by Mathiowitz and Langer, J. Controlled Release, 5:13-22 (1987); Mathiowitz, et al., Reactive Polymers, 6:275-283 (1987); and Mathiowitz, et al., J. Appl. Polymer Sci., 35:755-774 (1988).

[0210] Devices can be formulated for local release to treat the implanted or injected site—which typically delivers a much smaller dosage than would be required for whole-body treatment—or for systemic delivery. They can be implanted or injected subcutaneously, intramuscularly, or into fat, or swallowed.

[0211] III. Manufacturing method A. How to make antibodies Antibodies can be produced in cell culture, phage, or in various animals, including but not limited to, cows, rabbits, goats, mice, rats, hamsters, guinea pigs, sheep, dogs, cats, monkeys, chimpanzees, and apes. Thus, in one embodiment, the antibody is a mammalian antibody. Phage technology can be used to isolate initial antibodies or to generate variants with altered specificity or avidity characteristics. Such techniques are routine and well known in the art. In one embodiment, antibodies are produced by recombinant means known in the art. For example, recombinant antibodies can be made by transfecting a vector containing a DNA sequence encoding the antibody into a host cell. One or more vectors can be used to transfect a host cell with DNA sequences expressing at least one VL region and one VH region. Exemplary descriptions of recombinant means of generating and producing antibodies include Delves, Antibody Production: Essential Techniques (Wiley, 1997), Shepherd, et al., Monoclonal Antibodies (Oxford University Press, 2000), Goding, Monoclonal Antibodies: Principles And Practice (Academic Press, 1993), and Current Protocols In Immunology (John Wiley & Sons, most recent edition).

[0212] The disclosed antibodies can be modified by recombinant means to enhance the antibody's effectiveness in mediating a desired function. Accordingly, it is within the scope of the present invention to use recombinant means to modify antibodies by substitution. Typically, the substitutions will be conservative. For example, at least one amino acid in the antibody's constant region can be replaced with a different residue. See, e.g., U.S. Pat. Nos. 5,624,821, 6,194,551, WO 9958572, and Angal et al., Mol. Immunol. 30:105-08 (1993). Amino acid modifications include, for example, amino acid deletions, additions, and substitutions. In some cases, such changes are made to reduce undesired activities, such as complement-dependent cytotoxicity. Antibodies are often labeled, either covalently or noncovalently, with a substance that provides a detectable signal. A wide variety of labeling and conjugation techniques are known and are widely reported in both the scientific and patent literature. These antibodies can be screened for binding to LAIR-1 or LAIR-2 proteins, polypeptides, or fusion proteins. See, e.g., Antibody Engineering: A Practical Approach (Oxford University Press, 1996).

[0213] For example, suitable antibodies with desired biological activity can be identified using in vitro assays, including, but not limited to, in vivo assays such as proliferation, migration, adhesion, soft agar growth, angiogenesis, cell-cell communication, apoptosis, trafficking, signal transduction, and tumor growth inhibition. The antibodies provided herein may also be useful for diagnostic applications. Screening for the ability to bind to a particular antigen without inhibiting the receptor binding activity or biological activity of the antigen can be performed on antibodies as capture antibodies or non-neutralizing antibodies. Antibodies as neutralizing antibodies may be useful in competitive binding assays.

[0214] Antibodies that can be used in the disclosed compositions and methods include, for example, whole immunoglobulins (i.e., complete antibodies) of any class, fragments thereof, and synthetic proteins containing at least the antigen-binding variable domain of an antibody. The variable domains vary in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, variability is not always uniformly distributed throughout the variable domains of antibodies. It is typically concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions in both light and heavy chain variable domains. The more highly conserved portions of the variable domains are called framework regions (FRs). Natural heavy and light chain variable domains each contain four FR regions connected to three CDRs and generally arranged in a beta-sheet configuration, with the CDRs forming loops that connect, and in some cases form part of, the beta-sheet structure. The CDRs of each chain are held together in close proximity by the FR regions and, together with the CDRs of the other chain, contribute to the formation of the antigen-binding site of antibodies.

[0215] Further disclosed are biologically active antibody fragments, which contain insertions, deletions, substitutions, or other selected modifications of specific regions or specific amino acid residues, whether or not attached to other sequences, provided that the activity of the fragment is not significantly altered or impaired relative to the unmodified antibody or antibody fragment.

[0216] Techniques can also be adapted to produce single-chain antibodies specific to antigenic peptides. Methods for producing single-chain antibodies are well known to those skilled in the art. Single-chain antibodies can be produced by fusing the variable domains of heavy and light chains together using a short peptide linker, thereby reconstituting an antigen-binding site on a single molecule. Single-chain antibody variable fragments (scFvs) have been developed in which the C-terminus of one variable domain is tethered to the N-terminus of the other variable domain by a 15-25 amino acid peptide or linker without significantly disrupting antigen binding or binding specificity. The linker is selected to allow the heavy and light chains to bind to each other in their appropriate conformational orientation.

[0217] Bivalent single-chain variable fragments (di-scFvs) can be constructed by linking two scFvs. This can be done by generating two VH and two VL regions along a single peptide chain, resulting in a tandem scFv. scFvs can also be constructed with a linker peptide (approximately 5 amino acids) that is too short for the two variable regions to fold together, forcing the scFvs to dimerize. This type is known as a diabody. Diabodies have dissociation constants that are 40-fold lower than those of the corresponding scFvs, meaning they have much higher affinities for their targets. Even shorter linkers (1 or 2 amino acids) lead to the formation of trimers (triabodies or tribodies). Tetrabodies have also been constructed; they exhibit even higher affinities for their targets than diabodies.

[0218] Monoclonal antibodies are obtained from a substantially homogeneous antibody population, i.e., the individual antibodies in the population are identical except for naturally occurring mutations that may be present in a small subset of the antibody molecules. Monoclonal antibodies also include "chimeric" antibodies and fragments of such antibodies, so long as they exhibit the desired antagonistic activity, in which a portion of the heavy and / or light chain is identical to or homologous to corresponding sequences in antibodies from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical to or homologous to corresponding sequences in antibodies from another species or belonging to another antibody class or subclass.

[0219] Monoclonal antibodies can be made using any procedure that produces monoclonal antibodies. In the hybridoma method, a mouse or other suitable host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that specifically bind to the immunizing agent. Alternatively, lymphocytes may be immunized in vitro.

[0220] Antibodies may be made by recombinant DNA methods. DNA encoding the disclosed antibodies can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Phage display technology can also be used to generate and screen libraries of antibodies or active antibody fragments.

[0221] Methods for producing antibodies using protein chemistry are also known in the art. One method for generating proteins, including antibodies, is to link two or more peptides or polypeptides together using protein chemistry techniques. For example, peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using Fmoc (9-fluorenylmethyloxycarbonyl) or Boc (tert-butyloxycarbonyl) chemistry (Applied Biosystems, Inc., Foster City, CA). Those skilled in the art will readily recognize that peptides or polypeptides corresponding to, for example, antibodies can be synthesized using standard chemical reactions. For example, a peptide or polypeptide can be synthesized and left intact on the synthesis resin, while the other fragment of the antibody can be synthesized and subsequently cleaved from the resin, thus exposing functionally blocked terminal groups on the other fragment. These two fragments can be covalently joined by peptide bonds at their respective carboxy and amino termini through a peptide condensation reaction to form an antibody or fragment thereof. Alternatively, peptides or polypeptides can be independently synthesized in vivo as described above. Once isolated, these independent peptides or polypeptides can be linked by similar peptide condensation reactions to form antibodies or antigen-binding fragments thereof.

[0222] For example, enzymatic ligation of cloned or synthetic peptide segments allows for the splicing of relatively short peptide fragments to generate larger peptide fragments, polypeptides, or entire protein domains. Alternatively, natural chemical ligation of synthetic peptides can be utilized to synthetically construct large peptides or polypeptides from shorter peptide fragments. This method involves two chemical reactions. In the first step, an unprotected synthetic peptide-alpha-thioester is chemoselectively reacted with another unprotected peptide segment containing an amino-terminal Cys residue to yield a thioester-linked intermediate as the initial covalent product. Without modification of the reaction conditions, this intermediate undergoes a spontaneous and rapid intramolecular reaction to form a native peptide bond at the ligation site.

[0223] B. Methods for Producing Proteins The disclosed proteins, polypeptides, fragments, variants, and fusions thereof can be produced using conventional techniques known in the art. Isolated fusion proteins can be obtained, for example, by chemical synthesis or recombinant production in a host cell. To recombinantly produce a protein, polypeptide, fragment, variant, or fusion, a nucleic acid containing a nucleotide sequence encoding the protein, polypeptide, fragment, variant, or fusion can be transformed, transfected, or transfected into a bacterial or eukaryotic host cell (e.g., insect, yeast, or mammalian cell). Generally, a nucleic acid construct includes a regulatory sequence operably linked to a nucleotide sequence encoding the protein, polypeptide, fragment, variant, or fusion. Regulatory sequences (also referred to herein as expression control sequences) typically do not encode a gene product but instead affect the expression of a nucleic acid sequence to which they are operably linked.

[0224] Prokaryotic and eukaryotic systems useful for expression and production of polypeptides are well known in the art, including, for example, Escherichia coli strains such as BL-21, and cultured mammalian cells such as CHO cells.

[0225] In eukaryotic host cells, a number of viral-based expression systems can be utilized to express fusion proteins. Viral-based expression systems are well known in the art and include, but are not limited to, baculovirus, SV40, retrovirus, or vaccinia-based virus vectors.

[0226] Mammalian cell lines stably expressing proteins, polypeptides, fragments, variants, or fusions thereof can be produced using expression vectors with appropriate regulatory elements and selectable markers. For example, the eukaryotic expression vectors pCR3.1 (Invitrogen Life Technologies) and p91023(B) (see Wong et al. (1985) Science 228:810-815) are suitable for expressing proteins, polypeptides, fragments, variants, or fusions thereof in, for example, Chinese hamster ovary (CHO) cells, COS-1 cells, human embryonic kidney 293 cells, NIH3T3 cells, BHK21 cells, MDCK cells, and human vascular endothelial cells (HUVEC). Further suitable expression systems include, for example, the GS Gene Expression System™ available from Lonza Group Ltd.

[0227] Following introduction of the expression vector by electroporation, lipofection, calcium phosphate or calcium chloride co-precipitation, DEAE-dextran, or other appropriate transfection method, stable cell lines can be selected (e.g., by metabolic selection or antibiotic resistance to G418, kanamycin, or hygromycin). The transfected cells can be cultured to express the polypeptide of interest, and the polypeptide can be recovered, for example, from the cell culture supernatant or lysed cells. Alternatively, proteins, polypeptides, fragments, variants, or fusions thereof can be produced by (a) ligating the amplified sequence into a mammalian expression vector such as pcDNA3 (Invitrogen Life Technologies), and (b) in vitro transcription and translation using wheat germ extract or rabbit reticulocyte lysate.

[0228] Proteins, polypeptides, fragments, variants, or fusions thereof can be isolated using chromatographic methods, such as affinity chromatography, ion exchange chromatography, hydrophobic interaction chromatography, DEAE ion exchange, gel filtration, and hydroxyapatite chromatography. In some embodiments, proteins, polypeptides, fragments, variants, or fusions thereof can be engineered to contain an additional domain containing an amino acid sequence that enables the polypeptide to be captured on an affinity matrix. For example, a Protein A column can be used to isolate Fc-fusion polypeptides in cell culture supernatants or cytoplasmic extracts. Additionally, tags such as c-myc, hemagglutinin, polyhistidine, or Flag™ (Kodak) can be used to aid in polypeptide purification. Such tags can be inserted anywhere within the polypeptide, including at the carboxy or amino terminus. Other potentially useful fusions include enzymes, such as alkaline phosphatase, that aid in polypeptide detection. Immunoaffinity chromatography can also be used to purify polypeptides. Fusion proteins can also be engineered to contain a secretion signal that causes the protein, polypeptide, fragment, variant, or fusion thereof to be secreted by the cell that produces it (if a secretion signal is not already present). The secreted protein, polypeptide, fragment, variant or fusion thereof can then be conveniently isolated from the cell culture medium.

[0229] C. Methods for Producing Isolated Nucleic Acid Molecules Isolated nucleic acid molecules can be generated by standard techniques, including, but not limited to, common molecular cloning and chemical nucleic acid synthesis techniques. For example, polymerase chain reaction (PCR) techniques can be used to obtain isolated nucleic acids encoding mutant polypeptides. PCR is a technique for enzymatically amplifying target nucleic acids. Typically, sequence information from the ends of a region of interest or beyond can be used to design oligonucleotide primers that are identical in sequence to the opposing strand of the template to be amplified. PCR can be used to amplify specific sequences from DNA and RNA, including sequences from entire genomic DNA or entire cellular RNA. Primers are typically 14 to 40 nucleotides in length, but can range from 10 to several hundred nucleotides in length. General PCR techniques are described, for example, in "PCR Primer: A Laboratory Manual," ed. by Dieffenbach and Dveksler, Cold Spring Harbor Laboratory Press, 1995. When RNA is used as a template, a complementary DNA (cDNA) strand can be synthesized using reverse transcriptase. Ligase chain reaction, strand displacement amplification, self-sustained sequence replication, or nucleic acid sequence-based amplification can also be used to obtain isolated nucleic acids. See, e.g., Lewis (1992) Genetic Engineering News 12:1, Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878, and Weiss (1991) Science 254:1292-1293.

[0230] Isolated nucleic acids can be chemically synthesized as single nucleic acid molecules or as a series of oligonucleotides (e.g., using phosphoramidite technology for automated 3' to 5' DNA synthesis). For example, one or more pairs of long (e.g., more than 100 nucleotides) oligonucleotides containing the desired sequence can be synthesized, each pair containing a short complementary segment (e.g., about 15 nucleotides) that forms a duplex when the oligonucleotide pair is annealed. DNA polymerase can be used to extend the oligonucleotides, resulting in one double-stranded nucleic acid molecule per pair of oligonucleotides, which can then be ligated into a vector. Isolated nucleic acids can also be obtained by mutagenesis. Protein-encoding nucleic acids can be mutated using standard techniques, including oligonucleotide-directed mutagenesis and / or PCR-mediated site-directed mutagenesis. See, for example, Short Protocols in Molecular Biology, Chapter 8, Green Publishing Associates and John Wiley & Sons, edited by Ausubel et al., 1992.

[0231] IV. Assays and Antibody Screening The production of LAIR-2Fc fusion protein ("LAIR-2-Fc") for cancer therapy avoids the need for the development and screening of LAIR-1 mAbs. Because LAIR-2 has a higher affinity than LAIR-1, in some embodiments, LAIR-2-Fc is preferred over LAIR-1 Fc fusion protein ("LAIR-1-Fc") as a therapeutic treatment. In some embodiments, LAIR-1-Fc can be utilized in mouse preclinical models due to the absence of LAIR-2 in mice.

[0232] A. LAIR-2-Fc Assay 1. Confirmation by ELISA of the ability to bind to multiple forms of collagen, SP-D, C1q and MBL. 2. Confirmation of the ability of LAIR-2-Fc to inhibit the binding of multiple collagens, SP-D, and C1q to LAIR-1. This can be tested by 1) an ELISA competition assay and 2) flow cytometry using LAIR-1-transfected cells incubated in the presence of titrated amounts of LAIR-2-Fc and fluorescently labeled LAIR ligands. 3. Analysis of the binding affinity of LAIR-2-Fc to its ligands compared to LAIR-1. 4. Functional assays to confirm that LAIR-2-Fc blocks signaling by LAIR-1-expressing cells. Reporter cells may be utilized for these assays, or primary LAIR-1+ cells are another option.

[0233] B. Assay and antibody screening of LAIR-2 blocking mAbs Because LAIR-2 is absent in mice, wild-type mice can be used to generate high-affinity mAbs against LAIR-2. Because LAIR-2 is soluble and binds to soluble ligands, screening of transfected cells is not an option for this molecule. 1. Stage I screening: Binding of mAbs to LAIR-2 but not LAIR-1 by ELISA. These mAbs should be highly specific for LAIR-2. 2. Stage II screening: LAIR-2-specific mAbs should block LAIR-2 binding to multiple collagens, SP-D, C1q, and MBL. No single mAb may block binding to all three ligands, and therefore, multiple LAIR-2 mAbs may need to be used simultaneously in a formulation that blocks all interactions to achieve maximum therapeutic efficacy. 3. Phase III screening: Functional assays to confirm that LAIR-2 mAbs or mAb combinations increase LAIR-1 signaling in the presence of titrating amounts of soluble LAIR-2 and titrating amounts of multiple collagens, SP-D, C1q, and MBL. (i.e., LAIR-2 mAbs must block ligand access to soluble LAIR-2, thereby allowing ligand to bind to cell surface LAIR-1 and induce negative signaling pathways.) The Tier II and III assays can be used to predict the concentration of LAIR-2 mAb(s) required to block physiological levels of the ligand in vivo.

[0234] C. Assay and antibody screening of LAIR-1 blocking or LAIR-1 depleting mAbs LAIR-1 deficient ("knockout") or wild-type mice can be utilized to generate high affinity mAbs against LAIR-1 using proprietary immunization techniques. 1. Stage I screening: mAb binding to LAIR-1 but not LAIR-2 by ELISA. mAb binding to cell lines transfected to express cell surface LAIR-1. In addition, mAbs must have the ability to bind to endogenously expressed LAIR-1 on the surface of a subset of primary human cells. These mAbs must be highly specific for LAIR-1. 2. Stage II screening: LAIR-1-specific mAbs must block LAIR-1 binding to one or more of collagens, SP-D, and C1q. No single mAb may block binding to all three ligands; therefore, multiple LAIR-1 mAbs may need to be used simultaneously in a formulation that blocks all interactions to achieve maximum therapeutic efficacy. 3. Phase III screening: Functional assays to confirm that LAIR-1 mAbs or combinations of mAbs reduce LAIR-1 signaling (are antagonistic or blocking mAbs) in the presence of titrated amounts of multiple collagens, SP-D, and C1q. These assays will assess function in the presence of LAIR-1 mAbs using cell lines expressing endogenous LAIR-1, such as THP-1 cells, or primary cells, such as human monocyte, macrophage, and dendritic cell subsets. Additionally, reporter cell lines may be used to determine whether signaling pathways such as NFkB (NFkB reporter) or NFAT (NFAT reporter) are altered after incubation with LAIR-1 mAbs. 4. Stage IV screening: Functional assays to determine whether LAIR-1 mAbs can induce cell apoptosis in LAIR-1-expressing cell lines by antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or other mechanisms. In particular, the ability of LAIR-1 mAbs to deplete leukemia cell lines, such as THP-1, which are known to express LAIR-1 on their cell surface, by one of these methods will be tested. LAIR-1 mAbs may also be engineered to deplete LAIR-1-expressing cells and tested by known methods as described later in this document. 5. Stage V Screening: Functional assays to determine whether LAIR-1 mAbs can transmit or induce negative signals in LAIR-1-expressing cells via LAIR-1 to suppress cellular function (are agonists). Cell lines that endogenously express LAIR-1, such as THP-1 or U937, or transfected K562 cells, will be evaluated for suppression after incubation with LAIR-1 mAbs. Other assays will use reporter cell lines to determine whether LAIR-1 mAbs attenuate positive signaling pathways, such as NF-kB (NF-kB reporter) or other known cell signaling reporters. Induction of apoptosis in cell lines such as THP-1 and U937 will also be evaluated. The Tier II and III assays can be used to predict the concentration of LAIR-1 mAb(s) required to block physiological levels of the ligand in vivo.

[0235] V. How to use Evidence to date indicates an inhibitory role for the LAIR-1 cell surface receptor and suggests that LAIR-2 indirectly antagonizes LAIR-1 function by binding to the same ligand as LAIR-1, thereby essentially acting as a decoy receptor. The tumor microenvironment is often rich in extracellular matrix proteins (ECM), including the LAIR-1 ligand collagen (Rygiel et al., 2011, Mol. Immunol. 49:402-406). Therefore, LAIR-1-expressing cells localized in the tumor microenvironment can be significantly suppressed by LAIR-1 collagen cross-linking and subsequent inhibitory signaling. Increased LAIR-1 expression and signaling have been shown to suppress the proliferation, differentiation, and function of several immune cell subsets, and therefore are thought to suppress antitumor immunity, particularly in tumor microenvironments with elevated levels of the LAIR-1 ligands collagen, C1q, and SP-D.

[0236] Both collagen and C1q have been shown to limit or alter the differentiation and activation of antigen-presenting cells (monocytes, macrophages, and dendritic cells (DCs)) through LAIR-1. LAIR-1 has also been found to be expressed on NK cells and T cells, albeit at much lower levels than on APCs. Nevertheless, studies have shown that LAIR-1 cross-linking in NK cells and T cells can suppress their proliferation and function. Therefore, it is believed that reducing LAIR-1 cross-linking can enhance immune responses to cancer and infectious diseases. Elevated levels of LAIR-2 are thought to promote antitumor immunity through the same mechanism. Therefore, soluble LAIR-1 and soluble LAIR-2, including LAIR-1 and LAIR-2 polypeptides and LAIR-1 and LAIR-2 fusion proteins, can be used to treat human diseases. For example, LAIR-2 Fc protein can be used for cancer immunotherapy to enhance immune function by preventing ligand binding to LAIR-1. This strategy holds great promise because LAIR-2 binds to ligands with higher affinity than LAIR-1.

[0237] Alternatively, LAIR-1-mediated signaling on AML cancer cells expressing high levels of LAIR-1 maintains the self-renewal capacity or "stemness" of AML cells by suppressing apoptosis and differentiation via a unique LAIR-1-SHP-1-CAMK1-CREB pathway (Kang et al., 2015, Nat. Cell Biol. 17:665-677). In these cancers, reduced LAIR-1 signaling leads to AML cell death. Therefore, blocking (i.e., antagonizing) LAIR-1 signaling in leukemia is considered a therapeutic approach for eradicating leukemia. Therefore, blocking LAIR-1 signaling with LAIR-1 monoclonal antibodies or with soluble LAIR-1 and soluble LAIR-2, including LAIR-1 and LAIR-2 polypeptides and LAIR-1 and LAIR-2 fusion proteins, can be used to treat leukemia by directly suppressing cancer cell survival and promoting antitumor immune responses.

[0238] Conversely, decreased expression or function of LAIR-1 is associated with several autoimmune symptoms, whereas overexpression of LAIR-2 can promote autoimmunity through decoy binding of LAIR-1 ligands. Binding of LAIR-2 to LAIR-1 ligands can essentially reduce cell surface crosslinking of LAIR-1, limiting inhibitory signaling pathways that lead to overreactive immune function. Therefore, increased crosslinking of LAIR-1 is thought to reduce overactive or inappropriate immune responses, for example, in cases of autoimmune disease or inflammation. For example, blocking LAIR-2 with mAbs could be used to treat autoimmune diseases, as this would increase ligand binding to LAIR-1 and thus downregulate the immune response. Targeting LAIR-2 would be highly effective in diseases where there is an expression imbalance between LAIR-1 and soluble LAIR-2 on the cell surface, as shown in the case of rheumatoid arthritis (Lebbink et al., 2008, J. Immunol 180:1662-1669).

[0239] Exemplary methods are described in more detail below.

[0240] A. Stimulation of the immune response 1. Treatment strategies Methods for eliciting or enhancing an immune response in a subject are provided. Typically, the methods involve administering to the subject an effective amount of an immunomodulatory agent, or cells primed ex vivo with an immunomodulatory agent. The immune response can be, for example, a primary immune response to an antigen or an enhancement of effector cell function, such as increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation, or a combination thereof. In some embodiments, the agent can enhance the development of naive T cells into Th1, Th17, Th22, or other cells that secrete or cause other cells to secrete proinflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs. In some embodiments, the agent can reduce or suppress the activity of Tregs, reduce the production of cytokines such as IL-10 from Tregs, reduce the differentiation of Tregs, reduce the number of Tregs, reduce the proportion of Tregs in an immune cell population, or reduce the survival of Tregs. The immunomodulatory agent can be administered to a subject in need thereof in an amount effective to overcome T cell exhaustion and / or T cell anergy. Overcoming T cell exhaustion or T cell anergy can be determined by measuring T cell function using known techniques.

[0241] The method can be used in vivo or ex vivo as a therapeutic application for stimulating an immune response. Thus, in some embodiments, the agent, or a nucleic acid encoding the agent, is administered directly to a subject. In some embodiments, the agent, or a nucleic acid encoding the agent, is contacted with cells (e.g., immune cells) ex vivo, and the treated cells are administered to a subject (e.g., adoptive transfer). Overall, the disclosed immunomodulatory agents can be used to treat subjects with or predisposed to any disease or disorder to which an immune response is directed by the subject's immune system. The agent can enable a more robust immune response. The disclosed compositions are useful for stimulating or enhancing T cell-mediated immune responses.

[0242] Immunomodulatory agents used to enhance immune responses typically decrease LAIR-1 expression, ligand binding, cross-linking, negative signaling, or a combination thereof. For example, the agent may be an LAIR-1 antagonist, such as an antagonist (blocking) anti-LAIR-1 antibody or an antigen-binding fragment thereof. In some embodiments, the antagonist binds to the LAIR-1 collagen-binding domain (see, e.g., Brondijk, et al., Blood, 18(115):1364-73 (2010) and Zhou, et al., Blood, 127(5):529-537 (2016) and supplementary information therein, which are specifically incorporated by reference in their entirety). In some embodiments, the LAIR-1 antagonist, e.g., a function-blocking antibody or functional fragment thereof, specifically binds to an epitope comprising one or more of R59, E61, R62, E63, R65, S66, Y68, N69, I102, R100, W109, E111, Q112, and Y115 of LAIR-1 (e.g., with respect to SEQ ID NO:1). The agent can also be a LAIR-1 polypeptide, e.g., a soluble polypeptide or a fusion protein thereof, capable of serving as a decoy receptor for one or more LAIR-1 ligands. The agent can also be LAIR-2, or a functional fragment or fusion protein thereof, capable of serving as a decoy receptor for one or more LAIR-1 ligands.

[0243] For example, in some embodiments, an effective amount of an LAIR-2 fusion protein, e.g., LAIR-2-Fc, is administered to a subject with cancer or an infectious disease. Treatment of the patient with LAIR-2-Fc will reduce cross-linking of LAIR-1 receptors, which in turn will reduce inhibitory signaling in LAIR-1+ cells and improve immune function. Tipping the ratio toward increasing the levels of soluble LAIR-2 relative to cell-surface LAIR-1 will be advantageous for enhancing anti-tumor immunity, particularly in the tumor microenvironment where LAIR-1 / 2 ligands are highly expressed.

[0244] Tumor microenvironments with high levels of both collagen, SP-D, and / or C1q and immune infiltrates expressing high levels of LAIR-1 would be ideal for the disclosed immunotherapies (e.g., LAIR-2-Fc immunotherapy). Ovarian cancer has high levels of collagen, but it is unclear whether it also has high levels of SP-D and C1q. In contrast, lung cancer and gastrointestinal cancer may have high levels of both collagen and SP-D and therefore may be targeted by LAIR-2-Fc. Other embodiments utilize soluble LAIR-2, soluble LAIR-1, or an LAIR-1 fusion protein (e.g., LAIR-1-Fc). In some embodiments, molecules based on LAIR-2 may be selected because LAIR-2 binds to ligands with higher affinity than LAIR-1.

[0245] LAIR-1 blockade, e.g., using function-blocking anti-LAIR-1 antibodies, can be an alternative or complement to soluble LAIR-1 and LAIR-2 polypeptides and fusion proteins. For example, in some embodiments, LAIR-1 blockade is combined with a decoy receptor, such as soluble LAIR-1 or LAIR-2, or a fusion protein thereof. Combination treatments (e.g., LAIR-2-Fc and LAIR-1 blockade) can be complementary.

[0246] In some embodiments, immune response-stimulating therapy (e.g., in the treatment of cancer or infectious diseases) involves depletion of LAIR-1+ cells. LAIR-1 is highly expressed in mouse and human ovarian cancer ascites. LAIR-1 upregulation is limited to immunoregulatory macrophages and F4 / 80+ DCs, both of which co-express high levels of PD-L1. Therefore, targeted depletion of LAIR-1-expressing cells may improve the ovarian manifestations of the tumor microenvironment by eliminating immunoregulatory populations. Although LAIR-1 expression has not been observed on other cell subsets in ovarian cancer, because LAIR-1 is universally suppressive, depletion of other LAIR-1+ cells may also have the effect of reducing immunosuppression and improving antitumor immunity. LAIR-1 has also been shown to be expressed on the surface of acute myeloid leukemia cancer and is essential for its development (Kang et al., Nature Cell Biology, Vol. 17, No. 5, 2015; pp. 665-679). Thus, depletion of hematopoietic ("blood") cancers with LAIR-1-depleting mAbs would have a direct effect in reducing or eradicating LAIR-1-positive cancers.

[0247] Development and identification of LAIR-1-depleting mAbs can be performed according to known construction and screening methods, including those described herein. See, for example, Reff, et al., Blood. Vol. 83, No. 2, 1994: pp. 435-445, which describes the generation of an anti-CD20 chimeric antibody that binds to human C1q and mediates complement-dependent cell lysis (CDCC) in the presence of human complement and antibody-dependent cellular cytotoxicity (ADCC) by human effector cells. Rituximab destroys B cells and is therefore used to treat diseases characterized by B cell hyperactivity, dysfunction, or excessive numbers. Other B cell-depleting antibodies include, for example, ocrelizumab and ofatumumab. In another example, CD3 Abs can be used to deplete CD4 + Foxp3 +These antibodies can preferentially target and deplete activated effector T cells while sparing Tregs. These antibodies transiently deplete T cells, which exhibit little or no complement- and antibody-dependent cytotoxicity. However, the redirected cytolysis due to their ability to crosslink CD3 molecules expressed by two different cells (one cytotoxic CD8+ T cell and the other target T cell) indicates that T cell depletion occurs primarily through AICD (reviewed in You, Front Immunol. 2015;6:242).

[0248] In some embodiments, the cell depleting antibody reduces the number of LAIR-1 positive macrophages, F4 / 80+ DCs, cancer cells, or a combination thereof.

[0249] 2. Subjects to be treated Cancer treatment The disclosed compositions and methods can be used to treat cancer. Generally, the agents are used to stimulate or enhance an immune response to cancer in a subject by administering to the subject an amount of an immunomodulatory agent that reduces LAIR-1 expression, ligand binding, cross-linking, negative signaling, or a combination thereof. The methods can alleviate one or more symptoms of cancer.

[0250] The immune system is a proven defense against cancer initiation and growth. Regulation of the immune response is governed by cell surface interactions that direct immune cell function along specific pathways, including cancer cell activation or suppression. LAIR-1 is an inhibitory receptor on the surface of several immune cell (leukocyte) subsets that prevents optimal immune responses. In contrast, LAIR-2 is a soluble homolog that functions as a decoy to block LAIR-1-mediated suppression.

[0251] In one embodiment, LAIR-2 Fc fusion proteins promote immune responses in vitro and in vivo. In another embodiment, LAIR-2 Fc reduces tumor growth and promotes survival. In yet another embodiment, LAIR-2 Fc promotes anti-PD-1 immunotherapy. The data provided herein demonstrate that LAIR-1 mAbs have activity in vitro in human T cell and myeloid cell lines, and demonstrate the specific agonist and antagonist activities of specific mAb clones. These findings demonstrate the potential modulation of the LAIR-1 pathway by LAIR-2 Fc or LAIR-1 mAbs for immunotherapeutic intervention in cancer and other diseases.

[0252] In another embodiment, LAIR-Fc enhances the responsiveness of primary human T cells to TCR stimulation. In another embodiment, LAIR-2 Fc enhances antigen-specific T cell responses in vivo.

[0253] During their development, cancer cells acquire a set of characteristic functional capabilities, albeit through various mechanisms. Such capabilities include, for example, evasion of apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion / metastasis, unlimited developmental potential, and sustained angiogenesis. The term "cancer cell" is meant to encompass both pre-malignant and malignant cancer cells. In some embodiments, cancer refers to a benign tumor that remains localized. In other embodiments, cancer refers to a malignant tumor that has spread to distant sites, invading and destroying nearby body structures. In still other embodiments, cancer is associated with a specific cancer antigen (e.g., pan-carcinoma antigen (KS1 / 4), ovarian carcinoma antigen (CA125), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), CD19, CD20, HER2 / neu, etc.).

[0254] The methods and compositions disclosed herein are useful for treating or preventing a variety of cancers or other neoproliferative disorders, including (but not limited to): carcinomas, including squamous cell carcinomas, including those of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, uterus, thyroid, and skin; hematopoietic malignancies of the lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, and Burkitt's lymphoma; acute lymphoblastic leukemia, including acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, and Burkitt's lymphoma; acute lymphoblastic leukemia, including acute lymphoblastic leukemia, acute lymphoblastic leukemia, and acute lymphoblastic leukemia; acute lymphoblastic leukemia, including acute lymphoblastic leukemia, ... Hematopoietic tumors of the myeloid lineage, including myeloid and chronic myeloid leukemia, promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; other tumors, including melanoma, seminoma, tetratocarcinoma, neuroblastoma, and glioma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma, and schwannoma; tumors of mesenchymal origin, including fibrosarcoma, rhabdomyosarcoma, and osteosarcoma; and other tumors, including melanoma, xenoderma pegmentosum, keratoactanthoma, seminoma, follicular thyroid carcinoma, and teratocarcinoma.

[0255] Cancers caused by abnormalities in apoptosis can also be treated with the disclosed methods and compositions. Such cancers can include, but are not limited to, follicular lymphoma, carcinomas with p53 mutations, hormone-dependent tumors of the breast, prostate, and ovary, and precancerous lesions such as familial adenomatous polyposis and myelodysplastic syndromes. In specific embodiments, the methods and compositions treat or prevent malignant tumors or neoproliferative changes (e.g., metaplasia and dysplasia) or hyperproliferative disorders in the ovary, bladder, breast, colon, lung, skin, pancreas, or uterus. In other specific embodiments, the methods and compositions treat or prevent sarcomas, melanomas, or leukemias.

[0256] The disclosed compositions and methods are particularly useful for treating cancers associated with cells expressing abnormally high levels of LAIR-1, high levels of LAIR-1 ligand, low levels of LAIR-2, or a combination thereof.

[0257] Specific cancers and related disorders that can be treated or prevented with the methods and compositions disclosed herein include, but are not limited to, leukemias, such as, but not limited to, acute leukemia, acute lymphocytic leukemia, acute myeloid leukemia, including myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemic leukemia, and myelodysplastic syndromes; chronic leukemias, including, but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas, including, but not limited to, Hodgkin's disease or non-Hodgkin's disease lymphomas (e.g., diffuse anaplastic lymphoma kinase (ALK)-negative large B-cell lymphoma). (DLBCL), diffuse anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (DLBCL), anaplastic lymphoma kinase (ALK)-positive ALK+ anaplastic large B-cell lymphoma (ALCL), acute myeloid lymphoma (AML); multiple myeloma, including but not limited to, smoldering multiple myeloma, non-secretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma, and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; sarcomas of bone and connective tissue, including but not limited to, osteosarcoma sarcoma), osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft tissue sarcoma, angiosarcoma, fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, schwannoma, rhabdomyosarcoma, synovial sarcoma; brain tumors, including but not limited to glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, non-glial tumors, acoustic neurinoma, Craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary cerebral lymphoma; breast cancer, including but not limited to adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast carcinoma, mucinous breast carcinoma, tubular breast carcinoma, papillary breast carcinoma, Paget's disease, and inflammatory breast carcinoma; adrenal gland cancer, including but not limited to chromaffin cell and adrenal cortical carcinoma; thyroid cancer, including but not limited to papillary or follicular thyroid carcinoma, medullary thyroid carcinoma, and anaplastic thyroid carcinoma;Pancreatic cancer, including but not limited to insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumors, and carcinoid or islet cell tumors; pituitary cancer, including but not limited to Cushing's disease, prolactin-secreting tumors, acromegaly, and diabetes insipidus; ocular cancer, including but not limited to ocular melanoma, including iris melanoma, choroidal melanoma, and ciliary body melanoma, and retinoblastoma; vaginal cancer, including but not limited to vulvar cancer, including but not limited to squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer, including but not limited to squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancer, including but not limited to squamous cell carcinoma and adenocarcinoma; uterine cancer, including but not limited to endometrial carcinoma and uterine sarcoma; ovarian cancer, including but not limited to ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; esophageal cancer, including but not limited to squamous cell carcinoma Cancer, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; gastric cancer, including but not limited to adenocarcinoma, fungus-like (polypoid), ulcerating, superficial spreading, diffuse spreading malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; colon cancer; rectal cancer; liver cancer, including but not limited to hepatocellular carcinoma and hepatoblastoma; gallbladder cancer, including but not limited to adenocarcinoma; bile duct carcinoma, including but not limited to lung cancer, including but not limited to non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large cell carcinoma, and small cell lung cancer; testicular cancer, including but not limited to germ cell tumor, seminoma, dysplastic, classic (typical), spermatocytic non-seminoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma (yolk sac tumor); prostate cancer, including but not limited to adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penile cancer oral cancers, including but not limited to squamous cell carcinoma; basal carcinoma; salivary gland cancers, including but not limited to adenocarcinoma, mucoepidermoid carcinoma, and adenoid cystic carcinoma; pharyngeal cancers, including but not limited to squamous cell carcinoma and verrucous melanoma; skin cancers, including but not limited to basal cell carcinoma, squamous cell carcinoma, and melanoma, superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentigo melanoma; kidney cancers, including but not limited to renal cell carcinoma, adenocarcinoma, adrenal nephroma, fibrosarcoma, transitional cell carcinoma (renal pelvis and / or ureter); Wilms' tumor;Bladder cancer, including, but not limited to, transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, and carcinosarcoma. Further cancers include, for example, myxosarcoma, osteogenic sarcoma, endothelial sarcoma, lymphangioendothelial sarcoma, mesothelioma, synovial tumor, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, and papillary adenocarcinoma (for reviews of such disorders, see Fishman et al., 1985, Medicine, 2nd Ed., J.B. Lippincott Co., Philadelphia, and Murphy et al., 1997, Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery, Viking Penguin, Penguin Books USA, Inc., United States of America).

[0258] b. Treating infections The disclosed compositions and methods can be used to treat infectious diseases and infectious disorders. Generally, the agents are used to stimulate or enhance an immune response to an infectious agent in a subject by administering to the subject an amount of an immunomodulatory agent that reduces LAIR-1 expression, ligand binding, cross-linking, negative signaling, or a combination thereof. This method can alleviate one or more symptoms of an infectious disease. Furthermore, because soluble LAIR-1 and / or LAIR-2 can bind to complement factor C1q, in some cases, subjects expressing abnormally high levels of soluble LAIR-1 or LAIR-2 may have reduced complement-mediated immune clearance of infection. Therefore, subjects with abnormally high levels of LAIR-1 or LAIR-2 and identified as exhibiting impaired complement function can be administered agents that block the binding of LAIR-1 and LAIR-2 to complement factor C1q, such as LAIR-1 mAb and LAIR-2 mAb, respectively, to improve the complement cascade and, therefore, the innate immune response to infection.

[0259] Infection or disease can be caused by bacteria, viruses, protozoa, helminth parasites, or other microbial pathogens that invade cells and are attacked, ie, by cytotoxic T lymphocytes.

[0260] Infection or disease can be acute or chronic.Acute infection is typically a short-lasting infection.During acute bacterial infection, immune cells begin to express immunomodulatory receptors.Therefore, in some embodiments, the method comprises increasing the immune stimulatory response to acute infection.

[0261] The infection may be caused by, for example, but not limited to, Candida albicans, Listeria monocytogenes, Streptococcus pyogenes, Streptococcus pneumoniae, Neisseria meningitidis, Staphylococcus aureus, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, or Mycobacterium.

[0262] In some embodiments, the disclosed compositions are used to treat chronic infections, such as infections in which T cell exhaustion or T cell anergy occurs, causing the infection to persist in the host for an extended period of time.

[0263] Exemplary infections to be treated are chronic infections caused by hepatitis virus, human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), herpes virus, Epstein-Barr virus, or human papillomavirus.

[0264] Because viral infections are primarily cleared by T cells, enhancing T cell activity would be therapeutically useful in situations where more rapid or complete clearance of infectious viral agents would be beneficial for animal or human subjects. Thus, the disclosed compositions can be administered to treat local or systemic viral infections, including, but not limited to, immunodeficiency (e.g., HIV), papilloma (e.g., HPV), herpes (e.g., HSV), encephalitis, influenza (e.g., human influenza virus A), and the common cold (e.g., human rhinovirus), as well as other viral infections caused by, for example, HTLV, hepatitis virus, respiratory syncytial virus, vaccinia virus, and rabies virus. Molecules can be administered locally to treat viral skin diseases, such as herpes lesions or shingles, or genital warts. Molecules can also be administered systemically to treat systemic viral diseases, including, but not limited to, AIDS, influenza, the common cold, or encephalitis.

[0265] Representative infections that can be treated include, but are not limited to, Actinomyces, Anabaena, Bacillus, Bacteroides, Bdellovibrio, Bordetella, Borrelia, Campylobacter, Caulobacter, Chlamydia, Chlorobium, and the like. bium, Chromatium, Clostridium, Corynebacterium, Cytophaga, Deinococcus, Escherichia, Francisella, Halobacterium, Heliobacter, Haemophilus, Haemophilus influenzaeInfluenza type B (HIB), Hyphomicrobium, Legionella, Leptospirosis, Listeria, Meningococcus A, B, and C, Methanobacterium, Micrococcus, Myobacterium, Mycoplasma, Myxococcus, Neisseria, Nitrobacter, Oscillatoria, Prochlorous, Proteus, Pseudomonas (P) seudomonas, Phodospirillum, Rickettsia, Salmonella, Shigella, Spirillum, Spirochaeta, Staphylococcus, Streptococcus, Streptomyces, Sulfolobus, Thermoplasma, Thiobacillus, as well as Treponema, Vibrio, Yersinia, and Cryptococcus neoformans, Histoplasma capsulatum, Candida albicans, Candida tropicalis, Nocardia asteroides, Rickettsia rickettsii, Rickettsia typhi, Mycoplasma pneumoniae, Chlamydial psittaci, Chlamydial trachomatisThese include infections caused by microorganisms including Plasmodium trachomatis, Plasmodium falciparum, Trypanosoma brucei, Entamoeba histolytica, Toxoplasma gondii, Trichomonas vaginalis, and Schistosoma mansoni.

[0266] Other microorganisms that can be treated using the disclosed compositions and methods include, for example, bacteria, such as bacteria of the genera Klebsiella, Serratia, and Pasteurella; pathogens associated with cholera, tetanus, botulism, anthrax, plague, and Lyme disease; or fungal or parasitic pathogens, such as Candida (e.g., albicans, krusei, glabrata, and tropicalis), Cryptococcus, Aspergillus (e.g., fumigatus and niger), Mucorales, and the like. Mucorales (mucor, absidia, rhizophus), Sporothrix (schenkii), Blastomyces (dermatitidis), Paracoccidioides (brasiliensis), Coccidioides (immitis) and Histoplasma (capsulatuma), Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba sp., Giardia lambia), Cryptosporidium sp.), Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Toxoplasma gondii, etc.), Sporothrix, Blastomyces, Paracoccidioides, Coccidioides, Histoplasma, Entamoeba histolytica, Balantidium, Naegleria, Acanthamoeba, Giardia, Cryptosporidium, Pneumocystis, Plasmodium, Babesia, or Trypanosoma.

[0267] B. Suppression of immune response 1. Treatment strategies Methods for reducing or suppressing an immune response in a subject are provided. Typically, the methods involve administering to the subject an effective amount of an immunomodulatory agent or cells primed ex vivo with an immunomodulatory agent. The immune response can be, for example, a primary immune response to an antigen or an enhancement of effector cell function, such as increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation, or a combination thereof. Thus, in some embodiments, the agent reduces T cell proliferation, T cell cytokine production, T cell differentiation, or a combination thereof. In some embodiments, the agent can reduce the development of naive T cells into Th1, Th17, Th22, or other cells that secrete or cause other cells to secrete proinflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs. In some embodiments, the agent can increase or promote the activity of Tregs, enhance the production of cytokines such as IL-10 from Tregs, enhance the differentiation of Tregs, increase the number of Tregs, increase the proportion of Tregs in an immune cell population, or increase the survival of Tregs.

[0268] The method can be used in vivo or ex vivo for therapeutic applications to suppress immune responses. Thus, in some embodiments, the agent, or a nucleic acid encoding the agent, is administered directly to a subject. In some embodiments, the agent, or a nucleic acid encoding the agent, is contacted with cells (e.g., immune cells) ex vivo, and the treated cells are administered to a subject (e.g., adoptive transfer). Generally, the disclosed immunomodulatory agents can be used to treat subjects with or predisposed to any disease or disorder in which an overactive or inappropriate immune response is directed by the subject's immune system. The agent can enable a less robust immune response. The disclosed compositions are useful for reducing or suppressing T cell-mediated immune responses.

[0269] Immunomodulatory agents utilized to reduce immune responses typically increase LAIR-1 expression, ligand binding, cross-linking, negative signaling, or a combination thereof. For example, the agent can be an LAIR-1 agonist, such as an agonistic (stimulating) anti-LAIR-1 antibody or an antigen-binding fragment thereof. The agent can also be an LAIR-2 antagonist, such as an antagonistic (blocking) anti-LAIR-2 antibody, that reduces the ability of LAIR-2 to act as a decoy receptor for one or more LAIR-1 ligands.

[0270] For example, in some embodiments, an effective amount of an agent that induces LAIR-2 blockade is administered to a subject with an autoimmune or inflammatory disease or disorder. LAIR-1 signaling functions to limit immune responses, which is crucial for preventing the manifestations of autoimmunity and immune autoreactivity. Therefore, reduced LAIR-1 expression may increase autoimmunity. Alternatively, elevated levels of LAIR-2 can promote autoimmunity by preventing ligand cross-linking and inhibitory signaling by LAIR-1. In fact, elevated levels of LAIR-2 have been reported in patients with rheumatoid arthritis (Olde Nordkamp et al. 2011, Arthritis Rheum. 63:3749-3757). Thus, despite elevated levels of LAIR-1 in rheumatoid arthritis patients, increased LAIR-1 expression would have little effect because LAIR-2 has a higher ligand affinity. Therefore, blocking LAIR-2 binding to collagen, SP-D, and C1q would increase LAIR-1 cross-linking and reduce the subsequent immune-inflammatory pathway. mAbs that deplete LAIR-2 or block LAIR-2 ligand binding may be highly effective in treating autoimmune diseases in which systemic or localized LAIR-2 levels are elevated. In fact, autoimmune diseases in which both LAIR-2 and LAIR-1 expression are elevated may be most likely to benefit from successful LAIR-2 mAb immunotherapy, because once LAIR-2 is neutralized, high levels of LAIR-1 will have a greater inhibitory effect than diseases in which LAIR-1 expression levels are low. Thus, in some embodiments, LAIR-2 mAb immunotherapy is utilized to treat subjects with rheumatoid arthritis.

[0271] A inflammatory response The disclosed compositions and methods can be used to treat inflammation. Generally, the agents are used to reduce or suppress immune responses in a subject by administering to the subject an amount of an immunomodulatory agent that increases LAIR-1 expression, ligand binding, cross-linking, negative signal transduction, or a combination thereof. The methods can alleviate one or more symptoms of inflammation. The inflammation can be acute, chronic, or persistent inflammation.

[0272] In some embodiments, the immunomodulatory agent slows down the immune system. For example, the agent can be used to control excessive inflammatory responses that cause damage to healthy tissue. Thus, in some embodiments, the agent is administered to a subject suffering from an excessive inflammatory response. In such cases, controlling the excessive immune response can be beneficial to the subject.

[0273] b. Inflammatory and autoimmune diseases / disorders Agents that increase LAIR-1 expression, ligand binding, cross-linking, negative signaling, or a combination thereof can also be used to treat inflammatory or autoimmune diseases and disorders, including, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome (ALPS), autoimmune thrombocytopenic purpura (ATP), Behçet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue dermatitis, chronic fatigue immune deficiency syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, and cicatricial pemphigoid. , cold agglutinin disease, CREST syndrome, Crohn's disease, Degos disease, dermatomyositis, juvenile dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Graves' disease, Guillain-Barré, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, insulin-dependent diabetes mellitus (type 1), juvenile arthritis, Meniere's disease, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndrome syndromes), polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, sarcoidosis, scleroderma, Sjogren's syndrome, generalized ankylosis syndrome, Takayasu's arteritis, temporal arteritis / giant cell arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo, and Wegener's granulomatosis.

[0274] In some embodiments, the inflammatory or autoimmune disease is caused by a pathogen or is the result of an infection.

[0275] V. Combination Therapy The disclosed immunomodulatory agents can be administered to a subject in need thereof alone or in combination with one or more additional therapeutic agents. In some embodiments, the immunomodulatory agent and the additional therapeutic agent are administered separately but simultaneously. The immunomodulatory agent and the additional therapeutic agent can also be administered as part of the same composition. In other embodiments, the immunomodulatory agent and the second therapeutic agent are administered separately but at different times as part of the same treatment regimen.

[0276] The subject may be administered a first therapeutic agent 1, 2, 3, 4, 5, 6 hours or more or 1, 2, 3, 4, 5, 6, 7 days or more before the administration of the second therapeutic agent. In some embodiments, the subject may be administered one or more doses of the first agent, each time 1, 2, 3, 4, 5, 6, 7, 14, 21, 28, 35, or 48 days before the first administration of the second agent. The immunomodulatory agent may be the first or second therapeutic agent.

[0277] The immunomodulatory agent and additional therapeutic agent can be administered as part of a treatment regimen. For example, if a subject is administered a first therapeutic agent every four days, the second therapeutic agent can be administered on the first, second, third, or fourth day, or a combination thereof. The first or second therapeutic agent can also be administered repeatedly throughout the treatment regimen.

[0278] Exemplary molecules include, but are not limited to, cytokines, chemotherapeutics, radionuclides, other immunotherapeutics, enzymes, antibiotics, antivirals (particularly protease inhibitors alone or in combination with nucleosides for the treatment of HIV or Hepatitis B or C), antiparasitic (helminth, protozoan) agents, growth factors, growth inhibitors, hormones, hormone antagonists, antibodies and biologically active fragments thereof (including humanized, single chain and chimeric antibodies), antigen and vaccine formulations (including adjuvants), peptide drugs, anti-inflammatory drugs, ligands that bind to Toll-like receptors and activate the innate immune system (including, but not limited to, CpG oligonucleotides), molecules that mobilize and optimize the adaptive immune system, and other molecules that activate or upregulate the action of cytotoxic T lymphocytes, natural killer cells and helper T cells, and other molecules that inactivate or downregulate suppressor or regulatory T cells.

[0279] The additional therapeutic agent is selected based on the condition, disorder, or disease being treated. For example, an immunomodulatory agent can be co-administered with one or more additional agents that enhance or promote the immune response, or that decrease or suppress the immune response.

[0280] A. Increasing the immune response 1. Antimicrobial drugs For example, LAIR-1 or LAIR-2 immunomodulatory agents can be used in a preventative or prophylactic role to treat and prevent diseases such as those mentioned above, and in connection with severe trauma such as large burns, open fractures, accidental amputations, or other wounds. Thus, LAIR-1 or LAIR-2 immunomodulatory agents can be administered to a subject in combination with antimicrobial agents such as antibiotics, antifungals, antivirals, antiparasitics, or essential oils.

[0281] In some embodiments, subjects are administered an LAIR-1 or LAIR-2 immunomodulatory agent and / or an antimicrobial agent upon admission to a hospital to prevent further bacterial, fungal, or viral complications. The antibiotic can target pathogens, and the LAIR-1 or LAIR-2 immunomodulatory agent can stimulate the immune system to produce an enhanced response, which can treat or prevent further infection or disease.

[0282] 2. Chemotherapeutic agents LAIR-1 or LAIR-2 immunomodulatory agents can be combined with one or more chemotherapeutic agents and apoptosis inducers. Representative chemotherapeutic agents include, but are not limited to, amsacrine, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, crisantaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, hydroxycarbamide, idarubicin, ifosfamide, irinotecan, leucovorin, and rifametin. Examples of apoptosis inducers include liposomal doxorubicin, liposomal daunorubicin, lomustine, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, pentostatin, procarbazine, raltitrexed, satraplatin, streptozocin, tegafur-uracil, temozolomide, teniposide, thiotepa, thioguanine, topotecan, treosulfan, vinblastine, vincristine, vindesine, vinorelbine, or combinations thereof. Representative apoptosis inducers include, but are not limited to, fludarabinetaurosporine, cycloheximide, actinomycin D, lactosylceramide, 15d-PGJ(2), and combinations thereof.

[0283] 3. Other immunomodulatory drugs a.PD-1 antagonist In some embodiments, the LAIR-1 or LAIR-2 immunomodulatory agent is co-administered with a PD-1 antagonist. Programmed death-1 (PD-1) is a member of the CD28 family of receptors that, when induced on T cells, mediates negative immune responses. Contact of PD-1 with one of its ligands (B7-H1 or B7-DC) induces an inhibitory response that reduces T cell proliferation and / or the strength and / or duration of the T cell response. Suitable PD-1 antagonists are described in U.S. Patent Nos. 8,114,845, 8,609,089, and 8,709,416, which are specifically incorporated by reference in their entireties, and include compounds or agents that bind to and block a ligand of PD-1, preventing or inhibiting binding of the ligand to the PD-1 receptor, or that directly bind to and block the PD-1 receptor without inducing inhibitory signaling through the PD-1 receptor.

[0284] In some embodiments, the PD-1 receptor antagonist binds directly to the PD-1 receptor without triggering inhibitory signaling, and also binds to a ligand of the PD-1 receptor, reducing or preventing the ligand from triggering signaling through the PD-1 receptor. By reducing the number and / or amount of ligands that bind to the PD-1 receptor and trigger inhibitory signaling, fewer cells are compromised by the negative signals delivered by PD-1 signaling, resulting in a more robust immune response.

[0285] PD-1 signaling is thought to be driven by binding of PD-1 ligands (e.g., B7-H1 or B7-DC) in close proximity to peptide antigens presented by the major histocompatibility complex (MHC) (see, e.g., Freeman, Proc. Natl. Acad. Sci. USA, 105:10275-10276 (2008)). Thus, proteins, antibodies, or small molecules that prevent the juxtaposition of PD-1 and TCR on the T cell membrane are also useful PD-1 antagonists.

[0286] In some embodiments, the PD-1 receptor antagonist is a small molecule antagonist or antibody that reduces or prevents PD-1 receptor signaling by binding to a PD-1 ligand or to PD-1 itself, particularly when such binding does not result in parallel binding of PD-1 to the TCR and therefore does not trigger inhibitory signaling through the PD-1 receptor. Other PD-1 antagonists contemplated by the methods of the invention include antibodies that bind to PD-1 or a PD-1 ligand, as well as other antibodies.

[0287] Suitable anti-PD-1 antibodies include, but are not limited to, those described in the following publications: PCT / IL03 / 00425(Hardy et al.,WO / 2003 / 099196) PCT / JP2006 / 309606(Korman et al.,WO / 2006 / 121168) PCT / US2008 / 008925(Li et al.,WO / 2009 / 014708) PCT / JP03 / 08420(Honjo et al.,WO / 2004 / 004771) PCT / JP04 / 00549(Honjo et al.,WO / 2004 / 072286) PCT / IB2003 / 006304(Collins et al.,WO / 2004 / 056875) PCT / US2007 / 088851(Ahmed et al.,WO / 2008 / 083174) PCT / US2006 / 026046(Korman et al.,WO / 2007 / 005874) PCT / US2008 / 084923(Terrett et al.,WO / 2009 / 073533) Berger et al., Clin. Cancer Res., 14:30443051 (2008).

[0288] A specific example of an anti-PD-1 antibody is the antibody described in Kosak, US20070166281 (published July 19, 2007, paragraph 42), which is a human anti-PD-1 antibody, which in some embodiments is administered at a dose of 3 mg / kg.

[0289] Exemplary anti-B7-H1 antibodies include, but are not limited to, those described in the following publications: PCT / US06 / 022423 (WO / 2006 / 133396, published December 14, 2006) PCT / US07 / 088851 (WO / 2008 / 083174, published July 10, 2008) US 2006 / 0110383 (released May 25, 2006).

[0290] A specific example of an anti-B7-H1 antibody is the antibody described (WO / 2007 / 005874, published Jan. 11, 2007), which is a human anti-B7-H1 antibody.

[0291] Additional anti-PD-1 and anti-B7-H1 antibodies are disclosed in 2014 / 0044738, which is specifically incorporated by reference in its entirety.

[0292] For anti-B7-DC antibodies, see 7,411,051, 7,052,694, 7,390,888, and U.S. Published Application No. 2006 / 0099203.

[0293] Other exemplary PD-1 receptor antagonists include, but are not limited to, B7-DC polypeptides, including homologs and variants thereof, and active fragments of any of the above, as well as fusion proteins incorporating any of the foregoing. In some embodiments, the fusion protein comprises a soluble portion of B7-DC linked to the Fc portion of an antibody, such as human IgG, without incorporating all or part of the transmembrane portion of human B7-DC.

[0294] The PD-1 antagonist can also be a fragment of mammalian B7-H1, e.g., from a primate, e.g., mouse or human, that binds to and blocks PD-1 but does not lead to PD-1-mediated inhibitory signaling, or the fragment can be part of a fusion protein, e.g., an Ig fusion protein.

[0295] Other useful polypeptide PD-1 antagonists include those that bind to ligands of the PD-1 receptor. These include PD-1 receptor proteins or soluble fragments thereof that can bind to PD-1 ligands, such as B7-H1 or B7-DC, and prevent binding to endogenous PD-1 receptors, thereby preventing inhibitory signaling. B7-H1 has also been shown to bind to the protein B7.1 (Butte et al., Immunity, Vol. 27, pp. 111-122, (2007)). Such fragments also include soluble ECD portions of PD-1 proteins containing mutations that improve binding to natural ligands, such as the A99L mutation (Molnar et al., PNAS, 105:10483-10488 (2008)). Also useful are B7-1 or soluble fragments thereof that can bind to B7-H1 ligands and prevent binding to endogenous PD-1 receptors, thereby preventing inhibitory signaling.

[0296] PD-1 and B7-H1 antisense nucleic acids, whether DNA, RNA, or siRNA molecules, can be PD-1 antagonists. Such antisense molecules prevent the expression of PD-1 on T cells and the production of T cell ligands such as B7-H1, PD-L1, and / or PD-L2. For example, siRNA (e.g., an oligonucleotide approximately 21 nucleotides in length, specific for the gene encoding PD-1 or a PD-1 ligand, and readily available commercially) complexed to a carrier such as polyethyleneimine (see Cubillos-Ruiz et al., J. Clin. Invest. 119(8):2231-2244 (2009)) is readily taken up by cells expressing PD-1 and its ligand, reducing the expression of these receptors and ligands, resulting in reduced inhibitory signaling in T cells and thereby activating them.

[0297] b. CTLA4 antagonist Other molecules useful for mediating the effects of T cells in an immune response are also contemplated as additional therapeutic agents. In some embodiments, the molecule is a CTLA4 antagonist, such as an antagonistic anti-CTLA4 antibody. An example of an anti-CTLA4 antibody contemplated for use in the methods of the present invention is the antibody described in PCT / US2006 / 043690 (Fischkoff et al., WO / 2007 / 056539).

[0298] Dosages for anti-PD-1, anti-B7-H1, and anti-CTLA4 antibodies are known in the art and can range, for example, from 0.1 to 100 mg / kg, or more narrowly from 1 to 50 mg / kg or 10 to 20 mg / kg. Suitable doses for human subjects can be 5 to 15 mg / kg, and in a specific embodiment, 10 mg / kg of antibody (e.g., human anti-PD-1 antibody).

[0299] Specific examples of anti-CTLA4 antibodies useful in the methods of the invention are the human anti-CTLA4 antibody ipilimumab, administered at a dose of, for example, about 10 mg / kg, and the human anti-CTLA4 antibody tremelimumab, administered at a dose of, for example, about 15 mg / kg. See also Sammartino, et al., Clinical Kidney Journal, 3(2):135-137 (2010), published online in December 2009.

[0300] In another embodiment, the antagonist is a small molecule. A series of small organic compounds have been shown to bind to the B7-1 ligand and prevent its binding to CTLA4 (see Erbe et al., J. Biol. Chem., 277:7363-7368 (2002)). Such small organic compounds could be administered alone or together with anti-CTLA4 antibodies to reduce T cell inhibitory signaling.

[0301] 4. Strengtheners In some embodiments, the additional therapeutic agent comprises a potentiator, which acts to improve the effectiveness of the immune response upregulator, possibly by more than one mechanism, although the precise mechanism of action is not essential to the broad practice of the invention.

[0302] In some embodiments, the potentiator is cyclophosphamide. Cyclophosphamide (CTX, Cytoxan®, or Neosar®) is an oxazaphosphorine drug, and analogs include ifosfamide (IFO, Ifex), perfosfamide, trofosfamide (trofosfamide; Ixoten), and pharmaceutically acceptable salts, solvates, prodrugs, and metabolites thereof (U.S. Patent Application Publication No. 20070202077, incorporated by reference in its entirety). Ifosfamide (MITOXANA®) is a structural analog of cyclophosphamide, and its mechanism of action is believed to be identical to or substantially similar to that of cyclophosphamide. Perfosfamide (4-hydroperoxycyclophosphamide) and trofosfamide are also alkylating agents structurally related to cyclophosphamide. For example, perfosfamide alkylates DNA, thereby inhibiting DNA replication and RNA and protein synthesis. Novel oxazaphosphorine derivatives have been designed and evaluated with the aim of reducing host toxicity and improving selectivity and response (Liang J, Huang M, Duan W, Yu XQ, Zhou S. Design of new oxazaphosphorine anticancer drugs. Curr Pharm Des. 2007;13(9):963-78. Review). These include mafosfamide (NSC345842), glufosfamide (D19575, beta-D-glucosylisophosphoramide mustard), S-(-)-bromophosphamide (CBM-11), NSC612567 (aldofosphamide perhydrothiazine), and NSC613060 (aldofosphamide thiazolidine). Mafosfamide is an oxazaphosphorine analogue that is a chemically stable 4-thioethanesulfonate salt of 4-hydroxy-CPA. Glufosfamide is an IFO derivative in which isophosphoramide mustard, an alkylated metabolite of IFO, is glycosidicly linked to a beta-D-glucose molecule.Additional cyclophosphamide analogs are described in US Pat. No. 5,190,929, entitled "Cyclophosphamide analogs useful as anti-tumor agents," which is incorporated herein by reference in its entirety.

[0303] Although CTX itself is nontoxic, some of its metabolites are cytotoxic alkylating agents that induce DNA cross-linking and, at higher doses, strand breaks. Many cells are resistant to CTX because they express high levels of the detoxifying enzyme aldehyde dehydrogenase (ALDH). Because lymphocytes (but not hematopoietic stem cells) express low levels of ALDH, CTX targets proliferating lymphocytes, and circulating cells are most sensitive to DNA alkylating agents.

[0304] Low doses of CTX (<200 mg / kg) have immunostimulatory effects, including stimulation of antitumor immune responses in human and mouse models of cancer (Brode & Cooke Crit Rev. Immunol. 28:109-126 (2008)). These low doses are subtherapeutic and lack direct antitumor activity. In contrast, high doses of CTX suppress antitumor responses. The role of CTX in enhancing antitumor immune responses can be explained by several mechanisms: (a) depletion of CD4+CD25+FoxP3+ Tregs (specifically, proliferating Tregs, which may be particularly suppressive); (b) depletion of B lymphocytes; (c) induction of nitric oxide (NO), which leads to tumor cell growth; and (d) recruitment and proliferation of CD11b+Gr-1+ MDSCs. These primary effects have many secondary effects; for example, after Treg depletion, macrophages produce more IFN-γ and less IL-10. CTX has also been shown to induce type I IFN expression and promote homeostatic proliferation of lymphocytes.

[0305] Treg depletion is the most commonly cited mechanism by which CTX enhances antitumor immune responses. This conclusion is based in part on the results of adoptive transfer experiments. In the AB1-HA tumor model, CTX treatment on day 9 resulted in a 75% cure rate. Transfer of purified Tregs on day 12 almost completely suppressed the CTX response (van der Most et al. Cancer Immunol. Immunother. 58:1219-1228 (2009)). Similar results were observed in the HHD2 tumor model, where adoptive transfer of CD4+CD25+ Tregs after CTX pretreatment abolished the therapeutic response to the vaccine (Taieb, JJ Immunol. 176:2722-2729 (2006)).

[0306] Numerous human clinical trials have demonstrated that low-dose CTX is a safe, well-tolerated, and effective agent for promoting anti-tumor immune responses (Bas, & Mastrangelo Cancer Immunol. Immunother. 47:1-12 (1998)).

[0307] The optimal dose of CTX to enhance anti-tumor immune responses is one that reduces total T cell numbers by lowering Treg levels below the normal range, but at sub-therapeutic levels (see Machiels et al. Cancer Res. 61:3689-3697 (2001)).

[0308] In human clinical trials using CTX as an immune enhancer, 2 A dose of 1.98 m² was typically used for an average male (6 ft, 170 lb (78 kg), body surface area 1.98 m²). 2 ) at 300 mg / m 2is 8 mg / kg, or 624 mg of total protein. In mouse models of cancer, efficacy has been seen at doses ranging from 15 to 150 mg / kg, which corresponds to 0.45 to 4.5 mg of total protein in a 30 g mouse (Machiels et al. Cancer Res. 61:3689-3697 (2001), Hengst et al. Cancer Res. 41:2163-2167 (1981), Hengst Cancer Res. 40:2135-2141 (1980)).

[0309] In the case of larger mammals, e.g., primates, e.g., human patients, such mg / m 2 Doses may be used, but unit doses administered over a finite time interval may also be used. Such unit doses may be administered on a daily basis for a finite period, such as 3 days or less, or 5 days or less, or 7 days or less, or 10 days or less, or 15 days or less, or 20 days or less, or 25 days or less, all of which are specifically contemplated by the present invention. The same dosing regimen may also be applied to the other fortifying agents listed herein.

[0310] In other embodiments, the potentiating agent is an agent that reduces the activity and / or number of regulatory T lymphocytes (T-regs), such as sunitinib (SUTENT®), anti-TGFβ, or imatinib (GLEEVAC®). The listed treatment regimens may also include administering an adjuvant.

[0311] Useful potentiating agents also include antimitotic drugs such as paclitaxol, aromatase inhibitors (e.g., letrozole) and antiangiogenic drugs (VEGF inhibitors, e.g., Avastin, VEGF-Trap) (see, e.g., Li et al., Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res. 2006 Nov 15;12(22):6808-16.), anthracyclines, oxaliplatin, doxorubicin, TLR4 antagonists and IL-18 antagonists.

[0312] B. Reduced immune response 1. Immunosuppressive agents In some embodiments, an immune response or inflammatory / autoimmune disease / disorder is treated by administering to a subject an LAIR-1 or LAIR-2 immunomodulatory agent and a second agent that is an immunosuppressant. Immunosuppressive agents include, but are not limited to, antibodies against other lymphocyte surface markers (e.g., CD40, alpha-4 integrin) or cytokines, fusion proteins (e.g., CTLA-4-Ig (Orencia®), TNFR-Ig (Enbrel®)), TNF-α blockers such as Enbrel, Remicade, Cimzia, and Humira, cyclophosphamide (CTX) (i.e., Endoxan®, Cytoxan®, Neosar®, Procytox®, Revimmune™), methotrexate (MTX) (i.e., Rheumatrex®, Trexall®), belimumab (i.e., Benlysta®), or other immunosuppressants (e.g., cyclosporin A, FK506-like compounds, rapamycin compounds, or steroids), antiproliferative agents, cytotoxic agents, or other compounds that may assist in immunosuppression.

[0313] The therapeutic agent can be a CTLA-4 fusion protein, such as CTLA-4-Ig (abatacept). CTLA-4-Ig fusion proteins compete with the costimulatory receptor CD28 on T cells for binding to CD80 / CD86 (B7-1 / B7-2) on antigen-presenting cells, thus functioning to suppress T cell activation. In another embodiment, the therapeutic agent is the CTLA-4-Ig fusion protein known as belatacept. Belatacept contains two amino acid substitutions (L104E and A29Y) that significantly improve its affinity for CD86 in vivo. In another embodiment, the therapeutic agent is Maxy-4.

[0314] In another embodiment, the therapeutic agent is cyclophosphamide (CTX). Cyclophosphamide (generic names for Endoxan®, Cytoxan®, Neosar®, Procytox®, and Revimmune™), also known as cytophosphan, is a nitrogen mustard alkylating agent derived from the oxazofurin family. It is used to treat various types of cancer and some autoimmune disorders. Cyclophosphamide (CTX) is the primary drug used for diffuse proliferative glomerulonephritis in patients with nephrogenic lupus.

[0315] Therapeutic agents can be administered in an amount effective to reduce blood or plasma levels of anti-double-stranded DNA (anti-dsDNA) autoantibodies and / or reduce proteinuria in a patient in need thereof.

[0316] In another embodiment, the therapeutic agent increases the amount of adenosine in serum. See, e.g., WO08 / 147482. For example, the second therapeutic agent can be CD73-Ig, recombinant CD73, or another agent (e.g., a cytokine, monoclonal antibody, or small molecule) that increases the expression of CD73. See, e.g., WO04 / 084933. In another embodiment, the therapeutic agent is interferon-beta.

[0317] A therapeutic agent can be a small molecule that inhibits differentiation, proliferation, activity, and / or cytokine production and / or secretion by Th1, Th17, Th22, and / or other cells that secrete, or cause other cells to secrete, proinflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-18, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs. In another embodiment, a therapeutic agent is a small molecule that interacts with Tregs, enhances Treg activity, promotes or enhances IL-10 secretion by Tregs, increases the number of Tregs, improves the suppressive capacity of Tregs, or a combination thereof.

[0318] In some embodiments, the composition increases the activity or production of Tregs. Exemplary Treg enhancers include, but are not limited to, the glucocorticoid fluticasone, salmeteroal, antibodies against IL-12, IFN-γ, and IL-4; vitamin D3, and dexamethasone, and combinations thereof.

[0319] In some embodiments, the therapeutic agent is an antibody, eg, a function-blocking antibody against a pro-inflammatory molecule such as IL-6, IL-23, IL-22, or IL-21.

[0320] As used herein, the term "rapamycin compound" includes the neutral tricyclic compound rapamycin, rapamycin derivatives, rapamycin analogs, and other macrolide compounds believed to have the same mechanism of action as rapamycin (e.g., inhibition of cytokine function). The phrase "rapamycin compound" also includes compounds that are structurally similar to rapamycin, e.g., compounds with a similar macrocyclic structure, that have been modified to enhance their therapeutic effectiveness. Examples of rapamycin compounds are known in the art (see, e.g., WO95122972, WO95116691, WO95104738, U.S. Patent Nos. 6,015,809, 5,989,591, 5,567,709, 5,559,112, 5,530,006, 5,484,790, 5,385,908, 5,202,332, 5,162,333, 5,780,462, 5,120,727).

[0321] The term "FK506-like compounds" includes FK506 as well as derivatives and analogs of FK506, such as compounds structurally similar to FK506, e.g., compounds having a similar macrocyclic structure that has been modified to enhance therapeutic efficacy. Examples of FK506-like compounds include, for example, those described in WO00101385. In some embodiments, the term "rapamycin compounds" as used herein does not include FK506-like compounds.

[0322] 2. Anti-inflammatory drugs Other suitable therapeutic agents include, but are not limited to, anti-inflammatory agents. The anti-inflammatory agent may be non-steroidal, steroidal, or a combination thereof. Some embodiments provide oral compositions containing about 1% (w / w) to about 5% (w / w), typically about 2.5% (w / w), of an anti-inflammatory agent. Representative examples of nonsteroidal anti-inflammatory agents include, but are not limited to, oxicams such as piroxicam, isoxicam, tenoxicam, sudoxicam; salicylates such as aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal; acetic acid derivatives such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acemetacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, and ketolon. Examples of nonsteroidal anti-inflammatory drugs include: lac; fenamates such as mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, and tolfenamic acid; propionic acid derivatives such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic; pyrazoles such as phenylbutazone, oxyphenbutazone, feprazone, azapropazone, and trimethasone. Mixtures of these nonsteroidal anti-inflammatory drugs may also be used.

[0323] Representative examples of steroidal anti-inflammatory drugs include, but are not limited to, corticosteroids such as hydrocortisone, hydroxytriamcinolone, alpha-methyldexamethasone, dexamethasone phosphate, beclomethasone dipropionate, clobetasol valerate, desonide, desoximetasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluchlorolone acetonide, fludrocortisone, flumethasone pivalate, fluocinolone acetonide, fluocinonide, flucortine butyl ester, fluocortolone, fluprednidene (fluprednylidene) acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone, thiamin These include cinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenolone, fludrocortisone, diflurosone diacetate, fluradrenolone acetonide, medrysone, amcinafide, amcinafide, betamethasone and its ester equilibria, chloroprednisone, chloroprednisone acetate, chlorocorterone, clescinolone, dichlorisone, difluprednate, flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone cyclopentylpropionate, hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, triamcinolone, and mixtures thereof.

[0324] VI. AML Biomarkers One embodiment provides a method for evaluating or predicting the efficacy of a treatment using an anti-LAIR binding moiety by evaluating cells of a subject in need of treatment to determine whether the cells express LAIR, a binding partner of LAIR, or both. Examples of cells to be tested include, but are not limited to, cancer cells obtained from the subject. Examples of cancer cells include, but are not limited to, acute myeloid leukemia (AML) cells. Cancer cells expressing multiple interacting inhibitory receptors are believed to respond well to treatment using an anti-LAIR binding moiety. Examples of LAIR binding partners include, but are not limited to, transmembrane collagens (XIII, XVII, and XXIII) and LILRB4. Figure 3 shows predicted treatment outcomes based on the presence of LAIR-1 or a binding partner of LAIR-1 on cancer cells.

[0325] VII. Kit The disclosed LAIR-1 and LAIR-2 immunomodulatory agents can be packaged in airtight containers, such as ampoules or sachets, labeled with a quantity. The agents can be supplied as dry, sterilized, lyophilized powders or water-free concentrates in airtight containers, which can be reconstituted with, for example, water or saline to a concentration suitable for administration to a subject. For example, the agents can be supplied as dry, sterile, lyophilized powders in airtight containers in unit dosages of at least 5 mg, or at least 10 mg, at least 15 mg, at least 25 mg, at least 35 mg, at least 45 mg, at least 50 mg, or at least 75 mg. The lyophilized agents can be stored in their original containers at 2-8°C and are typically administered within 12 hours, 6 hours, 5 hours, 3 hours, or 1 hour after reconstitution.

[0326] In alternative embodiments, the drug is supplied in liquid form in an airtight container labeled with the quantity and concentration, hi some embodiments, the liquid form of the drug is supplied in an airtight container containing at least 1 mg / ml, or at least 2.5 mg / ml, at least 5 mg / ml, at least 8 mg / ml, at least 10 mg / ml, at least 15 mg / ml, at least 25 mg / ml, at least 50 mg / ml, at least 100 mg / ml, at least 150 mg / ml, or at least 200 mg / ml of drug.

[0327] Pharmaceutical packs and kits comprising one or more containers filled with a pharmaceutical agent are also provided. Additionally, one or more other prophylactic or therapeutic agents useful for treating disease may also be included in the pharmaceutical pack or kit. The pharmaceutical pack or kit may also comprise one or more containers filled with one or more of the ingredients of the disclosed pharmaceutical compositions. In some cases, such container(s) may be affixed with a notice reflecting approval by the agency for manufacture, use, or sale for human administration, in a form prescribed by a government agency regulating the manufacture, use, or sale of pharmaceuticals or biological products.

[0328] Kits designed for the above methods are also provided. Embodiments typically include one or more LAIR-1 and / or LAIR-2 immunomodulatory agents. In certain embodiments, the kit further includes one or more other prophylactic or therapeutic agents useful for the treatment of cancer in one or more containers. In other embodiments, the kit further includes one or more anti-inflammatory agents useful for the treatment of inflammatory and autoimmune diseases in one or more containers. [Example]

[0329] Example 1: LAIR antibodies and their heavy and light chain sequences Materials and Methods Mouse anti-human LAIR-1 monoclonal antibody Mice were immunized with soluble human LAIR-1 (soluble LAIR-1 refers to the extracellular domain of LAIR-1) fused to mouse G2a Fc (SEQ ID NO: 10). Two weeks later, the mice were challenged with the same immunogen. Two weeks later, the mice received a third dose of antigen. Three days after the final boost, mouse splenocytes were harvested, resuspended in RPMI supplemented with 10% FBS and glutamine, and subsequently fused to form hybridomas.

[0330] RACE Identification of heavy and light chains by RACE (rapid amplification of cDNA ends) was performed according to the following protocol: (1) mRNA denaturation, (2) cDNA synthesis, (3) 5' RACE reaction, (4) analysis of PCR results (agarose gel to visualize the amplified DNA fragments; the correct antibody variable region DNA fragment should have a size of 500-700 base pairs), (5) TOPO cloning of PCR-positive bands, (6) PCR amplification of TOPO clones followed by gel electrophoresis and recovery from the agarose gel, (7) sequencing of a total of 218 clones, and (8) performing CDR analysis using the sequencing data (CDR regions were defined using VBASE2, available at vbase2.org).

[0331] result Antibodies were cloned using the RACE method. Antibody sequence analysis identified one variable heavy chain and one variable light chain for 13 antibody hybridomas, designated herein as 1E11, 1G7, 4B3, 5A6, 5E1, 6B2, 6F4, 6G6, 7G3, 9H6, 11B3, 12E10a, and 12E10b. The sequences are provided below and above. The heavy and light chain sequences and CDRs are provided above and below, and are shown in Figures 1A and 1B.

[0332] 1E11 array Amino acid sequence of 1E11 VL TIFF0007595113000021.tif19136

[0333] CDR1 of 1E11 VL The amino acid sequence of CDR1 of 1E11 VL is: Includes TIFF0007595113000022.tif4128.

[0334] CDR2 of 1E11 VL The amino acids of CDR2 of 1E11 VL are: QMSSLAS(SEQ ID NO:21) Includes.

[0335] CDR3 of 1E11 VL The amino acids of CDR3 of 1E11 VL are: AQNLELPLT (SEQ ID NO: 22) Includes.

[0336] 1E11 VH amino acid sequence TIFF0007595113000023.tif19135

[0337] CDR1 of 1E11 VH The amino acid sequence of CDR1 of 1E11 VH is SYDIN (SEQ ID NO: 24) Includes.

[0338] CDR2 of 1E11 VH The amino acids of CDR2 of 1E11 VH are: Includes TIFF0007595113000024.tif4128.

[0339] CDR3 of 1E11 VH The amino acids of CDR3 of 1E11 VH are: GGYYDYDGY (SEQ ID NO: 26) Includes.

[0340] 1G7 sequence Amino acid sequence of 1G7 VL TIFF0007595113000025.tif19137

[0341] CDR1 of IG7 VL The amino acids of CDR1 of 1G7 VL are: LASQTIGTWLA (SEQ ID NO: 28) Includes.

[0342] CDR2 of IG7 VL The amino acids of CDR2 of 1G7 VL are: AATSLAD (SEQ ID NO: 29) Includes.

[0343] CDR3 of IG7 VL The amino acids of CDR3 of 1G7 VL are: QQLYSTPLT( SEQ ID NO:30 ) Includes.

[0344] Amino acid sequence of 1G7 VH TIFF0007595113000026.tif19136

[0345] CDR1 of 1G7 VH The amino acids of CDR1 of 1G7 VH are: TNAMY( SEQ ID NO:32 ) Includes.

[0346] CDR2 of 1G7 VH The amino acids of CDR2 of 1G7 VH are: Includes TIFF0007595113000027.tif4128.

[0347] CDR3 of 1G7 VH The amino acids of CDR3 of 1G7 VH are: GGSGFFAY( SEQ ID NO:34 ) Includes.

[0348] 4B3 sequence Amino acid sequence of 4B3 VL TIFF0007595113000028.tif19137

[0349] CDR1 of 4B3 VL The amino acids of CDR1 of 4B3 VL are: Includes TIFF0007595113000029.tif4128.

[0350] CDR2 of 4B3 VL The amino acids of CDR2 of 4B3 VL are: GASTRES( SEQ ID NO:37 ) Includes.

[0351] CDR3 of 4B3 VL The amino acids of CDR3 of 4B3 VL are: QNDHSYPFT( SEQ ID NO:38 ) Includes.

[0352] Amino acid sequence of 4B3 VH TIFF0007595113000030.tif19136

[0353] CDR1 of 4B3 VH The amino acids of CDR1 of 4B3 VH are: SYGLN( SEQ ID NO:40 ) Includes.

[0354] CDR2 of 4B3 VH The amino acids of CDR2 of 4B3 VH are: Contains TIFF0007595113000031.tif4128.

[0355] CDR3 of 4B3 VH The amino acids of CDR3 of 4B3 VH are: Includes TIFF0007595113000032.tif4128.

[0356] 5A6 sequence Amino acid sequence of 5A6 VL TIFF0007595113000033.tif19137

[0357] CDR1 of 5A6 VL The amino acids of CDR1 of 5A6 VL are: RASQDIGSSLN( SEQ ID NO:44 ) Includes.

[0358] CDR2 of 5A6 VL The amino acids of CDR2 of 5A6 VL are: ATSSLDS( SEQ ID NO:45 ) Includes.

[0359] CDR3 of 5A6 VL The amino acids of CDR3 of 5A6 VL are: LQYDSFPYT( SEQ ID NO:46 ) Includes.

[0360] Amino acid sequence of 5A6 VH TIFF0007595113000034.tif19136

[0361] CDR1 of 5A6 VH The amino acids of CDR1 of 5A6 VH are: SYGIS( SEQ ID NO:48 ) Includes.

[0362] CDR2 of 5A6 VH The amino acids of CDR2 of 5A6 VH are: Includes TIFF0007595113000035.tif4128.

[0363] CDR3 of 5A6 VH The amino acids of CDR3 of 5A6 VH are: QLFAY( SEQ ID NO:50 ) Includes.

[0364] 5E1 sequence Amino acid sequence of 5E1 VL TIFF0007595113000036.tif19137

[0365] CDR1 of 5E1 VL The amino acid sequence of CDR1 of 5E1 VL is RASQDISNYLN (SEQ ID NO: 52) Includes.

[0366] CDR2 of 5E1 VL The amino acid sequence of CDR2 of 5E1 VL is YTSRLHS (SEQ ID NO: 53) Includes.

[0367] CDR3 of 5E1 VL The amino acid sequence of CDR3 of 5E1 VL is QQGNTLPRT(SEQ ID NO:54) Includes.

[0368] Amino acid sequence of 5E1 VH TIFF0007595113000037.tif19137

[0369] CDR1 of 5E1 VH The amino acid sequence of CDR1 of 5E1 VH is GYFMN (SEQ ID NO: 56) Includes.

[0370] CDR2 of 5E1 VH The amino acid sequence of CDR2 of 5E1 VH is Contains TIFF0007595113000038.tif4128.

[0371] CDR3 of 5E1 VH The amino acid sequence of CDR3 of 5E1 VH is FDYSNSFAY (SEQ ID NO: 58) Includes.

[0372] 6B2 sequence Amino acid sequence of 6B2 VL TIFF0007595113000039.tif19137

[0373] CDR1 of 6B2 VL The amino acid sequence of CDR1 of 6B2 VL is LASQTIGTWLA (SEQ ID NO: 60) Includes.

[0374] CDR2 of 6B2 VL The amino acid sequence of CDR2 of 6B2 VL is AATSLAD (SEQ ID NO: 61) Includes.

[0375] CDR3 of 6B2 VL The amino acid sequence of CDR3 of 6B2 VL is QQLYSTPLT(SEQ ID NO:62) Includes.

[0376] Amino acid sequence of 6B2 VH TIFF0007595113000040.tif19138

[0377] CDR1 of 6B2 VH The amino acid sequence of CDR1 of 6B2 VH is INAMN (SEQ ID NO: 64) Includes.

[0378] CDR2 of 6B2 VH The amino acid sequence of CDR2 of 6B2 VH is Includes TIFF0007595113000041.tif4128.

[0379] CDR3 of 6B2 VH The amino acid sequence of CDR3 of 6B2 VH is SLWFVY(SEQ ID NO:66) Includes.

[0380] 6F4 sequence Amino acid sequence of 6F4 VL TIFF0007595113000042.tif19137

[0381] CDR1 of 6F4 VL The amino acid sequence of CDR1 of 6F4 is KASQDINSYLS (SEQ ID NO: 68) Includes.

[0382] CDR2 of 6F4 VL The amino acid sequence of CDR2 of 6F4 is RANRLVD (SEQ ID NO: 69) Includes.

[0383] CDR3 of 6F4 VL The amino acid sequence of CDR3 of 6F4 is LQYDEFPPYT (SEQ ID NO: 70) Includes.

[0384] Amino acid sequence of 6F4 VH TIFF0007595113000043.tif19137

[0385] CDR1 of 6F4 VH The amino acid sequence of CDR1 of 6F4 VH is SYWMH (SEQ ID NO: 72) Includes.

[0386] CDR2 of 6F4 VH The amino acid sequence of CDR2 of 6F4 VH is Includes TIFF0007595113000044.tif4128.

[0387] CDR3 of 6F4 VH The amino acid sequence of CDR3 of 6F4 VH is NFDQ(SEQ ID NO:74) Includes.

[0388] 6G6 array 6G6 VL amino acid sequence TIFF0007595113000045.tif19137

[0389] CDR1 of 6G6 VL The amino acid sequence of CDR1 of 6G6 VL is KASQNVGTAVA (SEQ ID NO: 76) Includes.

[0390] CDR2 of 6G6 VL The amino acid sequence of CDR2 of 6G6 VL is WASIRHT (SEQ ID NO: 77) Includes.

[0391] CDR3 of 6G6 VL The amino acid sequence of CDR3 of 6G6 VL is QQYSSHPYT(SEQ ID NO:78) Includes.

[0392] 6G6 VH amino acid sequence TIFF0007595113000046.tif19136

[0393] CDR1 of 6G6 VH The amino acid sequence of CDR1 of 6G6 VH is TYYMN(SEQ ID NO:80) Includes.

[0394] CDR2 of 6G6 VH The amino acid sequence of CDR2 of 6G6 VH is Includes TIFF0007595113000047.tif4128.

[0395] CDR3 of 6G6 VH The amino acid sequence of CDR3 of 6G6 VH is GKSLAY (SEQ ID NO: 82) Includes.

[0396] 7G3 sequence 7G3 VL amino acid sequence TIFF0007595113000048.tif19137

[0397] CDR1 of 7G3 VL The amino acid sequence of CDR1 of 7G3 VL is Includes TIFF0007595113000049.tif4128.

[0398] CDR2 of 7G3 VL The amino acid sequence of CDR2 of 7G3 VL is QMSNLAS(SEQ ID NO:85) Includes.

[0399] CDR3 of 7G3 VL The amino acid sequence of CDR3 of 7G3 VL is AQNLEFPLT (SEQ ID NO: 86) Includes.

[0400] 7G3 VH amino acid sequence TIFF0007595113000050.tif19138

[0401] CDR1 of 7G3 VH The amino acid sequence of CDR1 of 7G3 VH is TYDIN (SEQ ID NO: 88) Includes.

[0402] CDR2 of 7G3 VH The amino acid sequence of CDR2 of 7G3 VH is Contains TIFF0007595113000051.tif4128.

[0403] CDR3 of 7G3 VH The amino acid sequence of CDR3 of 7G3 VH is GGYYDYDGY (SEQ ID NO: 90) Includes.

[0404] 9H6 arrangement Amino acid sequence of 9H6 VL TIFF0007595113000052.tif19137

[0405] CDR1 of 9H6 VL The amino acid sequence of CDR1 of 9H6 VL is LASQTIGTWLA (SEQ ID NO: 92) Includes.

[0406] CDR2 of 9H6 VL The amino acid sequence of CDR2 of 9H6 VL is AATSLAD (SEQ ID NO: 93) Includes.

[0407] CDR3 of 9H6 VL The amino acid sequence of CDR3 of 9H6 VL is QQLYSTPFT(SEQ ID NO:94) Includes.

[0408] Amino acid sequence of 9H6 VH TIFF0007595113000053.tif19137

[0409] CDR1 of 9H6 VH The amino acid sequence of CDR1 of 9H6 VH is THAMN (SEQ ID NO: 96) Includes.

[0410] CDR2 of 9H6 VH The amino acid sequence of CDR2 of 9H6 VH is Includes TIFF0007595113000054.tif4128.

[0411] CDR3 of 9H6 VH The amino acid sequence of CDR3 of 9H6 VH is LRGGFLDY(SEQ ID NO:98) Includes.

[0412] 11B3 sequence Amino acid sequence of 11B3 VL TIFF0007595113000055.tif19138

[0413] CDR1 of 11B3 VL The amino acid sequence of CDR1 of 11B3 VL is KASEDIYIRLA (SEQ ID NO: 100) Includes.

[0414] CDR2 of 11B3 VL The amino acid sequence of CDR2 of 11B3 VL is TATSLET (SEQ ID NO: 101) Includes.

[0415] CDR3 of 11B3 VL The amino acid sequence of CDR3 of 11B3 VL is QQYWSTPYT(SEQ ID NO:102) Includes.

[0416] Amino acid sequence of 11B3 VH TIFF0007595113000056.tif19136

[0417] CDR1 of 11B3 VH The amino acid sequence of CDR1 of 11B3 VH is TYAMH (SEQ ID NO: 104) Includes.

[0418] CDR2 of 11B3 VH The amino acid sequence of CDR2 of 11B3 VH is Includes TIFF0007595113000057.tif4128.

[0419] CDR3 of 11B3 VH The amino acid sequence of CDR3 of 11B3 VH is DRYGGAMDY (SEQ ID NO: 106) Includes.

[0420] Array of 12E10a Clone 12E10 was found to have two light chains (12E10a and 12E10b).

[0421] Amino acid sequence of 12E10a VL TIFF0007595113000058.tif19138

[0422] CDR1 of 12E10a VL The amino acid sequence of CDR1 of 12E10a VL is KASQNVRSAVA (SEQ ID NO: 108) Includes.

[0423] CDR2 of 12E10a VL The amino acid sequence of CDR2 of 12E10a VL is LASNRHT (SEQ ID NO: 109) Includes.

[0424] CDR3 of 12E10a VL The amino acid sequence of CDR3 of 12E10a VL is LQHWNYPLT(SEQ ID NO:110) Includes.

[0425] Amino acid sequence of 12E10(a and b) VH TIFF0007595113000059.tif19136

[0426] CDR1 of 12E10 VH The amino acid sequence of CDR1 of 12E10 VH is SCGLS (SEQ ID NO: 112) Includes.

[0427] CDR2 of 12E10 VH The amino acid sequence of CDR2 of 12E10 VH is Includes TIFF0007595113000060.tif4128.

[0428] CDR3 of 12E10 VH The amino acid sequence of CDR3 of 12E10 VH is Includes TIFF0007595113000061.tif4128.

[0429] Amino acid sequence of 12E10b VL TIFF0007595113000062.tif19136

[0430] CDR1 of 12E10b VL The amino acid sequence of CDR1 of 12E10b VL is RASQSISNNLH (SEQ ID NO: 116) Includes.

[0431] CDR2 of 12E10b VL The amino acid sequence of CDR2 of 12E10b VL is YASQSIS (SEQ ID NO: 117) Includes.

[0432] CDR3 of 12E10b VL The amino acid sequence of CDR3 of 12E10b VL is QQSNSWPLT(SEQ ID NO:118) Includes.

[0433] Example 2: Purification of LAIR-2 Fc Methods and Materials LAIR-2 hIgG1 (hereafter referred to as LAIR-2 Fc) was generated using the CHOK1SV KO parental cell line transfected with the Lonza GS vector. This cell line was used to express both the lead candidate LAIR-2 hIgG1 (native IgG1) and the mutant Fc form LAIR2-hIgG1 Fc (L145A / L146A). LAIR-2 Fc was purified by protein A chromatography and its purity was assessed by SDS-PAGE (Figure 6A) and size-exclusion chromatography (Figure 6B). LAIR-1 Fc was similarly produced as the control LAIR-2 Fc, purified by size-exclusion chromatography, and visualized using SDS-PAGE.

[0434] result Figure 6A is an SDS-PAGE gel showing LAIR-2 Fc under reducing and non-reducing conditions. Figure 6B is a chromatogram showing a single major peak at 38:550 min. The data confirm the predicted size of LAIR-2 Fc and the high level of purity of the LAIR-2 Fc protein used in the studies described here.

[0435] Example 3: LAIR-2Fc binds to collagen Materials and Methods K562 AML cell lines stably expressing collagen 17 or controls lacking collagen 17 were stained with 1 μg of LAIR-2 Fc and LAIR-1 Fc and incubated on ice for 30 minutes. Cells were then washed in FACS buffer (PBS + 1% FBS) and stained with 0.05 μg of anti-hIgG-PE for 30 minutes on ice. Cells were washed, resuspended in FACS fixation buffer (3% paraformaldehyde in PBS), and evaluated by flow cytometry.

[0436] result The functionality of LAIR-2 Fc (Figures 7A and 7B) and LAIR-1 Fc (Figures 7C and 7D) was assessed by their ability to bind to the endogenous transmembrane ligand collagen 17 expressed on the surface of K562 cells. SDS-PAGE analysis of LAIR-2 Fc and LAIR-1 Fc was used to assess the purity of the proteins used in this and subsequent studies (Figures 7E and 7F). Greater than 95% purity of LAIR-2 Fc and LAIR-1 Fc was the standard for all data presented here.

[0437] Example 4: LAIR-1 expression in AML cell lines and binding of LAIR-1 Fc and LAIR-2 Fc Methods and Materials Jurkat T cells, K562 Col17 cells, and THP-1 cells were stained with 10 mg / mL anti-LAIR-1-PE (eBioscience, NKTA255) or 10 mg / mL biotinylated LAIR-1 Fc or LAIR-2 Fc after Fc receptor blockade with TruStain FcX (Biolegend) and hIgG (Innovative Research). After 30 minutes of incubation, cells were washed with FACS buffer and stained with 0.4 μg / mL streptavidin-PE. Expression was assessed by flow cytometry.

[0438] result LAIR-1 has been confirmed to be highly expressed in certain AML cell lines. LAIR-2 Fc binds to unknown molecules on the surface of certain AML cell lines, whereas LAIR-1 Fc does not.

[0439] To evaluate cell lines useful for in vitro assays, hematopoietic-derived AML cell lines were evaluated for LAIR-1 expression and potential binding by LAIR-2 Fc and LAIR-1 Fc binding (Figures 8A-8I).

[0440] Figures 8A-8I show flow cytometry histograms of the indicated cell lines treated with anti-LAIR-1, LAIR-1 Fc, or LAIR-2 Fc, and Figures 8A-8C show Jurkat cells treated with anti-LAIR-1, LAIR-1 Fc, and LAIR-2 Fc, respectively.

[0441] Figures 8D to 8F show K562 Col17 cells treated with anti-LAIR-1, LAIR-1 Fc, and LAIR-2 Fc, respectively.

[0442] 8G to 8I show THP-1 cells treated with anti-LAIR-1, LAIR-1 Fc, and LAIR-2 Fc, respectively.

[0443] As shown, both Jurkat T cells, a T-cell leukemia, and THP-1 cells, a monocytic leukemia, expressed high levels of LAIR-1, whereas K562 cells did not. Furthermore, LAIR-2 Fc bound to THP-1 cells and positive control K562-collagen 17-expressing cells, but not to Jurkat T cells. Based on these results, Jurkat T cells and THP-1 cells transduced with signaling pathway reporters were selected for in vitro studies.

[0444] Example 5: LAIR-2 Fc induces NF-kB and NFAT signaling in Jurkat T cells Materials and Methods 96-well flat-bottom plates were coated overnight with titrated amounts of anti-CD3 (OKT3) and then aspirated prior to cell addition. Jurkat T cells carrying the NF-kB-GFP pathway reporter were seeded at 50,000 cells / well in 200ul of RPMI-C in the presence of 10ug / ml LAIR-2 Fc or control Fc, or no protein. Cells were cultured for one day. Cells were harvested from the plates and assessed for GFP expression by flow cytometry.

[0445] Jurkat T cells carrying an NFAT pathway reporter were cultured in the presence of coated anti-CD3 at 0.5 μg / mL and titrated amounts of soluble LAIR-2 Fc or control Fc. Approximately 24 hours later, the levels of secreted Lucia in the supernatant were assessed according to the protocol (Invivogen). Readings were recorded on a Perkin-Elmer Envision plate reader.

[0446] IL-2 and TNF levels in supernatants from Jurkat-NFAT-Lucia T cells treated with 10 ug / ml of LAIR-2 Fc or control Fc were assessed by MSD cytokine analysis.

[0447] result In vitro assays indicate that LAIR-2 Fc can induce the activity of hematopoietic leukemia cell lines. Jurkat T cells carrying an NF-kB-GFP pathway reporter were cultured with titrated concentrations of coated anti-CD3 in the presence of 10 μg / ml of LAIR-2 Fc, control Fc, or medium control, and NF-kB induction was assessed by analyzing the percentage of GFP+ cells by flow cytometry (Figure 9A). This assay demonstrates that LAIR-2 Fc promotes the induction of NF-kB signaling in Jurkat T cells. This effect occurred without apparent binding of LAIR-2 Fc to Jurkat T cells, thus indicating that LAIR-2 Fc acts as a decoy for the ligand that binds to LAIR-1 expressed on the plasma membrane of Jurkat T cells.

[0448] Using a second Jurkat T cell line carrying an NFAT-Lucia pathway reporter, we demonstrated that LAIR-2 Fc dose-dependently induced NFAT in the presence of a set concentration of anti-CD3 (Fig. 9B).

[0449] Supernatants from Jurkat T cells in the presence of 10 μg / ml of LAIR-2 Fc or control Fc in an NFAT reporter assay were tested for IL-2 and TNF cytokine levels (Figures 9C and 9D). Jurkat T cells cultured with LAIR-2 Fc exhibited higher levels of both cytokines, consistent with pathway reporter induction. Because LAIR-2 Fc has not been shown to directly bind to Jurkat T cells, we speculate that LAIR-2 Fc interferes with the interaction of LAIR-1 with soluble factors or interferes with LAIR-1-mediated inhibitory signaling by other mechanisms to enhance Jurkat reporter activity.

[0450] Example 6: LAIR-2 Fc binds to THP-1 cells and induces reporter activity Materials and Methods After Fc receptor blocking with Trustain FcX (Biolegend) and hIgG (Innovative Research), 0.1 μg / ml biotinylated LAIR-2 Fc was added to THP-1 cells on ice. Cells were then washed with FACS buffer and stained with 0.4 μg / mL streptavidin-PE secondary (Biolegend) for 30 minutes on ice. Cells were washed, fixed, and analyzed by flow cytometry.

[0451] THP-1 cells were plated at 50,000 cells / well in a 96-well flat-bottom plate. LPS or RPMI complete medium was added at a final concentration of 1 μg / ml, followed by LAIR-2 Fc or control Fc at a final concentration of 10 μg / ml. All wells contained a final volume of 200 μl. Cells were incubated for the indicated days, after which supernatants were analyzed for secreted Lucia according to the protocol (Invivogen). Readings were performed using a Perkin-Elmer Envision plate reader.

[0452] result The response of THP-1 pathway reporter cells in the presence of LAIR-2 Fc or control Fc was also evaluated. Interestingly, in addition to LAIR-1 expression, LAIR-2 Fc was found to bind to THP-1 cells in a dose-dependent manner (Figure 10A). This is likely because THP-1 cells express transmembrane collagen, a known LAIR-2 ligand (data not shown). THP-1 cells were cultured with or without LPS, a Toll-like receptor ligand known to induce the interferon pathway in THP-1 cells. In the presence of LPS and LAIR-2 Fc, interferon regulatory factor (IRF) induction was significantly increased compared with the presence of LPS and control Fc (Figure 10B). Moreover, LAIR-2 Fc was able to induce interferon signaling even in the absence of LPS, indicating that it has a direct effect on THP-1 cells without the need for co-signaling (Figure 10C). Since it is unlikely that LAIR-2 Fc can induce signaling through transmembrane collagen, the mechanism of action may be blocking the binding of LAIR-1 to transmembrane collagen.

[0453] Example 7: LAIR-2 Fc enhances proliferation of primary T cells Materials and Methods Pan-T cells, including CD4+ and CD8+ T cells, were isolated from PBMCs of healthy donors. CD4+ and CD8+ T cells were isolated from total PBMCs by MACS magnetic bead enrichment (Miltenyi), labeled with 1 μM CFSE (Life Technologies), and added to 96-well plates pre-coated with titrated amounts of anti-CD3 (OKT3) and incubated overnight at 4°C. 10 μg / ml LAIR-2 Fc or control Fc was added, and cells were cultured for 72 hours before analysis by flow cytometry. For flow cytometric analysis of specific T cell subsets, cells were stained with anti-CD4 and anti-CD8 mAbs. CD4 and CD8 T cell subsets were screened in this manner, and CFSE attenuation was assessed as a measure of proliferation.

[0454] result The effect of LAIR-2 Fc on primary human T cells was then evaluated, and the results indicated that both CD4+ and CD8+ T cells showed increased proliferation in the presence of LAIR-2 Fc (Figures 11A and 11B).

[0455] Example 8: LAIR-2 Fc does not directly bind to human PBMC cell subsets Materials and Methods Fresh human PBMCs from three normal healthy donors were stained for CD3+CD4+ T cells, CD3+CD8+ T cells, CD3-CD16+CD56+ NK cells, and CD14+ monocytes and analyzed by flow cytometry.

[0456] result To determine whether this effect was due to binding of LAIR-2 Fc to T cells, PBMCs from healthy donors were stained with LAIR-2 Fc. Figures 12A-12D show CD4, CD8, NK cells, and monocytes, respectively, from donor 1710 treated with LAIR-2 Fc. Figures 12E-12H show CD4, CD8, NK cells, and monocytes, respectively, from donor 1711 treated with LAIR-2 Fc. Figures 12I-12L show CD4, CD8, NK cells, and monocytes, respectively, from donor 1712 treated with LAIR-2 Fc.

[0457] The data indicate that LAIR-2 Fc did not directly bind to human T cells. Moreover, LAIR-2 Fc did not appear to bind to any significant levels to any PBMC cell subsets. Therefore, LAIR-2 Fc may interfere with the interaction of LAIR-1 with LAIR ligands present or expressed in this culture system. These findings further suggest that LAIR-2 Fc should have no effect on hematopoietic cell depletion in vivo, although cells expressing transmembrane LAIR ligands may potentially be depleted or directly affected in other, unexplored ways.

[0458] Example 9: LAIR-2 Fc promotes proliferation of antigen-specific CD8+ T cells in vivo Materials and Methods CD8+ T cells specific for the model antigen chicken egg ovalbumin (OVA) in the context of murine C57BL / 6 MHC class I (H-2Kb) were used. CD8+ OT-I T cells recognize the OVA peptide SIINFEKL (SEQ ID NO:119) when bound to H-2Kb. In the presence of adjuvant, OT-I T cells undergo a proliferation phase followed by a contraction phase. OVA and poly I:C adjuvant were used to determine whether OT-I proliferation was increased and / or contraction was delayed.

[0459] The experimental design is shown in Figure 13A. Ten mice per group were treated with 500 μg of control Fc or LAIR-2 Fc on days -2 and 5. CD8+ T cells were isolated from OT-I x Ly5.1 F1 mice by MACS separation (Miltenyi) on day 0, and 2e5 cells were injected intraperitoneally. On day 1, 100 μg of SIINFEKL (SEQ ID NO:119) peptide (Peptides International) and 150 μg of poly I:C adjuvant (Invivogen) were injected intraperitoneally in a total volume of 300 μl per mouse. Mice were bled on day 0 before immunization and on days 1, 3, 5, 7, 10, and 14, and circulating OT-I T cells were analyzed by flow cytometry by filtering for TCR Vβ2+CD8+ T cells and Ly5.1 (CD45.1).

[0460] result LAIR-2 Fc was next tested in vivo to determine whether it enhances antigen-specific T cell responses. Figure 13B shows that the percentage of OT-I to CD8+ T cells is significantly increased by day 5 compared to control Fc. The results indicate that in the presence of LAIR-2 Fc, OT-I T cells undergo significantly enhanced proliferation compared to mice treated with control Fc (Figure 13B). These results are directly relevant to the OVA-expressing tumor model evaluating tumor antigen-specific T cell responses.

[0461] Example 10: LAIR-2 Fc-treated mice exhibit significantly improved antigen-specific recall responses Materials and Methods Approximately 10 weeks after initial expansion, mice were challenged with equal numbers (1e6 each) of CD45.1 splenocytes that had either been loaded with OVA peptide (CFSE high) or no peptide (CFSE low). Forty-eight hours later, mice were euthanized, and splenocytes were assessed by flow cytometry for the ratio of OVA-loaded to unloaded splenocytes, as a measure of OT-I-mediated antigen-specific memory CTL killing activity.

[0462] result Mice from the OT-I expression experiment (Example 9) were rested for approximately 10 weeks and then assessed for antigen-specific memory CTL recall responses to determine whether LAIR-2 Fc-enhanced proliferation translated into enhanced functional recall responses as evidenced by CTL killing of antigen-loaded splenocytes.

[0463] Non-injected controls were evaluated for gating on the CFSE peak and starting ratio (Figures 14A-14C). Representative examples of the CFSE high to CFSE low ratios for each group are shown in Figures 14D-14F. The results show that mice treated with LAIR-2 Fc during the initial expansion of OT-I T cells (note that no treatment was administered during the recall response) had significantly better recall responses, as measured by specific lysis of OVA-challenged splenocytes (Figure 14C).

[0464] Example 11: LAIR-2 Fc controls 1D8-OVA ovarian cancer growth and prolongs survival Materials and Methods C57BL / 6 mice were intraperitoneally injected with 5e6 ID8-OVA cells, followed three weeks later by 1e6 CD8+ OT-I T cells. Mice were then treated with LAIR-2 Fc or control Fc every four days, starting one day after OT-I transfer, for a total of five treatments. Weight gain was monitored every two to three days. To assess viability, mice were euthanized when ascites production was observed and their body weight increased by 50% from the starting point. Figure 15A shows an exemplary treatment regimen in which 5e6 ID8-OVA tumor cells were intraperitoneally injected on day 0.

[0465] result We investigated whether the enhanced antigen-specific T cell responses mediated by LAIR-2 Fc translated into enhanced antitumor immunity using an OVA-expressing tumor model and OT-I T cells. We previously determined that OT-I T cells transferred 3 weeks after tumor inoculation were not protective and that OT-I T cells developed a dysfunctional or exhausted phenotype. Therefore, this is a useful model for evaluating immunotherapies that can enhance antigen-specific T cell responses and / or reverse / prevent exhaustion.

[0466] Results showed significantly delayed weight gain and significantly improved long-term survival (Figures 15B and 15C). Sixty percent of mice survived long-term, compared with 20% in controls, suggesting overall significant healing with LAIR-2 Fc (Figure 15C).

[0467] Example 12: LAIR-2 Fc and anti-PD-1 is an effective combination immunotherapy in ovarian cancer Materials and Methods Mice were treated as in Figure 15A, except that more ID8-OVA tumor cells (6e6) were injected intraperitoneally on day 0 and fewer OT-I T cells (5e5) were adoptively transferred at week 3. Treatment with 200 μg of LAIR-2 Fc or control Fc was administered every 4 days, beginning 1 day after T cell transfer, for a total of 5 doses. Mice were followed every 2-3 days for weight assessment and euthanized when ascites production was observed and mouse weight had increased 50% from the starting weight.

[0468] result To explore synergistic effects, LAIR-2 Fc alone was studied in comparison with anti-PD-1 immunotherapy and cisplatin chemotherapy, as well as in combination with PD-1 and cisplatin (Figure 16). Results show a modest effect of LAIR-2 Fc alone in this model. However, the greatest response was observed with the combination of LAIR-2 Fc and anti-PD-1, with 50% of mice surviving at 13 weeks. No mice survived to 13 weeks with other monotherapy or combination therapies.

[0469] Example 13: LAIR-2 Fc delays tumor growth and improves survival in a subcutaneous lymphoma model Materials and Methods 4e5 A20 tumor cells were implanted subcutaneously (sc) on day 0. Starting on day 4, 200 μg of LAIR-2 Fc or control Fc was administered intraperitoneally every 4 days for a total of 5 treatments. Tumor growth was followed and measured 2-3 times per week until the mean tumor diameter reached 15 mm or 2000 mm. 3 Mice were sacrificed when the tumor size reached 0. Figure 17A is an exemplary treatment regimen using the A20 tumor model.

[0470] result The results show that tumor growth was significantly delayed (Figure 17B). In addition, survival was significantly prolonged, with one animal remaining tumor-free over time (Figure 17C).

[0471] Example 14: Generation, selection and characterization of LAIR-1 mAbs Materials and Methods Immunization, fusion, and cloning of anti-human LAIR-1 mAb were performed using a product provided by Precision Antibody CRO. NextCure produced human LAIR-1 mG2a Fc fusion protein at Precision Antibody for immunization and boosting of five SJL mice. Electrofusion was performed using splenocytes and lymph nodes from two high-titer mice. Approximately 1,200 hybridoma clones were screened by ELISA for binding to the human LAIR-1 hG1 Fc fusion protein and by flow cytometry for binding to AML tumor cell lines (Jurkat, HL-60) that express endogenous LAIR-1.

[0472] Anti-human LAIR-1 hybridoma clone supernatants were incubated with cell lines known to express LAIR-1 (HL-60, MV-4-11), a LAIR-1-negative cell line transfected with LAIR-1 (K562-LAIR-1) to test for specificity, and a cell line known to be negative for LAIR-1 expression (U266B1). Briefly, 50 μl of supernatant was incubated with 1 e5 cells in a 96-well round-bottom plate for 30 minutes. Cells were washed with FACS buffer (PBS + 1% FBS) and stained with 0.05 μg of anti-mouse IgG-PE secondary antibody (Ab) for 30 minutes. Cells were washed and fixed in 100 μl of 3% paraformaldehyde in PBS for flow cytometry analysis. Data shown are the percentage of cells staining more intensely than the background medium + secondary staining control (last row).

[0473] result The results for the final 15 selected clones are shown in Figure 18. Supernatants from hybridomas had differential levels of binding to specific cell types. This may be due to varying levels of mAb in the cell supernatants or varying strengths of binding (avidity) to LAIR-1 on the plasma membrane. However, because some supernatants bound to LAIR-1 on specific cell types at higher levels, it remains possible that LAIR-1 mAb clones bind to specific glycoforms or modified forms of LAIR-1 on tumor cell lines.

[0474] In the sequences below, the underlined bold text represents the leader sequence. In some embodiments, the leader sequence is removed.

[0475] Sequence of chimera 1E11: hG1 HC The amino acid sequence of the hG1 heavy chain is TIFF0007595113000063.tif46128 (SEQ ID NO: 120). The nucleic acid sequence of the hG1 heavy chain is TIFF0007595113000064.tif141128 (SEQ ID NO: 121). hG4P HC The amino acid sequence of the hG4P heavy chain is TIFF0007595113000065.tif45128 (SEQ ID NO: 122). The nucleic acid sequence of hG4P is TIFF0007595113000066.tif142128 (SEQ ID NO: 123). Light chain The amino acid sequence of the light chain of chimera 1E11 is: TIFF0007595113000067.tif21128 (SEQ ID NO: 124). The nucleic acid sequence of the light chain of chimeric 1E11 is: TIFF0007595113000068.tif69128 (SEQ ID NO: 125).

[0476] Sequence of chimeric 5E1 hG1 HC The amino acid sequence of the hG1 heavy chain is TIFF0007595113000069.tif46128 (SEQ ID NO: 126). The nucleic acid sequence of the hG1 heavy chain is TIFF0007595113000070.tif142128 (SEQ ID NO: 127). hG4P HC The amino acid sequence of the hG4P heavy chain is TIFF0007595113000071.tif45128 (SEQ ID NO: 128). The nucleic acid sequence of the hG4P heavy chain is TIFF0007595113000072.tif141128 (SEQ ID NO: 129). Light chain The amino acid sequence of the light chain of chimeric 5E1 is: TIFF0007595113000073.tif21128 (SEQ ID NO: 130). The nucleic acid sequence of the light chain of chimeric 1E5 is: TIFF0007595113000074.tif69128 (SEQ ID NO: 131).

[0477] Sequence of chimeric 6G6 hG1 heavy chain The amino acid sequence of the hG1 heavy chain is TIFF0007595113000075.tif45128 (SEQ ID NO: 132). The nucleic acid sequence of the hG1 heavy chain is TIFF0007595113000076.tif141128 (SEQ ID NO: 133). The amino acid sequence of the hG4P heavy chain is TIFF0007595113000077.tif45128 (SEQ ID NO: 134). The nucleic acid sequence of the hG4P heavy chain is TIFF0007595113000078.tif142128 (SEQ ID NO: 135). The amino acid sequence of the light chain is TIFF0007595113000079.tif21128 (SEQ ID NO: 136). The nucleic acid sequence of the light chain is TIFF0007595113000080.tif69128 (SEQ ID NO: 137).

[0478] Sequence of chimeric 11B3 hG1 HC The amino acid sequence of the hG1 heavy chain is TIFF0007595113000081.tif46128 (SEQ ID NO: 138). The nucleic acid sequence of the hG1 heavy chain is TIFF0007595113000082.tif141128 (SEQ ID NO: 139). hG4P HC The amino acid sequence of the hG4P heavy chain is TIFF0007595113000083.tif46128 (SEQ ID NO: 140). The nucleic acid sequence of the hG4P heavy chain is TIFF0007595113000084.tif141128 (SEQ ID NO: 141). Light chain The amino acid sequence of the light chain is TIFF0007595113000085.tif21128 (SEQ ID NO: 142). The nucleic acid sequence of the light chain is TIFF0007595113000086.tif69128 (SEQ ID NO: 143).

[0479] Chimeric antibodies are made by combining a light chain with one of the disclosed heavy chains.

[0480] Example 15: Screening of LAIR-1 hybridoma supernatants for blocking or enhancing LAIR-1 Fc binding to collagen I and III Materials and Methods Collagen I or collagen III (Millipore) at 1 μg / ml in PBS was coated overnight (separate plates for separate screenings). Plates were washed and blocked with ELISA blocking buffer (5% BSA in PBS). After washing, 50 μl of LAIR-1 hybridoma supernatant was added to the plate, followed by 50 μl of 2 μg / ml human LAIR-1 Fc-biotin. Plates were washed and SA-HRP (eBio) was added at a 1:10,000 dilution. After a 30-minute incubation, TMB was added, followed by stop solution. Absorbance was determined on a PerkinElmer Envision analyzer.

[0481] result Figure 19 shows the results of LAIR-1 hybridoma screening. Clones P1-A4, P1-D6, and P6-F4 were identified as enhancers of LAIR-1 Fc binding to collagen I and III. Clones P1-E11, P2-A10, P4-B3, P5-A6, P5-E1, P6-B2, P6-G6, P7-G3, P9-H6, P10-G7, P11-B3, and P12-E10 were found to be blockers of LAIR-1 Fc binding to collagen I and III.

[0482] Example 16: Screening of LAIR-1 hybridoma supernatants for blocking or enhancing LAIR-1 Fc binding to C1q and SP-D Materials and Methods C1q (Sigma) or SP-D (R&D Systems) at 1 μg / ml in PBS was coated overnight (separate plates for separate screenings). Plates were washed and blocked with ELISA blocking buffer (5% BSA in PBS). After washing, 50 μl of LAIR-1 hybridoma supernatant was added to the plate, followed by 50 μl of 2 μg / ml human LAIR-1Fc-biotin. Plates were washed and SA-HRP (eBio) was added at a 1:10,000 dilution. After a 30-minute incubation, TMB was added, followed by stop solution. Absorbance was determined on a PerkinElmer Envision analyzer.

[0483] result Figure 20 shows the results of the screening assay. Clones P1-A4, P1-D6, and P6-F4 were found to enhance LAIR-1 Fc binding to C1q and SP-D. Clones P1-E11, P2-A10, P4-B3, P5-A6, P5-E1, P6-B2, P6-G6, P7-G3, P9-H6, P10-G7, P11-B3, and P12-E10 were found to be blockers of LAIR-1 Fc binding to C1q and SP-D.

[0484] Example 17: LAIR-1 chimeric mAb binning Methods and Materials An Octet RED96 instrument (ForteBio) was used for the binning assay. LAIR-1 Fc (hIgG1) was conjugated to an anti-human IgG sensor. After confirming the stability of LAIR-1 Fc on the sensor, the sensor was placed in a well containing the first mAb listed in the left column. Binding of the first mAb was saturated by allowing excess mAb to bind to LAIR-1 Fc. The sensor was then placed in a well containing the second mAb, as shown across the top row. As can be seen when the same mAb is used as the first and second mAb, mAbs binding to the same epitope will be blocked from binding to LAIR-1 Fc due to binding saturation (Figure 21, stippled cells without underlining). The lack of blocking suggested distant epitopes and a lack of steric hindrance. Partial blocking may be due to slight overlap of the epitopes or steric hindrance of binding due to the proximity of the mAb binding sites. Three of the clones were excluded from further testing based on very weak binding (low avidity), leaving 12 clones. Two commercially available anti-human LAIR-1 clones, DX26 and NKTA, were included for comparison purposes.

[0485] result Figure 21 shows the results of LAIR-1 chimeric Ab binning. No blocking is indicated by single underlining. Blocking is indicated by double underlining. The data allowed the identification of mAbs that bind to similar, overlapping, or distinct sites (epitopes) on the extracellular domain (ECD) of LAIR-1, allowing the construction of an epitope map of LAIR-1 mAb binding.

[0486] The binning results determined that there were four major bins of mAbs within this set of 12 clones (Figure 22): Bin 1: 11B3, 6B2, 6F4; Bin 2: 5E1 and 4B3; Bin 3: 5A6 and 6G6; Bin 4: 1E11, 7G3, 1A4, and 10G7.

[0487] Example 18: LAIR-1 chimeric mAb binning map Materials and Methods To visualize the relative binding sites, a map of the binding sites was constructed in 2D format using the binned data generated in Figure 21 .

[0488] result To visualize the relative binding sites, a binding site map was constructed in 2D format using the binning data generated in Example 17 (Figure 22). This map demonstrates that there is significant overlap of the mAbs. At the same time, many mAbs occupy distinct sites on the LAIR-1 molecule. mAbs with the greatest overlap and greatest blocking of binding to LAIR-1 are considered bins. Taken together, this data suggests that the mAb panel covers a large portion of the LAIR-1 protein.

[0489] Example 19: Optimized affinity evaluation was performed using an Octet RED96 instrument (ForteBio) Materials and Methods An anti-human IgG capture sensor was used to couple chimeric LAIR-1 mAb at a density ensuring 1:1 binding with various concentrations of monomeric LAIR-1-His (R&D Systems) in solution. The assay buffer was PBS containing 0.05% Tween-20, and the regeneration buffer was 10 mM glycine at pH 1.5. The chimeric LAIR-1 mAb was first loaded onto the sensor. This was followed by an association step with LAIR-1-His and a dissociation step in a separate well lacking LAIR-1-His. Data were processed using ForteBio Data Analysis Software 9.0. A global fit was used after subtraction of the reference well. The reported average KD values ​​are from at least three independent Octet runs, with high accuracy based on X2 and R2 values. Note that two chimeric forms of 12E10 were tested. Both had relatively low affinity, but the 12E10V2 mAb was excluded from use due to its very low affinity.

[0490] result Figure 23 shows the results of affinity evaluation. The dissociation constants (Kd) are shown in the third column in nM values ​​based on the dissociation rate (Kdis) and the association rate (Kon). Most mAbs had very strong association rates but also relatively fast dissociation rates. 1E11, 7G3 and 11B3, 5E1 and 6G6 all had Kd values ​​less than 5 nM, suggesting very strong affinity for LAIR-1.

[0491] Example 20: LAIR-1 mAb demonstrates differential induction of interferon reporter activity in THP-1 cells Materials and Methods THP-1-Dual cells (Invivogen) carrying an interferon regulatory factor (IRF) reporter were seeded at 25,000 cells / well in 96-well plates either pre-coated with LAIR-1 mAb (10 μg / ml) (Figure 24A) or uncoated (Figure 24B). In Figure 24B, LAIR-1 mAb was added as soluble protein at 10 μg / ml. Additionally, LAIR-2 Fc or control Fc was coated (Figure 24A) or added as soluble protein (Figure 24B) as positive and negative controls.

[0492] To test whether the LAIR-1 mAb enhances or inhibits IRF pathway induction, LPS was added at 1 μg / ml for low-level IRF induction. At 72 hours, 10 μl of supernatant was removed from the assay plate and transferred to a separate analytical plate. Quanti-luc (Invivogen) was added according to the protocol, and luminescence was measured on a PerkinElmer Envision.

[0493] result Plate-bound LAIR-1 mAbs suggested that three mAbs, 11B3, 6G6, and 5E1, could enhance IRF signaling, while two mAbs, 1E11 and 7G3, had little or no effect on IRF induction (Figure 24A). The mAbs had similar effects in soluble form (Figure 24B). Interestingly, 1E11 and 7G3, which fall into the same bin, appear to have similar functions. In contrast, 11B3, 6G6, and 5E1, which fall into separate bins, appear to have similar functions, in contrast to clones 1E11 and 7G3.

[0494] Example 21: LAIR-1 mAb screening for induction of Jurkat T cell reporter activity Materials and Methods 96-well plates were coated with 0.5 μg / ml anti-CD3 (OKT3) overnight at 4°C. Unbound CD3 was removed by aspiration. After removal of OKT3, 10 μg / ml LAIR-1 mAb or LAIR-2 Fc and control Fc were coated for 24 hours (Figure 25A). Unbound protein was aspirated before adding Jurkat T cell NFAT-Lucia pathway reporter cells (Invivogen). Jurkat T cells were seeded at 50,000 cells / well in a total volume of 200 μl. At 48 hours, 10 μl of supernatant was removed and transferred to a separate plate. Quanti-Luc (Invivogen) was added according to the protocol. Luminescence was assessed using a Perkin Elmer Envision plate reader. Figure 25B was performed as in Figure 25A, except that the protein was added in soluble form rather than coated onto the plate.

[0495] result The results showed that 1E11 had little or no effect on NFAT reporter induction, while 11B3, 6G6, and 5E1 induced NFAT induction (Figure 25A). In a similar assay, LAIR-1 mAb or LAIR-2 Fc and control Fc were added as soluble proteins (Figure 25B). In this assay, little effect was observed with any of the treatments. Note that 7G3 was only tested in the THP-1 assay, not the Jurkat assay.

[0496] Overall, the data in the Examples demonstrate the specific functionality of LAIR-1 mAb in cell line pathway reporter-based assays.

[0497] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.

[0498] Those skilled in the art will know, or be able to find using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein, and such equivalents are intended to be encompassed by the following claims.

[0499] Sequence information SEQUENCE LISTING <110> NextCure, Inc <120> COMPOSITIONS AND METHODS FOR MODULATING LAIR SIGNAL TRANSDUCTION <150> US 62 / 370,334 <151> 2016-08-03 <150> US 62 / 450,300 <151> 2017-01-25 <160> 143 <170> PatentIn version 3.5 <210> 1 <211> 287 <212> PRT <213> homo sapiens <400> 1 Met Ser Pro His Pro Thr Ala Leu Leu Gly Leu Val Leu Cys Leu Ala 1 5 10 15 Gln Thr Ile His Thr Gln Glu Glu Asp Leu Pro Arg Pro Ser Ile Ser 20 25 30 Ala Glu Pro Gly Thr Val Ile Pro Leu Gly Ser His Val Thr Phe Val 35 40 45 Cys Arg Gly Pro Val Gly Val Gln Thr Phe Arg Leu Glu Arg Glu Ser 50 55 60 Arg Ser Thr Tyr Asn Asp Thr Glu Asp Val Ser Gln Ala Ser Pro Ser 65 70 75 80 Glu Ser Glu Ala Arg Phe Arg Ile Asp Ser Val Ser Glu Gly Asn Ala 85 90 95 Gly Pro Tyr Arg Cys Ile Tyr Tyr Lys Pro Pro Lys Trp Ser Glu Gln 100 105 110 Ser Asp Tyr Leu Glu Leu Leu Val Lys Glu Thr Ser Gly Gly Pro Asp 115 120 125 Ser Pro Asp Thr Glu Pro Gly Ser Ser Ala Gly Pro Thr Gln Arg Pro 130 135 140 Ser Asp Asn Ser His Asn Glu His Ala Pro Ala Ser Gln Gly Leu Lys 145 150 155 160 Ala Glu His Leu Tyr Ile Leu Ile Gly Val Ser Val Val Phe Leu Phe 165 170 175 Cys Leu Leu Leu Leu Val Leu Phe Cys Leu His Arg Gln Asn Gln Ile 180 185 190 Lys Gln Gly Pro Pro Arg Ser Lys Asp Glu Glu Gln Lys Pro Gln Gln 195 200 205 Arg Pro Asp Leu Ala Val Asp Val Leu Glu Arg Thr Ala Asp Lys Ala 210 215 220 Thr Val Asn Gly Leu Pro Glu Lys Asp Arg Glu Thr Asp Thr Ser Ala 225 230 235 240 Leu Ala Ala Gly Ser Ser Gln Glu Val Thr Tyr Ala Gln Leu Asp His 245 250 255 Trp Ala Leu Thr Gln Arg Thr Ala Arg Ala Val Ser Pro Gln Ser Thr 260 265 270 Lys Pro Met Ala Glu Ser Ile Thr Tyr Ala Ala Val Ala Arg His 275 280 285 <210> 2 <211> 144 <212> PRT <213> homo sapiens <400> 2 Gln Glu Glu Asp Leu Pro Arg Pro Ser Ile Ser Ala Glu Pro Gly Thr 1 5 10 15 Val Ile Pro Leu Gly Ser His Val Thr Phe Val Cys Arg Gly Pro Val 20 25 30 Gly Val Gln Thr Phe Arg Leu Glu Arg Glu Ser Arg Ser Thr Tyr Asn 35 40 45 Asp Thr Glu Asp Val Ser Gln Ala Ser Pro Ser Glu Ser Glu Ala Arg 50 55 60 Phe Arg Ile Asp Ser Val Ser Glu Gly Asn Ala Gly Pro Tyr Arg Cys 65 70 75 80 Ile Tyr Tyr Lys Pro Pro Lys Trp Ser Glu Gln Ser Asp Tyr Leu Glu 85 90 95 Leu Leu Val Lys Glu Thr Ser Gly Gly Pro Asp Ser Pro Asp Thr Glu 100 105 110 Pro Gly Ser Ser Ala Gly Pro Thr Gln Arg Pro Ser Asp Asn Ser His 115 120 125 Asn Glu His Ala Pro Ala Ser Gln Gly Leu Lys Ala Glu His Leu Tyr 130 135 140 <210> 3 <211> 263 <212> PRT <213> Mus musculus <400> 3 Met Ser Leu His Pro Val Ile Leu Leu Val Leu Val Leu Cys Leu Gly 1 5 10 15 Trp Lys Ile Asn Thr Gln Glu Gly Ser Leu Pro Asp Ile Thr Ile Phe 20 25 30 Pro Asn Ser Ser Leu Met Ile Ser Gln Gly Thr Phe Val Thr Val Val 35 40 45 Cys Ser Tyr Ser Asp Lys His Asp Leu Tyr Asn Met Val Arg Leu Glu 50 55 60 Lys Asp Gly Ser Thr Phe Met Glu Lys Ser Thr Glu Pro Tyr Lys Thr 65 70 75 80 Glu Asp Glu Phe Glu Ile Gly Pro Val Asn Glu Thr Ile Thr Gly His 85 90 95 Tyr Ser Cys Ile Tyr Ser Lys Gly Ile Thr Trp Ser Glu Arg Ser Lys 100 105 110 Thr Leu Glu Leu Lys Val Ile Lys Glu Asn Val Ile Gln Thr Pro Ala 115 120 125 Pro Gly Pro Thr Ser Asp Thr Ser Trp Leu Lys Thr Tyr Ser Ile Tyr 130 135 140 Ile Phe Thr Val Val Ser Val Ile Phe Leu Leu Cys Leu Ser Ala Leu 145 150 155 160 Leu Phe Cys Phe Leu Arg His Arg Gln Lys Lys Gln Gly Leu Pro Asn 165 170 175 Asn Lys Arg Gln Gln Gln Arg Pro Glu Glu Arg Leu Asn Leu Ala Thr 180 185 190 Asn Gly Leu Glu Met Thr Pro Asp Ile Val Ala Asp Asp Arg Leu Pro 195 200 205 Glu Asp Arg Trp Thr Glu Thr Trp Thr Pro Val Ala Gly Asp Leu Gln 210 215 220 Glu Val Thr Tyr Ile Gln Leu Asp His His Ser Leu Thr Gln Arg Ala 225 230 235 240 Val Gly Ala Val Thr Ser Gln Ser Thr Asp Met Ala Glu Ser Ser Thr 245 250 255 Tyr Ala Ala Ile Ile Arg His 260 <210> 4 <211> 123 <212> PRT <213> muscle muscle <400> 4 Gln Glu Gly Ser Leu Pro Asp Ile Thr Ile Phe Pro Asn Ser Ser Leu 1 5 10 15 Met Ile Ser Gln Gly Thr Phe Val Thr Val Val Cys Ser Tyr Ser Asp 20 25 30 Lys His Asp Leu Tyr Asn Met Val Arg Leu Glu Lys Asp Gly Ser Thr 35 40 45 Phe Met Glu Lys Ser Thr Glu Pro Tyr Lys Thr Glu Asp Glu Phe Glu 50 55 60 Ile Gly Pro Val Asn Glu Thr Ile Thr Gly His Tyr Ser Cys Ile Tyr 65 70 75 80 Ser Lys Gly Ile Thr Trp Ser Glu Arg Ser Lys Thr Leu Glu Leu Lys 85 90 95 Val Ile Lys Glu Asn Val Ile Gln Thr Pro Ala Pro Gly Pro Thr Ser 100 105 110 Asp Thr Ser Trp Leu Lys Thr Tyr Ser Ile Tyr 115 120 <210> 5 <211> 152 <212> PRT <213> homo sapiens <400> 5 Met Ser Pro His Leu Thr Ala Leu Leu Gly Leu Val Leu Cys Leu Ala 1 5 10 15 Gln Thr Ile His Thr Gln Glu Gly Ala Leu Pro Arg Pro Ser Ile Ser 20 25 30 Ala Glu Pro Gly Thr Val Ile Ser Pro Gly Ser His Val Thr Phe Met 35 40 45 Cys Arg Gly Pro Val Gly Val Gln Thr Phe Arg Leu Glu Arg Glu Asp 50 55 60 Arg Ala Lys Tyr Lys Asp Ser Tyr Asn Val Phe Arg Leu Gly Pro Ser 65 70 75 80 Glu Ser Glu Ala Arg Phe His Ile Asp Ser Val Ser Glu Gly Asn Ala 85 90 95 Gly Leu Tyr Arg Cys Leu Tyr Tyr Lys Pro Pro Gly Trp Ser Glu His 100 105 110 Ser Asp Phe Leu Glu Leu Leu Val Lys Glu Ser Ser Gly Gly Pro Asp 115 120 125 Ser Pro Asp Thr Glu Pro Gly Ser Ser Ala Gly Thr Val Pro Gly Thr 130 135 140 Glu Ala Ser Gly Phe Asp Ala Pro 145 150 <210> 6 <211> 131 <212> PRT <213> homo sapiens <400> 6 Gln Glu Gly Ala Leu Pro Arg Pro Ser Ile Ser Ala Glu Pro Gly Thr 1 5 10 15 Val Ile Ser Pro Gly Ser His Val Thr Phe Met Cys Arg Gly Pro Val 20 25 30 Gly Val Gln Thr Phe Arg Leu Glu Arg Glu Asp Arg Ala Lys Tyr Lys 35 40 45 Asp Ser Tyr Asn Val Phe Arg Leu Gly Pro Ser Glu Ser Glu Ala Arg 50 55 60 Phe His Ile Asp Ser Val Ser Glu Gly Asn Ala Gly Leu Tyr Arg Cys 65 70 75 80 Leu Tyr Tyr Lys Pro Pro Gly Trp Ser Glu His Ser Asp Phe Leu Glu 85 90 95 Leu Leu Val Lys Glu Ser Ser Gly Gly Pro Asp Ser Pro Asp Thr Glu 100 105 110 Pro Gly Ser Ser Ala Gly Thr Val Pro Gly Thr Glu Ala Ser Gly Phe 115 120 125 Asp Ala Pro 130 <210> 7 <211> 32 <212> PRT <213> mus musculus <400> 7 Ser Leu Pro Asp Ile Thr Ile Phe Pro Asn Ser Ser Leu Met Ile Ser 1 5 10 15 Gln Gly Thr Phe Val Thr Val Val Cys Ser Tyr Ser Asp Lys His Asp 20 25 30 <210> 8 <211> 32 <212> PRT <213> mus musculus <400> 8 Glu Leu Cys Leu Trp Phe Leu Leu Tyr Pro Trp Ala Thr Leu Glu Leu 1 5 10 15 Ile Met Cys Thr Trp Asp Ala Trp Lys Glu Thr Leu Glu Tyr Phe Leu 20 25 30 <210> 9 <211> 387 <212> PRT <213> artificial sequence <220> <223> synthetic construct <400> 9 Met Glu Trp Ser Trp Val Phe Leu Phe Phe Leu Ser Val Thr Thr Gly 1 5 10 15 Val His Ser Gln Glu Glu Asp Leu Pro Arg Pro Ser Ile Ser Ala Glu 20 25 30 Pro Gly Thr Val Ile Pro Leu Gly Ser His Val Thr Phe Val Cys Arg 35 40 45 Gly Pro Val Gly Val Gln Thr Phe Arg Leu Glu Arg Glu Ser Arg Ser 50 55 60 Thr Tyr Asn Asp Thr Glu Asp Val Ser Gln Ala Ser Pro Ser Glu Ser 65 70 75 80 Glu Ala Arg Phe Arg Ile Asp Ser Val Ser Glu Gly Asn Ala Gly Pro 85 90 95 Tyr Arg Cys Ile Tyr Tyr Lys Pro Pro Lys Trp Ser Glu Gln Ser Asp 100 105 110 Tyr Leu Glu Leu Leu Val Lys Glu Thr Ser Gly Gly Pro Asp Ser Pro 115 120 125 Asp Thr Glu Pro Gly Ser Ser Ala Gly Pro Thr Gln Arg Pro Ser Asp 130 135 140 Asn Ser His Asn Glu His Ala Pro Ala Ser Gln Gly Leu Lys Ala Glu 145 150 155 160 His Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 165 170 175 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 180 185 190 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 195 200 205 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 210 215 220 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 225 230 235 240 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 245 250 255 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 260 265 270 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 275 280 285 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 290 295 300 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 305 310 315 320 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 325 330 335 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 340 345 350 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 355 360 365 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 370 375 380 Ser Pro Gly 385 <210> 10 <211> 368 <212> PRT <213> artificial sequence <220> <223> synthetic construct <400> 10 Gln Glu Glu Asp Leu Pro Arg Pro Ser Ile Ser Ala Glu Pro Gly Thr 1 5 10 15 Val Ile Pro Leu Gly Ser His Val Thr Phe Val Cys Arg Gly Pro Val 20 25 30 Gly Val Gln Thr Phe Arg Leu Glu Arg Glu Ser Arg Ser Thr Tyr Asn 35 40 45 Asp Thr Glu Asp Val Ser Gln Ala Ser Pro Ser Glu Ser Glu Ala Arg 50 55 60 Phe Arg Ile Asp Ser Val Ser Glu Gly Asn Ala Gly Pro Tyr Arg Cys 65 70 75 80 Ile Tyr Tyr Lys Pro Pro Lys Trp Ser Glu Gln Ser Asp Tyr Leu Glu 85 90 95 Leu Leu Val Lys Glu Thr Ser Gly Gly Pro Asp Ser Pro Asp Thr Glu 100 105 110 Pro Gly Ser Ser Ala Gly Pro Thr Gln Arg Pro Ser Asp Asn Ser His 115 120 125 Asn Glu His Ala Pro Ala Ser Gln Gly Leu Lys Ala Glu His Asp Lys 130 135 140 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 145 150 155 160 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 165 170 175 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 180 185 190 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 195 200 205 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 210 215 220 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 225 230 235 240 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 245 250 255 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 260 265 270 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 275 280 285 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 290 295 300 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 305 310 315 320 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 325 330 335 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 340 345 350 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 355 360 365 <210> 11 <211> 393 <212> PRT <213> artificial sequence <220> <223> synthetic construct <400> 11 Met Glu Trp Ser Trp Val Phe Leu Phe Phe Leu Ser Val Thr Thr Gly 1 5 10 15 Val His Ser Gln Glu Glu Asp Leu Pro Arg Pro Ser Ile Ser Ala Glu 20 25 30 Pro Gly Thr Val Ile Pro Leu Gly Ser His Val Thr Phe Val Cys Arg 35 40 45 Gly Pro Val Gly Val Gln Thr Phe Arg Leu Glu Arg Glu Ser Arg Ser 50 55 60 Thr Tyr Asn Asp Thr Glu Asp Val Ser Gln Ala Ser Pro Ser Glu Ser 65 70 75 80 Glu Ala Arg Phe Arg Ile Asp Ser Val Ser Glu Gly Asn Ala Gly Pro 85 90 95 Tyr Arg Cys Ile Tyr Tyr Lys Pro Pro Lys Trp Ser Glu Gln Ser Asp 100 105 110 Tyr Leu Glu Leu Leu Val Lys Glu Thr Ser Gly Gly Pro Asp Ser Pro 115 120 125 Asp Thr Glu Pro Gly Ser Ser Ala Gly Pro Thr Gln Arg Pro Ser Asp 130 135 140 Asn Ser His Asn Glu His Ala Pro Ala Ser Gln Gly Leu Lys Ala Glu 145 150 155 160 His Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys 165 170 175 Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro 180 185 190 Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys 195 200 205 Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp 210 215 220 Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg 225 230 235 240 Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln 245 250 255 His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn 260 265 270 Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly 275 280 285 Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu 290 295 300 Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met 305 310 315 320 Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu 325 330 335 Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe 340 345 350 Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn 355 360 365 Ser Tyr Ser Cys Ser Val Val His Glu G...

Claims

1. A pharmaceutical composition for treating cancer, comprising a fusion protein comprising the amino acid sequence of SEQ ID NO: 16 and having LAIR-1 antagonist activity, wherein the pharmaceutical composition is used in combination with an anti-PD-1 antibody.

2. A pharmaceutical composition for treating ovarian cancer, comprising a fusion protein comprising the amino acid sequence of SEQ ID NO: 16 and having LAIR-1 antagonist activity, wherein the pharmaceutical composition is used in combination with an anti-PD-1 antibody.

3. A pharmaceutical composition for treating lymphoma, comprising a fusion protein comprising the amino acid sequence of SEQ ID NO: 16 and having LAIR-1 antagonist activity, wherein the pharmaceutical composition is used in combination with an anti-PD-1 antibody.

4. The pharmaceutical composition according to any one of claims 1 to 3, which is formulated for parenteral administration.

Citation Information

Patent Citations

  • Interfering in activation of an immune cell by influencing interaction of lair and collagen.

    WO2007102736A2